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Glycosaminoglycans (GAGs) are linear polysaccharides expressed ubiquitously on an-
imal cell surfaces and within extracellular matrices. GAGs usually occur as parts of
proteoglycans and often accomplish their biological functions through their interactions
with proteins. GAG oligosaccharides for this work were produced via enzymatic digest
of heparin, followed by gel filtration and ion exchange chromatography. Two tetrasac-
charide species obtained from this digest were characterised using 1H and 13C NMR
spectroscopy.
Complement factor H (fH) is a regulatory protein of the alternative pathway of the com-
plement system, a major component of human innate immunity. Acting as a cofactor to
factor I, fH inhibits C3b-initiated complement activation on host cells, protecting cells
from auto immune attack. This study focused on the interaction of factor H with GAGs,
which are thought to be among the markers allowing factor H to distinguish between self
and non self surfaces. Binding studies of two heparin-binding sites in fH are presented.
These include the C-terminal modules 19 and 20 (fH∼19-20) and fH∼7-8. FH∼7, fH∼7-8
and fH∼19-20 were produced recombinantly in various isotope forms. The techniques
used to study the protein-GAG interactions in this work encompass NMR spectroscopy,
mass spectrometry, gel mobility shift assays (GMSA) and chemical cross linking.
Several genetic studies suggest that a common polymorphism in the heparin-binding
module fH∼7, Y402H, plays a role in the development of age-related macular degener-
ation (AMD). The work presented here included preparation and backbone resonance
assignment of a 13C, 15N- labelled sample of fH∼ 7-8 via triple resonance NMR exper-
iments. Further NMR experiments were employed to investigate the role of the lysine
and arginine sidechains of fH∼7 in GAG binding. These studies were combined with
the preparation and characterisation of a covalently cross linked GAG-protein complex
using NMR and mass spectrometry.
A range of fH∼19-20 mutations that are linked to a severe kidney disease, atypical
haemolytic uraemic syndrome (aHUS), were characterised using GMSA. No correlation
between the disease and the heparin binding properties of the aHUS mutants was ob-
served. The mutant proteins were also characterised with respect to their ability to
compete with full-length fH in a physiological complement assay. Simultaneous binding
of WT fH∼19-20 to GAGs and C3d, the relevant fragment of C3b, was assessed using
NMR.
NMR experiments were also conducted with NK1, which comprises the two N-terminal
heparin-binding modules of hepatocyte growth factor/scatter factor (HGF/SF), and hep-
arin as well as dermatan sulfate-derived GAGs. Relaxation studies on a human defensin,
HBD2, were performed to assess the role of GAGs in HBD2 self-association.
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1 Introduction
1.1 The Complement System
The human complement system owes its name to Jules Bordet’s discovery that fresh
serum complements antibody activity (though the actual name complement was coined
by Paul Ehrlich). In a historic experiment, Bordet found that heated blood could no
longer lyse bacteria and that it regained this ability after the addition of fresh serum
which did not contain antibodies [1]. He concluded that the heated antibodies where
still active when complemented by a heat-sensitive serum component - the complement
system (more specifically its classical pathway). It was later found that the complement
system does also comprise an antibody-independent pathway (the alternative pathway)
that protects its host against microorganisms which have not previously been encoun-
tered, and for which the host lacks antibodies. Since this part of the complement system
- unlike the acquired immune system - does not require exposure to antigens prior to
functioning it is classified as part of the innate immune system. As such it poses an
early line of defence against invading microorganisms, including many bacteria, fungi
and viruses [2].
Defence mechanisms by which the complement system act include lysis of foreign cells
via the membrane attack complex, chemotaxis, increase of blood flow at infected sites,
and activation of leukocytes [3, 4, 5], including opsonisation for phagocytosis [6, 7]. The
complement system clears the host of immune complexes [8, 9, 10] and apoptopic cells
[11, 12, 13]. Through its link to the acquired immune system via the classical pathway
the complement system can augment the adaptive immune system’s response [14, 15].
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1.1.1 The Three Pathways of Complement
The complement system can be activated via three different pathways: the classical,
lectin and alternative pathway. The classical pathway is activated by binding of C1q
to IgG or IgM complexed with antigens or by directly binding to pathogen surfaces
[16, 17, 18]. The initiating complex of the lectin pathway is formed when mannose-
binding lectin (MBL) or ficolin bind to mannose residues on pathogen surfaces, making
the lectin pathway part of the antibody-independent innate immune system [19]. The
alternative pathway (AP) is permanently active on a low level, needs to be actively
controlled and can be boosted through a positive feedback loop upon encounter with
pathogens [16]. Of the three pathways of complement, this work is mostly concerned
with the alternative pathway.
1.1.2 Components of the Complement System
Complement proteins make up about 5% of the blood serum globulin fraction. Addition-
ally, the complement system contains a number of membrane bound immune receptors,
some of them integrins [7, 20]. Most of the serum proteins are present as zymogens, with
only a small portion being permanently activated (the so called complement “tick-over”
of the AP [21]). Many of the fluid phase proteins follow a simple nomenclature: one
group (proteins of the classical pathway and the membrane attack complex) comprises
C1q, C1s, C1r, C2, C3 etc. up to C9 (where C stands for C omplement component). A
second group (belonging to the alternative pathway) contains Factor B, Factor D, Factor
I (fI) and Factor H (fH). C3 is a central member of all three complement pathways. Some
proteins have individual names, such as properdin, decay accelerating factor (DAF) or
C4b binding protein (C4bBP). Complement receptors (CR) follow the cluster of differ-
entiation (CD) nomenclature but have often several names - DAF, for example, does
also have the systematic name CD55, and the integrins CR3 and CR4 have additional
names which follow the integrin nomenclature. The numbering of the C-type proteins
reflects the order of discovery rather than functional aspects.
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Upon proteolytic activation, C2-C5 and Factor B split into a (usually smaller) subunit,
named C3a, C5a etc. and a bigger subunit C3b, C5b etc (with the exception of C2, which
is composed of a smaller subunit C2b and a bigger subunit C2a). After cleavage, the a
and b subunits fulfil separate functions: while the bigger subunits form large complexes
like C3bBb or C3BbBb the smaller fragments fulfil signalling functions. C3a and C5a,
for example, are anaphylotoxins [22]. The large complexes are again proteolytic and go
on to activate further molecules, leading to a dramatic amplification and making the
complement system a triggered-enzyme cascade like the blood coagulation system.
1.1.3 The central role of C3b
All three pathways converge at the level of C3, which is comprised of an α chain (111
kDa) and a β chain (75 kDa), held together by a disulfide bond. It is cleaved into the
opsonin C3b (176 kDa) and the anaphylotoxin C3a (9 kDa) by either C4b2a (the classi-
cal and lectin pathway C3 convertase) or the alternative pathway C3 convertase C3bBb.
Nascent C3b exhibits an activated thioester which can covalently bind to cell surfaces,
making the attached C3b molecule the centre of more C3b production (after formation of
C3bBb) and thus initiating a positive feedback loop. C3bBb has a short life time (t1/2 of
only ca. 90 sec [23]) unless stabilized by properdin. After cleaving another C3 molecule
C3bBb forms C3b2Bb, the AP C5-convertase. C4b2a can also cleave C3 to yield the
classical pathway 5-convertase C4b2a3b. Proteolytic cleavage of C5 by C5-convertase
leads to formation of C5b, the starting point of the membrane attack complex (MAC).
C5b assembles C6, C7, C8 and multiple copies of C9. The C5bC6C7 complex is able
to insert into the phospholipid bilayer of cell membranes via a hydrophobic patch on
C7 that becomes exposed during the C5bC6C7 formation. After association of C8 and
up to 16 C9 molecules the complex forms a large pore in the bilayer that results in cell
lysis [24, 25, 26, 27]. C3a, on the other hand, acts as a signalling peptide, increasing
vasolidation, up-regulating complement receptors and serving as a chemo attractant for
leukocytes [28].
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The activation of the thioester bond in C3b - which originates from an unusual post
translational modification of Cys988 and Gln991 [29] - has been described as a two-step
mechanism [30, 31]: in C3, the thioester lies well-protected in a hydrophobic pocket be-
tween the TED (T hioE ster-containing Domain) and MG8 (M acroG lobulin 8) domains,
but cleavage of C3 into C3a and C3b triggers a conformational change which translocates
the TED domain and thioester by 85 Å, exposing the latter and bringing it into close
proximity with His1104 [32]. Following the domain rearrangement, an acyl-imidazole in-
termediate is formed with the His1104 side chain, releasing Cys988 from the ester. This
deprotonated thiolate now acts as a base, conferring higher nucleophilicity to hydroxyl
groups on the substrate surface, which in turn displaces the His1104 side chain from
the acyl-imidazole intermediate. The His-intermediate is extremely short lived with a
half life of less than 100 µs [33] and can be hydrolysed by solvent molecules like wa-
ter. Formation of nascent C3b is, however, likely to take place near target cell surfaces
or immune complexes because C3 convertases are generated on such sites. Thus, the
His-intermediate is likely to react with a cell surface hydroxyl group instead of a water
molecule, leading to covalent attachment of C3b through an ester bond with the Gln991
sidechain. It has been suggested that the presence of negatively charged cell surfaces
might facilitate the dislocation of the TED domain and exposure of the thioester through
electrostatic interactions between a positively charged patch on the TED domain and
the complementary charged cell surface [31]. Additionally, the exact chemical nature
of the binding nucleophile on the target surface has been shown to modulate binding
affinity of the thioester, providing some direct specificity for C3b deposition [34]. This
specificity, however, is not sufficient to discriminate between friend and foe, and in order
to protect autologous cells from deposition of C3b a range of complement regulators are
needed.
1.1.4 Fluid-phase activation of C3
The AP is permanently “switched on” due to a spontaneous albeit slow hydrolysis of
an internal thioester bond in C3 (t1/2 > 6 days, [35]). After hydrolysis, C3 is denoted
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C3(H2O), which has been shown to structurally resemble C3b [36], despite the fact
that it still contains the ANA domain which, after cleavage, forms the anaphylotoxin
C3a (Fig.1.1). The conformational change triggered by the hydrolysis reaction allows
C3(H2O) to bind factor B, which is then cleaved by factor D to yield the fluid-phase
C3 convertase C3(H2O)Bb. This convertase can now catalyse the production of C3b
through proteolysis of C3. Nascent C3b can either be deactivated by hydrolysis of the
critical thioester or follow the above outlined mechanism to opsonise target surfaces,
thereby triggering complement activation on cells.
Figure 1.1: C3 activation by slow hydrolysis (top) or enzymatic cleavage (bottom) lead to
conformational changes which displace the TED domain (dark green). Deactivation of
C3b by fI and co-factors leads to loss of the small C3f fragment, followed by the cleavage
of the TED domain, now dubbed C3dg. Figure taken from [37].
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1.2 Regulation of the Complement System
In order to protect host cells from the complement system it needs to be actively con-
trolled by a group of regulatory proteins, many of which are structurally homologous.
These are fH, C4b-binding protein (C4bBP), decay acceleration factor (DAF, or CD55),
membrane co-factor protein (MCP, also called CD46) and complement receptor type 1
(CR1, also called CD35). Their common structural basis are the so called C omplement
C ontrol Protein (CCP) modules or short consensus repeats (SCR). A CCP module is
typically made of approximately 60 residues which adopt an ellipsoid shape of ca. 30 Å
length and ca. 15 Å diameter. A hydrophobic core is wrapped in β-sheets and stabilized
by two disulfide bonds (cys1-cys3 and cys2-cys4). Conserved amino acids are - along
with the four cysteine residues involved in disulfide bridging - an almost invariant buried
tryptophan between cys3 and cys4, prolines and glycines as well as other hydrophobic
residues (Fig. 1.2). The CCP-domain boundaries are usually defined relative to the N-
and C-terminal cysteine residues cys1 and cys4, respectively, and connected by linker re-
gions of three to seven residues length and variable sequence [38]. N- and C-terminus of
a CCP module lie at opposite ends of the ellipsoid shape, conferring extended structures
to proteins with several CCP domains. FH, C4bBP and their viral analogue vaccinia
virus complement control protein (VCP), which all contain a high percentage of CCP
modules, have been shown to be extremely stable under adverse conditions such as high
temperature and extreme pH values [39, 40]. The high level of structural homology of
CCP domains suggests that this stability is a general feature of CCP domains. Presum-
ably the hydrophobic core and high number of proline residues - both characteristics
of thermophilic proteins - contribute to the stability of CCP modules as well as the
conserved disulfide bonds. Charged patches on the protein surfaces, as present in many
CCP modules, could additionally confer stability as they counteract protein aggregation.
Interestingly, the CCP domain structure has also been found in proteins outside the
complement system. One example is the GABA receptor GABA(B)R1a which occurs
in three splice variants in humans, two of which contain at least one N-terminal CCP
6
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Figure 1.2: NMR structure of the two N-terminal CCP-domains of factor H (CCP 1 and
CCP 2) with highlighted cysteine (orange) and conserved tryptophane residues (red).
PDB entry 1RLP [41].
module [42, 43]. The b subunit of the coagulation factor XIII is also made of 10 CCP
modules [44].
Most of the complement regulators are essentially co-factors to a central protease that
diffuses through blood in its activated form and that does not belong to the CCP struc-
tural family: complement factor I (fI) [45]. The regulators also accelerate the decay of
C3-convertase and act as inhibitors of the convertase formation, consequently their ac-
tivity is usually described as two-fold: decay acceleration and fI co-factor activity. FI can
cleave both C3b and its classical pathway analogue C4b only after co-factor assisted dis-
sociation of the convertase complexes. On cell surfaces, the decay accelerating proteins
comprise the fluid phase proteins factor H (for decay of C3bBb) and C4BP (for decay of
C4b2a) as well as the membrane bound co-factors CR1 (CD35) and DAF (CD55) (both
for decay of the classical and the alternative pathway convertase). After dissociation
from the convertase complex, C3b binds to factor H, CR1 or MCP and is subsequently
degraded to iC3b and C3f by fI [46]. C4b suffers the same fate after binding of C4BP,
CR1 or MCP, leaving C4c and C4d behind. MCP does not have decay accelerating ac-
tivity and DAF lacks co-factor activity. The dissociation and deactivation of fluid phase
C3bBb and C3b, which can arise from the activity of C3(H2O)Bb in solution, is only
assisted by fI and factor H, making factor H the main complement control protein in
7
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the fluid phase and on cell surfaces that lack membrane bound regulators [45]. In the
presence of its co-factor CR1, fI further cleaves iC3b into C3c (140 kDa) and C3dg (35
kDa) which remains bound to the cell surface (Fig.1.1) [47].
It has been noted that the fate of the central complement component C3b can be de-
scribed as a competition between Factor B and fH: binding of Factor B (in the presence
of factor D) initiates formation of C3bBb and the activation of the complement cascade,
while binding of fH (in the presence of fI) results in degradation and deactivation of C3b.
It appears that the immediate environment of C3b determines which of these two ways
is chosen, and subtle contributions of many (de)stabilizing factors could contribute to
the decision.
All regulators of complement activation (RCA) are encoded in a single gene cluster on
chromosome 1q32 [48, 49, 50] (along with CR2 which is also made of CCP modules but
does not share the regulatory functions of its genetic neighbours). Despite individual
activity profiles and some varying structural characteristics like membrane anchors, all
RCAs are entirely or almost entirely composed of CCP modules and form a homologous
protein family which could have arisen from gene duplication and exon shuffling.
Jules Bordet found as early as 1898 that exposure of serum to foreign erythrocytes leads
to cell lysis, easily detectable through the liberation of haemoglobin. It is now known
that some foreign erythrocytes act as AP activators (such as rabbit erythrocytes), while
others are non-activators of the AP (such as red blood cells from sheep).
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1.3.1 Biological significance and overall structure of Factor H
FH is the principal complement regulator in the fluid phase, but its significance extends
beyond the fluid phase. Some host structures lack membrane-bound regulators, among
them basement membranes and kidney glomeruli [51, 52]. For these cells, fH is the
only known down-regulator of the AP, and, through the central role of C3b, of the late
complement cascade. FH also seems to contribute significantly to the protection of at
least some cell types that do possess membrane-bound regulators, as has been shown for
human erythrocytes [53]. It is an abundant (100-500 µg/mL [54]), single chain plasma
glycoprotein of about 155 kDa (1213 residues) which is - like most complement proteins
- expressed mainly in hepatocytes [55]. Different opinions have been voiced with respect
to the question if fH undergoes self-association. Transmission electron microscopy has
led to the conclusion that fH is a monomer [46], while x-ray and neutron solution scat-
tering suggested dimerisation in the same concentration range (1-10 mg/ml) [56]. It is
possible that fH has a small tendency to multimerise and that this tendency increases
in the presence of metal ions or polyanions, the latter of which which are thought to be
an important ligand to fH [57, 58].
FH has nine potential N-glycosylation sites, eight of which exhibit glycosylation in vivo
[59]. The physiological glycosylation sites are located in fH∼9, fH∼12, fH∼13, fH∼14,
fH∼15 (twice), fH∼17 and fH∼18. Its protein moiety consists of a single polypeptide
chain of 20 CCP modules, while the carbohydrate moiety is inhomogeneous and not
required for fI co-factor activity [59, 60]. The 20 domains are connected through short
linker regions of 3-8 residues and fH is often schematically depicted as 20 “beads on a
string”. Transmission electron microscopy has shown that it is indeed elongated and
flexible, albeit not necessarily linear. Instead, the structural flexibility of at least some
of the linkers lead to a number of different conformations with differing cross sections
[46]. Sedimentation velocity experiments along with x-ray and neutron solution scatter-
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ing and molecular dynamics simulation led to the conclusion that full-length fH bends
back upon itself [61]. Recently, it has been found in a NMR structural study that not all
linker regions do confine flexibility. Long linkers in the middle region of fH might well
be rigid and responsible for significant back-bending of the protein, possibly bringing
binding sites for different interaction partners closer in space than a linear arrangement
would permit [62].
A number of so called factor H-related proteins (fHR1 - fHR5) are encoded in close
proximity of the fH encoding gene on 1q32. There is also a truncated splice variant of
fH (factor H-like protein, fHL-1) which maintains fI co-factor activity [63, 64, 65].
1.3.2 Interaction partners of fH
Two fH binding sites for C3b have been reported and confirmed by different studies, lo-
cated in fH∼1-4 and fH∼19-20 [66, 67, 68]. However, there is no consensus about a pos-
sible third binding site which has been proposed for fH∼6-10 [66] and alternatively near
or within fH∼12-14 [67]. Only fH∼1-3 is essential for the fI-co-factor activity, though
fH∼4 additionally contributes significantly to it [41]. The four N-terminal domains are
therefore usually referred to as the regulatory domains. A C-terminal C3b/polyanion
binding site in fH∼19-20 is necessary for the prevention of AP activation on host cells
[69] and therefore has been said to contain the central host recognition element. Cell
surface polyanions and sialic acid are known to play a central role in the recognition
process. Enzymatic removal of the latter from cell surfaces averts fH binding and turns
non-complement-activating sheep erythrocytes into complement activators [70]. Sialic
acid residues often form the head group of glycans, extracellular carbohydrate chains
that are attached to glycoproteins and gangliosides, which are both part of cell mem-
branes. Even a slight chemical alteration of cell surface sialic acid residues results in
loss of fH-mediated protection from the AP on sheep erythrocytes [71]. Synthetic li-
posomes that contain physiological glycolipids become subject to lysis through the AP
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upon removal of sialic acid residues [72]. Sialation of the complement activator Neisseria
gonorrhoeae results in C3 conversion to iC3b, signalling binding and co-factor activity of
fH. Mutant studies located the responsible binding site for this interaction in fH∼16-20
[73]. Heparin, a close relative of heparan sulfate which is found on cell surfaces as carbo-
hydrate moiety of proteoglycans (so-called heparan sulfate proteoglycans, HSPGs), can
convert activators of the AP into non-activators when associated with the cell surface
[74]. Several polyanions enhance the affinity of fH to activator-bound C3b, among them
dextran sulfate, heparin and DNA. Interestingly, polysialic acid did not show this effect,
provoking the hypothesis that the sialic acid head group might be part of a larger bind-
ing epitope which possibly contains further (negatively charged) carbohydrate residues
[75]. Since heparan sulfate does naturally occur on cell surfaces and in the extracellular
matrix it is among the possible ligands for fH, and heparin/HS are often employed as
mimics for the yet unidentified in vivo ligand. The quest for the physiological ligand is
complicated by the natural heterogeneity of cell surface polyanions and the fact that fH
protects a variety of cell surfaces, leaving the possibility of several structurally diverse
ligands instead of a single specific interaction.
Binding of fH to C3b-coated erythrocytes can be significantly inhibited by recombinant
fH∼19-20 for both human and sheep cells, while the fluid-phase regulation of C3b is
unaffected by the addition of fH∼19-20. It has been shown, however, that on a broader
range of cells contributions to the recognition process are made by different regions of
fH, and that the weight of each of these regions for a specific recognition process varies
among different AP activators [76]. While for C3b-coated sheep erythrocytes fH∼16-20
contribute most to the binding affinity of fH, fH∼1-10 seem most important for C3b-
coated human erythrocytes and fH∼6-10 as well as fH∼16-20 are central for C3b-coated
rabbit erythrocytes [76]. Cultured endothelial cells have been shown to bind full-length
fH and a truncated version of the protein encompassing fH∼ 15-20 with comparable
strength [77], but generally C3b deposition on cells seems to be a requirement for fH
binding to the cells [78].
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A cluster of mutations in the two C-terminal modules has been found to be related to
a rare but severe renal condition, atypical hemolytic uremic syndrome (aHUS), which
might be caused by a change in the polyanion recognition abilities of fH∼19-20 [69].
Indeed, several disease-linked mutations are found in the heparin binding site in fH∼20
[79]. Several genetic studies suggest that another mutation in fH, Y402H in fH∼7, plays
a role in the development of age-related macular degeneration (AMD) [80, 81, 82], the
leading cause of blindness in the elderly Western population. Although many factors
may contribute to this disease, including features of lifestyle such as smoking [83], the
existence of heparin binding sites in these modules point to the possibility of polyanion
involvement in the pathophysiology of the diseases. The connection of these conditions
with mutations in different fH modules supports the hypothesis that individual sites in
this multi-modular protein contribute differently to the recognition of various tissues,
relying on mediation by cell specific polyanion patterns.
FI needs fH or another co-factor to bind to C3b (or C4b) in order to fulfill its enzymatic
task of cleaving C3b into iC3b (at positions 1281 and 1299). The third cleavage, assisted
by CR1, produces C3c (140 kDa) and C3dg (35 kDa). FI activity can be tested via the
breakdown of fluid phase C3b in the presence of fH or another co-factor. After disulfide
reduction two fragments of the α’-chain of iC3b can be observed, one of 68 kDa and
one of 43 kDa size (Fig.1.3). This assay can also be employed to assess the fH co-factor
activity [45]. FI cleaves a range of bonds in both C3b and C4b and daughter products
and its specificity is relatively low. The amount and exact nature of all FI proteolysis
products in the presence of the co-factors depends on salt concentration and pH and
non-physiological co-factor activity of complement regulators has been described under
favourable conditions [47].
C-reactive protein (CRP), an acute phase protein whose concentration in the blood
plasma rises dramatically upon inflammation, has been reported to bind to fH∼7 and
fH∼8-11 [85, 86]. This interaction has been much disputed: in vivo CRP adopts a
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Figure 1.3: Schematic Figure of C3, C3b and iC3b with chains and cleavage positions of fI
in the presence of fH or another co-factor. Taken from [84].
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relatively fragile pentameric structure which is only stable in the presence of Ca2+, and
degradation or unfolding of this complex structure have been made responsible for the
binding of fH [87]. To date, no study has proved an interaction of the two proteins in
vivo.
1.3.3 FH-related disease
A number of diseases have been associated with deficiencies or genetic modifications
in the fH gene and/or other complement proteins. Deficiency of fH can, through high
turnover and consequently low C3 serum levels, lead to membranoproliferative glomeru-
lonephritis (MPGN or dense deposit disease) and, in case of homozygous deficiency,
atypical haemolytic-uraemic syndrome (aHUS) [88]. A cluster of mutations in the two
C-terminal modules has also been found to be linked to this rare but severe renal condi-
tion which might be caused by a change in the polyanion recognition abilities of fH∼19-20
[69]. Indeed, several disease-linked mutations are found in the heparin binding site in
fH∼20 [79]. Several genetic studies suggest that another mutation in fH, Y402H in fH∼7,
plays a role in the development of age-related macular degeneration (AMD) [80, 81, 82],
the leading cause of blindness in the elderly Western population. Although many factors
may contribute to this disease, including features of lifestyle such as smoking [83], the
existence of heparin binding sites in these modules point to the possibility of polyanion
involvement in the pathophysiology of the diseases. The connection of these conditions
with mutations in different fH modules supports the hypothesis that individual sites in
this multi-modular protein contribute differently to the recognition of various tissues,
relying on mediation by cell specific polyanion patterns.
1.3.4 Atypical haemolytic uraemic syndrome
AHUS is characterised by thrombocytopenia, renal impairment and microangiopathic
haemolytic anaemia. A possible mechanism for aHUS assumes a badly controlled AP
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which leads to excess deposition of C3b on renal cells and, simultaneously, to increased
inflammatory cell recruitment through release of the anaphylotoxin C3a. MAC forma-
tion and non-lytic membrane perturbation as consequences of uncontrolled C3b depo-
sition could be responsible for thrombosis in aHUS [89] and for a reduced flow across
the glomerular membrane, which could be blocked with immune complexes. Mutations
in fH which have been linked to aHUS cluster in the polyanion/C3b binding site in
fH∼19-20 but do also occur in other regions of fH [90]. Some of these mutations simply
lead to low expression levels of fH. Studies of aHUS associated mutations, along with
NMR- [79] and x-ray [91] structures of the two C-terminal domains of fH, have come
to different conclusions as to whether the C3b or polyanion binding site on fH∼19-20 is
disturbed by the mutations [92, 93, 94, 95]. Very recently, it was shown that neither of
both interaction partners alone is a marker for aHUS but that very likely the formation
of a ternary complex is impaired [96]. It seems evident that a slight misregulation of the
AP in some of the characterised aHUS mutants predisposes to aHUS. The hypothesis
that slight misregulations of the complement system are at the heart of diseases such
as aHUS and AMD is supported by the link of mutations in complement proteins other
than fH to these diseases. In particular, gain-in-function mutations in Factor B which
lead to increased stability of the C3bBb complex fit into this picture, underlining how
increased stability of C3-convertase could result in similar consequences as decreased
activity of fH or other complement regulators [97].
1.3.5 Age related macular degeneration
Age related macular degeneration (AMD), the leading cause of blindness in the elderly
Western population, is strongly linked to a common SNP in fH’s module 7, Y402H
[80, 81, 82, 98, 99]. Unlike aHUS, whose first outbreak is acute, AMD is a chronic
disease in which protein rich drusen is slowly accumulated between the basal lamina of
the retinal pigment epithelium (RPE) and the innermost layer of Bruch’s membrane,
which forms the layer between the retina and the choroid. Characterisation of the de-
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posit’s composition led to the discovery of an accumulation of complement proteins
(among other components) in the drusen and to the conclusion that AMD is histologi-
cally related to other extracellular deposit diseases, such as atherosclerosis, amyloidosis
(among which are Alzheimer disease and Prion diseases) and dense deposit disease (also
called Membranoproliferative glomerulonephritis, MPGN, affecting the kidney glomeru-
lus) [100]. AMD is further subdivided into wet and dry forms of the disease. Wet AMD is
associated with abnormal neovascularization, while dry AMD results in atrophy of RPE
cells. The formation of drusen occurs in dry and wet AMD, both of which eventually
lead to degeneration of the RPE and loss of macular vision. Among the complement
components found in drusen are C3, C5, C5b-C9 (the components of the membrane
attack complex), CRP and fH [100, 101, 102]. The link between the fH variant Y402H
and the disease has prompted the hypothesis that an altered ability to recognize RPE
cells in this variant could be responsible for the formation of drusen through diminished
protection from the complement system. A binding study using both protein variants
and primary RPE cells did not find different affinities for the two variants [103], while
another one did [104]. The controversy around potential reasons for the fH-linked genetic
predisposition for AMD generally overlaps with the controversy concerning the question
whether CRP and fH interact in vivo [103] since both proteins have been detected in
the deposits. The hypothesis that an altered recognition process is at the centre of
AMD is supported by age-related changes in the retinal cell surface charges: an altered
polyanion pattern on these surfaces could trigger the disease through impaired protec-
tion by factor H. Diabetis and smoking have been identified as risk factors for AMD,
both of which are associated with increased formation of so-called advanced glycation
endproducts (AGEs). The accumulation of AGEs in the retina has been linked to both
diabetic retinopathy and AMD and is a process that is generally enhanced in ageing eyes
[105, 106, 107].
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1.3.6 Complement evaders
It is noteworthy that while fH aims to prevent host cells from attacks by the comple-
ment system, some pathogens have developed ways to acquire fH and other complement
regulatory proteins in order to overcome the innate immune defence by “disguising” as
host cells [108]. Among these complement evaders is Neisseria menigitidis, the bacteria
responsible for meningitis, as well as Neisseria gonorrhoeae [109].
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Defensins are small (3.5-6 kDa) antimicrobial peptides which are rich in cysteine and
the cationic residues arginine and lysine. They act as bactericidal agents against Gram-
positive and -negative bacteria, fungi and some enveloped viruses, which they kill through
the formation of channels in lipid bilayers or disruption of these structures. They are
also cytotoxic and thus usually stored in granules, to be released only into the vacuoles of
phagocytic cells, so that no harm is done to the host organism [110]. The destabilization
of lipid bilayers might be conferred by the presence of aliphatic patches on their surfaces,
allowing the interaction with hydrophobic structures such as lipids. Among their targets
are Escherichia coli, Staphylococcus aureus (human beta defensin 3) Candida and the
Herpes simplex virus [111]. Just like many proteins of the Complement AP, defensins
are among the effector molecules which are mobilised or activated by the innate immune
system in response to a breech of the epithelial barrier by pathogenic microorganisms.
Defensins also act as chemokines and thus also play a role as mediators of the host
defence. Defensins contain a large proportion of cysteine residues and are classified
according to their disulfide pattern. In β-defensins, the disulfide scaffold follows the
pattern cys1-cys5, cys2-cys4, cys3-cys6 (in α-defensins, cys6 and cys5 are swapped). All
human β-defensins that have been structurally analysed so far - that is, HBD1-3 - display
pronounced positively charged patches. HBD2, in addition, bears a large hydrophobic
patch on the face opposite the positive patch (Fig 1.4).
HBD2 is produced and released by kerotinocytes following stimulation through contact
with the lipopolysaccharides on the surface of Gram-negative bacteria or through cy-
tokines such as interleukin (IL)-1β and tumor necrosis factor (TNF)-α. It possesses
antimicrobial activity against Gram-negative bacteria and the yeast Candida but not
the Gram-positive S. aureus, which is antagonised by HBD3 [113]. The permanent ex-
pression level of HBD-2 is low, but pro-inflammatory induction leads to a large increase
in expression. The main tissue types which produce HBD-2 are skin, lung and trachea
[113].
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Figure 1.4: Electropositive and aliphatic faces of monomeric solution structure of HBD2,
calculated in PyMOL. Red and blue refer to negative and positive electropotentials,
respectively (PDB entry 1FD3 [112]).
Due to their relative recent discovery, the amount of data on the biochemical nature
and mode of action of β-defensins (and defensins in general) in the literature is still
limited. However, one x-ray and two NMR structures of HBD2 have been published
[112, 114, 115]. Uniformly, the peptide has been described as containing a three-stranded
β-sheet which is stabilized by two disulfide bonds. Additionally, there is a small α-helix
which passes opposite the sheet and forms a disulfide bond with strand β2 (Fig. 1.5). In
the x-ray crystals, HBD2 forms dimers which - through interactions of the two β1 strands
- give rise to a six-stranded β-sheet [112]. Four such dimers are arranged in a symmetric
octameric assembly, with no evidence of formation of a pore between the monomers (Fig.
1.6). The mode of action by which HBD2 interrupts cellular integrity of invaders is thus,
according to the crystallographers, not to be described by membrane pore formation, a
mechanism that had been proposed elsewhere for the anti-microbiol activity of defensins
[116]. Instead, it was postulated that a uniformly positively charged site of the octamer
disrupts membranes via electrostatic interactions with the polar heads of the membrane-
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forming lipids. Both NMR structures describe HBD2 as a monomer in solution, assuming
the multimeric assembly found in the x-ray structure was mainly reflective of high protein
concentrations, but not entirely dismissing the proposed mechanism for possible high
local concentrations [115]. The absence of a hydrophobic core in HBD2 was noted [115],
stressing the importance of the conserved disulfides for the overall fold.
Figure 1.5: Secondary structure elements and disulfide bridges in HBD2: α-helix (blue)
from residues 4-11, β-strands (red) from residues 14-16, 25-28 and 36-39, and three
conserved disulfide bridges (green). PDB entry 1FD3 [112].
Figure 1.6: HBD2 a) monomer, b) dimer and c) octamer as found in the protein crystal.
Taken from [117].
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Growth factors are proteins which stimulate cell proliferation and differentiation and are
therefore critical during foetal development and for repair mechanisms following injury.
The hepatocyte growth factor / scatter factor (HGF/SF) was simultaneously discovered
in two different functions: as a mitogenic factor in hepatocytes and as a scattering fac-
tor in epithelial cells. HGF activates the receptor tyrosine kinase mesenchymal-epithelial
transition factor (MET, also called HGF-receptor) [118], which in turn initiates differ-
ent signal transduction pathways, all of which are related to developmental processes.
The mechanism by which HGF activates MET involves dimerisation of the membrane-
bound receptor upon binding of HGF to the extracellular portion. This dimerisation
activates MET for subsequent crosswise autophosphorylation of two tyrosine residues,
Y1234 and Y1235 [119]. Misregulation of the proto-oncogene met, which encodes the
transmembrane receptor, leads to tumorigenesis and metastasis [120]. Consequently, the
HGF-MET interaction is a target for cancer research [121].
The HGF precursor is a single polypeptide chain which is cleaved by HGF-activator
(HGFA) at position R494 to yield the so-called heavy chain (ca. 60 kDa) and light (ca.
34 kDa) chain. Both chains remain attached to each other through a disulfide bond
[122]. The heavy chain is comprised of an N-terminal domain (N) and 4 kringle domains
(K1-K4), each containing three conserved disulfide bonds. The light chain is structurally
classified as a serine protease-like domain (and thus abbreviated SP-domain) but it does
not show actual protease activity (Fig. 1.7).
The N-domain displays a largely positively charged surface as often seen for heparin
binding domains, and its interaction with heparin has been characterised by chemical
shift mapping and NMR dynamics measurements [124, 125] as well as by x-ray crystal-
lography [126]. Heparin rigidifies the otherwise relatively loose N-domain as indicated
by relaxation time measurements, additionally, the glycosaminoglycan increased the sta-
bility of the N-domain against disulfide bond reduction with dithiothreitol (DTT) [125].
The N-terminus of NK1 gave only weak electron density in a x-ray crystallography study
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Figure 1.7: Schematic overview of naturally occurring isoforms of HGF. In full-length HGF,
the heavy chain (red, comprised of the N-terminal and the four kringle domains) and
the light chain (blue, containing the SP domain) stay attached through a disulfide bond
after proteolytic cleavage at R494, while NK2 and NK1 are only comprised of heavy
chain modules. Taken from [123].
of the free protein [127] and no NH crosspeaks [124] in the isolated N-domain. A mu-
tagenesis study suggested that these residues are important for heparin binding [128],
yet most of the residues which were identified in this study are not part of the heparin
binding site as described in the x-ray study of the heparin-NK1 complex.
Heparin, heparan sulfate and dermatan sulfate have been shown to act as co-factors for
the HGF-MET interaction [129, 130, 131, 132, 133]. However, the question of whether
glycosaminoglycans (GAGs) are actually necessary for activation of MET by HGF is
somewhat controversial [134, 135, 136, 137]. It has been reported that MET, just like
HGF, has a high affinity for HS and that, in the presence of HS, MET activation can
take place even in the absence of full-length HGF but in the presence of its first kringle
domain, K1 [123]. The GAG-binding site in HGF, although mainly contained in the
N-terminal domain, extends into the first of the four kringle domains, together termed
NK1 [138, 125]. A smaller contribution to GAG binding is made by the kringle domain
2, and the protein comprised of these three domains was termed NK2 [139]. NK1 and
NK2 are both splice variants of HGF [140]. Their physiological role is not precisely
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known. NK1 has been characterised both as an HGF antagonist which competes with
HGF for binding of the MET receptor but does not trigger its autophosphorylation
and downstream signalling cascade [141] as well as a “partial agonist” which stimulates
cell proliferation, migration and branching morphogenesis through activation of MET
[140, 142, 143]. GAG binding to NK1 has been shown to be necessary at least for some
of HGF’s physiological functions that can be assumed by NK1 [134]. The crystal study
of the heparin-NK1 complex (using a heparin 14mer) reported two different types of
crystals but many conserved heparin-GAG interactions in all protomers present in these
two crystal types [126]. A network made of hydrogen bonds and ionic interactions is
observed in the N-domains of both crystals and involves residues K60 (sidechain), T61
(backbone), K63 (backbone) and R73 (sidechain). In one crystal form, K58 (sidechain)
and K62 (sidechain) provide additional hydrogen bonds. As often observed in protein-
GAG complexes the binding site was located on the surface of the protein and a relatively
short stretch of four pyranose residues was found to provide the key interactions in the
N-domain in both crystal types (Fig. 1.8). The longest heparin oligosaccharide which
was found to have a well-defined electron density in this study does additionally maintain
contacts to the K-domain of a different protomer.
Figure 1.8: Details from a NK1:heparin X-ray structure: A) N-domain with heparin binding




Glycosaminoglycans (GAGs) are linear polysaccharides of widely varying molecular
weights which are present on all animal cell surfaces and in the extracellular matrix.
GAGs are usually linked to protein side chains, forming the macromolecular superfamily
of proteoglycans. They are classified according to repeating disaccharide units which
make up their primary structure and which can be sulfated or acetylated to different de-
grees. A common classification of GAGs uses four different groups: the hyaluronic acid
type, the heparin/heparan sulfate (HS) type, the chondroitin/dermatan sulfate (DS)
type and the keratan sulfate type (Fig. 1.9). This work focuses mostly on heparin/HS
and dermatan sulfate.
Figure 1.9: Schematic overview of the different classes of GAGs. S and A labels in heparan
sulfate denote sulfated and non-sulfated domains, respectively. Taken from [144].
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1.6.1 Heparin and Heparan sulfate
Heparin is different from other GAGs - including HS - because it is synthesized as proteo-
glycan but subsequently cleaved from the protein core to give a heterogeneous mixture,
comprising linear chains of molecular weights between 5,000 and 25,0000 Da [145]. It
is then stored in secretory granules of mast cells where it was expressed until the gran-
ules are released upon external stimuli such as IgE-antigen complexes or complement
anaphylotoxins [146, 147]. Heparin is best known for its anti-inflammatory and antico-
agulating activities. HS, on the other hand, is expressed in a variety of different cells.
It is, however, structurally closely related to heparin and made from the same building
blocks. Both species share identical glycosidic linkages. Disaccharides of the heparin/HS
type are comprised of glucosamine and hexuronic acid residues, both of which can be
sulfated in different positions and, additionally, acetylated on the amino group of the
glucosamine. One structural difference between heparin and HS lies in the overall degree
of sulfation (Fig. 1.9): heparin exhibits a relatively homogeneous and high level of sul-
fation, while in HS sulfated domains (so called NS-domains) alternate with non-sulfated
domains (NA-domains), linked by transition domains with an intermediate degree of sul-
fation. The maximum length of one NS-domain is around 8-9 disaccharides [148, 149].
Small oligosaccharides from HS-NS-domains are identical to those isolated from heparin,
while less sulfated species can only be obtain from HS or from heparin after subsequent
chemical desulfation. Besides the higher degree of sulfation in heparin/HS-NS-domains
these structures differ from HS-NA-domains by the relative amounts of glucuronic acid
(GlcA) versus iduronic acid (IdoA), the latter of which is more abundant in heparin/HS-
NS-domains.
In vivo, HS is synthezised as linear chains of alternating α-D-GlcNAc-(1→4) and β-
D-GlcA-(1→4). Subsequently, both residues are modified by a set of specific enzymes
which catalyse deacetylation, sulfation and epimerisation (of D-GlcA to L-IdoA). How-
ever, these enzymes do not quantitatively modify the heparin/HS raw structure, even-
tually leading to a complex mixture of slightly differing stretches. Some of the process-
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ing steps are inter-dependent, i.e. deacetylation/sulfation of GlcNAc residues (yielding
GlcNS residues) allows epimerisation of the GlcA residues at the non-reducing end of
the GlcNS residues, giving rise to IdoA-GlcNS disaccharides. This stretch can further be
subject to O-sulfation on the C2 position in IdoA and the C-6 position in GlcNS [150].
O-3 sulfation of the GlcN residue is less frequent but essential for the HS-antithrombin
interaction. Antithrombin, a serine protease, acts as an inhibitor of the coagulation
cascade. Through formation of a complex with HS chains of proteoglycans on the lu-
men of vascular endothelial cells it is brought into proximity of its substrate thrombin,
which is generated at the blood-surface interface and which also binds to HS [151]. In
heparin and HS-NS-domains the most abundant disaccharide is α-L-IdoA2S-(1→4)-α-
D-GlcNS6S (Fig. 1.10). GlcA residues occur prevalently instead of IdoA residues in
the HS-NA-domains, leading to a smaller degree of overall sulfation as GlcA is less eas-
ily sulfated than IdoA by the 2-O-sulfating enzyme of the heparin building pathway,
urosonyl-2-O-sulfotransferase [152]. The glycosidic linkages in the heparin/HS group
of GAGs are 1→4 and the sugar rings adopt α, α(GlcN, IdoA)- or α, β(GlcN, GlcA)-
configuration, though an equilibrium between α- and β-configurations occurs in the
reducing end residue in isolated oligosaccharides. This is heavily shifted towards the
α-form.
Figure 1.10: The most abundant disaccharide in heparin, α-L-IdoA2S-(1→4)-α-D-
GlcNS6S.
HS is a regulator involved in a variety of processes, ranging from blood coagulation to
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angiogenesis. In HS, the sulfation density of the 2-position of IdoA and of the 6-position
as well as the amino group of GlcN vary depending on tissue type and organism and
are determined by the originating cell type and organism rather than the protein which
carries the HS chain [145, 153]. Taken together with the rare but biologically impor-
tant sulfation of the 3-position in GlcN and the alternation of GlcA and IdoA residues,
the incomplete sulfation of the IdoA and GlcN residues leads to an outstanding feature
of heparin/HS and other GAGs: pronounced chemical heterogeneity. The disaccharide
composition of HSPGs in different tissues has been identified as a possible bio-marker,
especially in the field of oncology [154, 155, 156]. Since the HS-fingerprint also changes
with age it has implications for age-related diseases [157, 158]. The great variety in com-
position and sulfation levels makes it difficult to investigate GAG-protein interactions
in detail. The question of the exact GAG epitope for a specific interaction is not trivial
and gains in complexity with increasing minimum GAG binding length - a heparin/HS
disaccharide can accommodate 23 different primary structures out of 48 theoretically
possible structures, some of which do not occur in vivo due to enzymatic restrictions in
the heparin/HS pathway [152]. Heparin obtained from different sources, if not further
processed and thoroughly characterised, may well lead to different results in a series of
analogous experiments due to different prevalences of sulfation composition in the indi-
vidual preparations.
The inherent flexibility of the glycosidic linkage and the coexistence of different confor-
mations of the IdoA residues lead to large potential flexibility in the structure of heparin.
While GlcNS and GlcA adopt the usual 4C1 chair conformation, internal IdoA residues
in heparin, HS and DS exist in an equilibrium between the 1C4 chair and the
2S0 skew-
boat conformations in the liquid state. In other scenarios, such as non-reducing terminal
residues, in monosaccharides or synthetic oligosaccharides, IdoA can also adopt the 4C1
chair conformation [159] (Fig. 1.11). The main conformation in a given polysaccharide is
influenced by other structural factors such as the preceding residue and the positions of
sulfate groups [160]. Coordination of counterions could also be an important factor as it
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requires a specific orientation of the ligating groups - copper, for example, is coordinated
by the IdoA residues in heparin and requires the planar orientation of the coordinating
groups that is often observed in copper complexes [161].
.
Figure 1.11: Conformations of IdoA. Internal IdoA residues in heparin, HS and DS inter
convert between the 1C4 chair and the
2S0 skew-boat. In other contexts, the
4C1 chair
has also been observed.
Complexes with some proteins have been found to favour one specific conformation of
the IdoA residues - the 2S0 skew-boat, for example, in the antithrombin III - heparin
pentasaccharide complex [162], the 1C4 chair in the histamine-heparin tetrasaccharide
complex [163] - while other proteins do not seem to lock the IdoA ring in any spe-
cific conformation [164]. Both heparin with all IdoA residues in the 2S0 conformation
and heparin with all IdoA residues in the 1C4 conformation result in overall similar 3D
structures, as elucidated by NMR and molecular modelling [165]. In this study, two
dodecasaccharides were generated based on NMR NOE data and molecular modelling.
Both forms adopt an α-helical shape with a pitch of ca. 17 Å, corresponding to ca. 4
residues per turn. This helical 3D structure has also been found by a recent 1H-1H NOE
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and molecular dynamics study on 13C labelled heparin and its precursors. The transition
from N-acetylheparan to heparin was accompanied by rigidification of the helical chain
[166]. It is noteworthy that the exact orientation of the sulfate groups with regard to the
helical axis changes when the IdoA residues undergo conformational changes despite the
preservation of the helical shape. Though the interconversion between the 1C4 and
2S0
ring forms provoke relatively small changes in the geometry of the glycosidic linkages to
neighbouring rings - hence the preservation of the helical shape - the spatial orientation
of sulfate groups in the IdoA residues experiences marked changes [167]. The inves-
tigation of a fully sulfated tetrasaccharide via NMR-measurements of residual dipolar
couplings also concluded that the flexibility of the IdoA residues had a limited effect on
the molecular shape of heparin [168]. The differences in the orientation of the sulfate
groups depending on the IdoA conformation might explain the preference of some pro-
teins to bind to specific conformations of the IdoA residues. Additional modifications in
the spacing and exact orientation of the sulfate groups can be accommodated by changes
in the glycosidic dihedral angles, leading to an improved fit of heparin into binding sites
of different proteins. The resulting oligosaccharide structures can be described as con-
taining kinks or helical overwinds when compared to the structure of free heparin [169].
During this project small oligosaccharides were used which were obtained from heparin
via enzymatic digestion with heparinase I. Heparinase III, which cleaves HS instead of
heparin, is less robust and therefore less suited for in vitro work. Because sulfated and
non-sulfated domains alternate in HS but not in the more heavily sulfated heparin (see
Fig. 1.9), enzymatic digestion of HS leads to a larger variety of oligosaccharides. In
the binding experiments conducted as part of this project, however, only fully sulfated
oligosaccharides were used as ligands (with the exception of the fH∼19-20 titration with
size-fractionated octasaccharide). These species can be obtained from both HS and
heparin, but yields are higher when using heparin. Since heparin and HS protein in-
teractions are very often dominated by charge-charge interactions [170, 171, 172] the
question of the raison d’être of non-sulfated domains in HS is at hand. It is possible
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that the reason for their existence is of more general nature than the specific interac-
tions with certain proteins. In their physiological environment, HS chains are attached
to protein cores of proteoglycans such as syndecans or collagen XVIII. Especially in an
extracellular environment proteoglycans often contribute to the physical properties of
their environment, conferring strength, elasticity or, in the case of hyaluronic acid in
the joints, viscosity. These physical properties are likely connected to the overall charge
and charge distribution of proteoglyan sidechains, for example via their degree of hy-
dration. Larger flexibility of non-sulfated regions in HS [166] may well be required for
proper positioning of sulfated domains near membrane bound receptors. Heparin, on
the other hand, is confined to intracellular vascules in mast cells and not found in the
extra cellular matrix. Being the physiological molecule with the largest negative charge
density it might be used to neutralize positively charged biomolecules (i.e. histamine and
proteases) stored in secretory granules [173]. In the light of the different physiological
distribution of heparin and HS it is possible that the dual function of HS - binding of
specific proteins as well as contributing to the physical properties of extracellular envi-
ronments - is represented in its irregular domain-based structure.
The physiological HS synthesis, unlike DNA and protein production, is a non-template
driven process. The exact nature of a HS molecule is a consequence of different enzymatic
modifications and is therefore, through expression and activity levels of the modifying
enzymes, linked to regulation processes which take place on a different cellular level,
making the field of ”heperonomics“ a subject matter for system biologists [174].
1.6.2 Dermatan sulfate
Dermatan sulfate (DS), originally termed chondroitin sulfate B, contains N -acetyl-galac-
tosamine residues instead of N -glucosamine, with β-D-GalNAc-(1→4) and α-L-IdoA-
(1→3) and α-L-IdoA-(1→4) glycosidic linkages. Unlike HS, DS exhibits relatively uni-
form 4-O-sulfation of the GalNAc residues, while 2-O-sulfation of IdoA is less frequent
than in HS. Additionally, 6-O-sulfation can occur in the GalNAc residues. The most
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abundant disaccharide unit in DS is α-L-IdoA-(1→3)-β-D-GalNAc4S (Fig. 1.12) leading
to a smaller overall sulfation density in DS when compared to heparin. Like HS, DS oc-
curs in the ECM and promotes angiogenesis and other developmental processes as well
as wound healing through its interaction with various growth factors [132, 175, 176].
DS interacts - albeit comparably weakly - with many HS/heparin-binding proteins
[177, 178, 179], suggesting an overall functional overlap for both GAGs.





HS-protein interactions play a key role in a wide range of biological contexts, many
of which are developmental processes. Among the interacting proteins are promoters
of angiogenesis (fibroblast growth factors), cell adhesion (fibronectin) and cell growth
(hepatocyte growth factor/scatter factor), regulators of cellular communication (inter-
ferons) as well as different enzymes of the blood coagulation cascade. HS chains make
up a part of the extracellular matrix where they fulfil scaffolding purposes. Many of
the HS/protein interactions are transient, serving the purpose of recruiting proteins
into proximity of other proteins or cell surfaces where they subsequently execute their
enzymatic functions. As a consequence, many HS-binding proteins lack a pronounced
binding groove and do not undergo large conformational rearrangements upon GAG
binding. This particular characteristic, along with the structural flexibility of the HS-
chains, make HS-protein interactions a challenging target for docking studies.
One of the best-studied protein-heparin interactions is the complex formed by antithrom-
bin and a heparin or HS pentasaccharide. Antithrombin is a serine protease inhibitor
which inactivates several enzymes of the coagulation cascade, among them thrombin
(hence its name) and Factor Xa. The interacting HS chains line the inner walls of the
micro vascular system. The interaction of antithrombin with thrombin (Factor IIa) and
Factor Xa is greatly enhanced in the presence of heparin, albeit to different degrees.
It has been shown that antithrombin is activated by a specific pentasaccharide mo-
tif with the sequence α-D-GlcNAc/NS(6S)-(1→4)-β-D-GlcA-(1→4)-α-D-GlcNS(3S,6S)-
(1→4)-α-L-IdoA(2S)-(1→4)-α-D-GlcNS(6S), with the rare 3-O-sulfation being of special
importance [180]. Binding to this oligosaccharide induces a conformational change in
antithrombin’s active site [181, 182]. Factor Xa does itself not bind to HS, but for
the inactivation of thrombin by antithrombin HS chains act as a scaffold for both pro-
teins, bringing them close enough in space for the enzymatic deactivation of thrombin.
The structural requirements of antithrombin and thrombin with respect to heparin/HS
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differ: while for antithrombin the above mentioned pentasaccharide binds with much
higher affinity than other heparin-derived oligosccharides, thrombin interacts with hep-
arin hexasaccharides without a pronounced preference for any primary structure [152].
In the tertiary complex both binding sites on the GAG chain need to be separated by
an octasaccharide, resulting in a minimum length of the binding HS oligosaccharide of
nineteen sugar units. Thus, although thrombin itself does not require a specific binding
motif there is a necessity for two protein binding sites in a defined distance on the HS
chain. Because one of these protein binding sites has specific requirements (the one for
antithrombin) the overall frequency of this arrangement is rare, imposing more specificity
on the thrombin-deactivation than its own binding requirements for HS chains suggest.
Another role of HS outside the coagulation cascade which has been the subject of much
attention is its interaction with growth factors, in particular the fibroblast growth factor
(FGF) family and, to a lesser extent, hepatocyte growth factor/scatter factor (HGF/SF).
The FGF family contains several isoforms, two of which have been crystallized in the
presence of heparin oligosaccharides (FGF-1 [183] and FGF-2 [184]). Additionally, struc-
tures of these two proteins in complex with their respective receptor (FGFR2 and
FGFR1) and heparin decasaccharides exist [185, 186]. Interestingly, two different ways
of preparation were used for these two ternary complexes, yielding strikingly different
geometries (for a comparison see [187]). It remains to be seen if these differences are
due to preparative differences or if FGF-heparin-FGFR complexes really lack a common
architecture. For both the FGF and HGF growth factor-receptor interactions heparin
as a third component increases the tendency to form the otherwise low-affinity protein-
protein complexes in the required stoichiometry. In the case of FGF heparin cross links
growth factors and receptors in a 2:2:1 (protein:protein:heparin) stoichiometry. For the
HGF-Met interaction, only the growth factor contains a heparin binding domain (NK1,
see above). However, because heparin increases the tendency of NK1/HGF to dimerise it
likely also promotes the formation of the signalling complex with the HGF-receptor: for
efficient signalling, two receptor molecules in close proximity might have to be activated
33
1.7 Protein-heparin/HS complexes
by binding to the HGF-dimer. It has been suggested that the necessity of a third inter-
action partner (heparin) for both the HGF and FGF signalling complex helps overcome
the otherwise low protein-protein affinities, which in turn guarantees a low noise level
in the respective signalling pathways [188]. In the case of the HGF/SF interaction with
heparin, charge density rather than a specific binding epitope seems to be the dominant
force [189, 172].
Another field in which charge-charge interactions are at the centre of GAG-protein in-
teractions are chemokines. These small (8-10 kDa) peptides are, among other processes,
involved in the recruitment of leukocytes from the vasculature into surrounding tissue.
The chemokines‘ role in this process consists in the adhesion of leukocytes on the en-
dothelial surface by means of interaction with G-protein-coupled receptors which are
expressed on the leukocyte surface. The chemokine gradient which directs this leuko-
cyte recruitment does in turn depend on a further interaction partner which protects the
gradient against shear forces and diffusion, and there is evidence suggesting that this
function is carried out by GAGs on the endothelial cell surfaces [190]. Mutagenesis stud-
ies for a range of chemokines - among them MCP-1, RANTES and IL-8 - have found that
basic residues such as arginine, lysine and, to a lesser extent, histidine residues are most
important for GAG-binding (for an overview see [191]). The majority of GAG-binding
chemokines posses pIs in the basic range, pointing to a high percentage of positively
charged residues. There are, however, also chemokines with acidic pIs which have never-
theless been implicated in GAG binding [190]. One of these acidic chemokines, MCP-I
(pI ∼4.5), has been shown to form tetramers in the presence of a heparin oligosaccharide,
thereby bringing the GAG-binding residues close in space and forming one continuous
basic patch on the surface of the tetramer despite its acidic pI [192].
In summary, in the field of GAG-protein interactions the lack of specificity for some
interactions seems to co-exists with strict structural requirements in other complexes,
making it difficult to combine the different types of interactions in a unifying model [152].
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It should be noted that HS also plays a role in infections as an “anchor” for invading
organisms [193]. Recently, it has been shown that sporozoites of the malaria-parasite
Plasmodium berghei migrate through cells expressing low-sulfated HSPGs in the skin and
endothelium before the highly sulfated HSPGs of hepatocytes activate the microorgan-
ism for invasion [194]. Similarly, the hepatitis B virus (HBV) attaches to hepatocyte-HS
chains in the initial phase of its entry process into liver cells [195]. During the internal-
ization of the transactivator protein of the human HI-virus, Tat, HSPGs might also act
as receptor molecules [196].
Methods to determine binding epitopes and affinities usually employ enzymatic or chem-
ical digestion and subsequent fractionation of heparin/HS according to length and chem-
ical composition/charge in an attempt to isolate homogeneous species from the complex
starting material. Following the separation of these smaller oligosaccharides different
biophysical methods can be employed to determine binding affinities and binding sites
of the well-defined oligosaccharides, among them ITC, SPR and NMR titrations. Other
methods do not attempt separation of the oligosaccharides prior to binding studies but
use the differential affinities to “pull out” the tightest binder from a mixture of oligosac-
charides by means of chromatography or mass spectrometry [197]. The disadvantage of
the first approach is the loss of rarely occurring oligosaccharide sequences during the
separation/purification process.
1.7.1 Preparation of heparin-derived oligosaccharides
In a medical context fractions of low molecular weight heparins (4-6 kDa) are often used
as anticoagulants. This fractionating does, however, not lead to sufficient homogeneity
for the investigation of protein-heparin interactions by NMR, especially if a distinct bind-
ing epitope is of interest. A combination of enzymatic digestion, size fractionation and
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ion-exchange chromatography can be used in order to obtain species of defined length,
composition and sulfation from heparin sources. The enzyme of choice is heparinase I.
Digests of heparin from different sources with heparinase I lead to a characteristic pattern
of distinct oligosaccharide species [198], reflecting the different compositions of individ-
ual heparin types. The enzymatic cleavage performed by heparinase I is a β-elimination
which produces an unsaturated uronic acid residue (∆UA2S) at the non-reducing end
of the oligosaccharides [199] (Fig. 1.13).
Figure 1.13: ∆UA2S forms the non-reducing end of all heparinase I-produced oligosaccha-
rides, giving rise to an absorbance at 230 nm.
The double bond in conjugation with the uronic acid carboxyl group absorbs in the
UV region with a maximum near 230 nm and can be used for detecting heparin-derived
oligosaccharides and for concentration measurements. The extinction coefficient at 230
nm (ε230) is almost unaffected by the presence of other functional groups found in heparin
[198], allowing the usage of the same coefficient for all heparinase derived oligosaccha-
rides. Following heparinase digestion, oligosaccharides can be size-fractionated using size
exclusion chromatography. Further purification by anion exchange allows separation of
chemically well-defined species with uniform sulfation and GlcA/IdoA content [172].
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1.8 Biomolecular NMR spectroscopy
Nuclear magnetic resonance spectroscopy (NMR) makes use of the microscopic magnetic
moments of atomic nuclei in order to gain information about the structure and dynamics
of molecules. Not all chemical elements and not all isotopes of one given element have
the same - or indeed any - magnetic moment. Some nuclei are not magnetic because
this quality is coupled to the nuclear spin, which is zero for some elements/isotopes.
Nuclei with a spin quantum number of 1/2 are most commonly used as magnetic probes
in biomolecules because their magnetic moments are conveniently described as dipoles,
while spin quantum numbers > 1/2 are technically demanding because for many such
nuclei electric quadrupole moments have to be taken into account additionally to the
magnetic moments. Coincidently, three of the most abundant nuclei in biomolecules
(proton, carbon and nitrogen nuclei) have isotopes with spin 1/2, these are 1H, 13C and
15N.
Like other types of spectroscopy, NMR spectroscopy creates non-equilibrium situations
in a sample which absorbs electromagnetic radiation. In NMR, the basis of this absorp-
tion is the interaction of the small nuclei magnetic moments with the electromagnetic
radiation from an external source. In thermal equilibrium, the sample is under the in-
fluence of a large (up to around 20 T) static magnetic field, which causes the nuclei
magnetic moments to align parallel or antiparallel to the external field (depending on
the sign of their gyromagnetic ratios) according to the Boltzmann distribution. At room
temperature, this leads to a very small population difference between the two energy lev-
els of spin 1/2 nuclei. The population difference is very small because the energy levels of
the nuclear magnetic moments are close to each other: at room temperature, the energy
differences between parallel and antiparallel orientations are in the range of kT even at
large field strengths, due to the small magnetic moments of even the most sensitive nu-
clei. Whether the alignment parallel or antiparallel to the external field is energetically
more favourable depends on the sign of the gyromagnetic ratio of the nucleus, the pro-
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portionality constant that links magnetic moment to spin. A perturbation of the thermal
equilibrium state is achieved through additional short-lived radiofrequency fields which
are applied perpendicular to the external field, permitting the magnetic moments to ab-
sorb energy at discrete frequencies in order to undergo energetic transitions. Generally,
one distinguishes between experimental setups in which this resonance process creates
magnetisation perpendicular to the static field (so-called transverse magnetisation) used
in Fourier transform (FT) NMR or (anti)parallel to it (longitudinal magnetisation) used
in continuous wave (CW) NMR. FT NMR is superior to CW NMR and only the former
is described here. Following the perturbing radiofrequency pulse in FT NMR experi-
ments the system starts to relax back to its equilibrium state while precessing around
the external magnetic field. Electromagnetic coils in close proximity to the NMR sample
record this process. The precessing magnetic spins induce small currents in the detection
coil which is oriented perpendicular to the static magnetic field.
The decay of the non-equilibrium components of the magnetisation is described by os-
cillating exponential functions. The oscillation results from the constant precession of
all spins around the z-axis (the direction of the external magnetic field, B0), a move-
ment that produces a frequency modulated, exponentially decaying electric current in
the detecting coil. The permanent precession of nuclei around B0 is a consequence of
the nuclei having spin and magnetic moment at the same time and is often compared to
the precession of a child’s top. By means of Fourier transform, the precession frequency
for individual groups of spins can be extracted from the oscillating currents that are
detected for the spin ensemble, yielding a distribution of resonance frequencies referred
to as the NMR spectrum.
The central position that NMR spectroscopy occupies in analytical chemistry and, along-
side x-ray crystallography, in structural biology, is rooted in the fact that resonance fre-
quencies are extremely sensitive to a spin’s chemical environment. NMR active chemical
elements/isotopes resonate within certain frequency ranges determined by the gyromag-
netic ratio, an inherent physical property of the nucleus. The resonance frequency (ν)
of a nucleus is given as
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ν = γB0/2π (1.1)
where γ is the gyromagnetic ratio and B0 is the magnetic field in Tesla. However, the
small magnetic moments which nearby electrons create in proximity to a given spin
lead to small changes in the experienced external field, slightly shifting the resonance
frequency. The parameter used to describe this phenomenon is the so-called shielding
constant σ, changing the resonance condition to
ν = γB0(1− σ)/2π. (1.2)
Rather than expressing the resonance frequency of each nucleus in absolute numbers, a





where νref is the frequency of a reference compound. This dimensionless parameter is
field independent, making spectra acquired at different field strengths directly compara-
ble.
Contributions to chemical shielding do not only arise from bonding electrons. Through
space effects such as magnetic fields produced by aromatic ring currents affect the overall
shielding. The resulting individual local environments experienced by chemical building
blocks of biomolecules (such as amino acids or nucleotides) allow the distinction between
identical residue types at different positions within a compound. Individual nuclei are
assigned their respective chemical shifts which function as “name tags”. This procedure
allows individual residues to be distinguished and subsequently allows determination
of individual spin systems and their interaction with other spin systems. In unfolded
proteins - where all amino acids experience very similar chemical environments - this
distinction becomes difficult as identical nuclei of amino acids of the same type resonate
close to a single frequency, termed the random coil frequency.
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Two of the most abundant biological nuclei, 14N and 12C, are not favourable for NMR
spectroscopy since they have spin quantum numbers of 1 and 0, respectively. Proteins
are therefore often isotopically labelled with 15N and/or 13C if the information gained
from protons is not sufficient. This technique allows for extended “name tags” in which
the chemical shift of several nuclei are observed at the same time, adding additional
resolution. Labelling a proton with the chemical shifts of a directly attached 15N or
13C atom gives rise to so-called two- and three-dimensional NMR spectroscopy. Addi-
tional dimensions can be used by adding frequencies of further neighbouring groups, but
such high-dimensional NMR spectroscopy usually requires extended measurement time,
large compound concentrations and non-Fourier transform processing. Alternatively,
pseudo nD spectroscopy methods have been developed [200, 201, 202].
Because 1H, 15N and 13C have different gyromagnetic ratios, their resonance frequencies
in biomolecules are well-separated from each other, and modern NMR spectrometers
have several channels for separate irradation of different nuclei. This design makes it
possible to excite only one isotope while leaving the other istopes in their equilibrium
state. Additionally, the bandwidth, shape and centre frequency of a pulse can be set to
selectively excite narrow frequency ranges within one channel (so-called selective pulses).
Following the excitation, the nuclei (usually starting on proton for sensitivity reasons)
are given time to dephase according to their different chemical shifts and scalar cou-
plings. After chemical shift rephasing, achieved through central 180◦ pulses and an
aedequate delay (so-called spin echos), magnetisation is transferred from the proton
spins to neighbouring heteronuclei (in homonuclear experiments the magnetisation is
transferred between different types of protons). The transfer is accomplished via simul-
taneous pulsing on both the proton and the heteronucleus. The polarization transfer can
be mediated through scalar couplings (J-couplings) between covalently linked nuclei. It
is also possible to transfer the magnetisation via dipole-dipole (DD) interactions through
space. In this case the interaction is based on the so-called Nuclear Overhauser Effect
(NOE) and decays rapidly with the distance r between the two dipoles, proportionally to
r−6. The NOE is essential for the use of NMR spectroscopy in structural biology because
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it allows the proximity of protons in space to be established. Thus, NOE experiments
are essential to establish tertiary and quaternary structures of biomolecules.
In recent years, efforts have been made in protein structure determination to replace
the traditional, NOE-based methodology by structural information gained entirely on
the basis of the chemical shifts of backbone atoms, which in principle reflect protein
dihedral backbone angles - the parameters which dictate the secondary structure of pro-
teins [203, 204]. These methods rely on secondary chemical shifts (the deviation of a
chemical shift from its random coil value) and on the bulk of chemical shifts and protein
structures that are deposited in databases. Methods based on chemical shifts require a
larger contribution of modelling techniques in order to determine likely orientations of
the sidechains since only backbone angles are found on an experimental basis.
For a rigorous description of the spin manipulations that take place during a NMR
experiment it is possible to describe the magnetisation of a given spin using its x-, y-
and z-components. For protons, the three Cartesian components are usually denoted Ix,
Iy and Iz, for heteronuclei (i.e.
15N or 13C) Sx, Sy and Sz are often used. Due to the
evolution of couplings mixed states arise, such as IxIy (a multiple quantum state) or IzSx
(an antiphase single quantum state). In weakly coupled systems, the single components
of these mixed states can be manipulated individually, i.e. a selective 90−z degree pulse
on the heteronuclear channel transforms IzSx into IzSy, leaving the proton component
unaffected. (Selective excitation of single nucleus types is possible because the Larmor
frequencies of different nuclei are sufficiently separated.) The so-called spin operator
formalism is used here to describe the INEPT experiment.
1.8.1 Multi-dimensional NMR
NMR experiments follow a common scheme of four essential steps: preparation, evolu-
tion, mixing and detection. The preparation does often simply consist of a delay that is
long enough for the spins to return to the thermal equilibrium before a new scan. This
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is important because each pulse sequence needs to be repeated many times in order to
obtain a good signal to noise ratio. Because many scans are added together it is essential
that they all start from the same well-defined spin state. The preparation can contain a
strong radio frequency field for one of the channels, leading to saturation of this nucleus.
Other nuclei can, at the same time, be in thermal equilibrium. In the last step of the
preparation period, spins are often placed at 90◦ with regard to the static field. This
provides a basis for the evolution period, in which chemical shift or coupling evolution
are allowed to take place. After a delay t1 each spin is in a distinct orientation as a result
of different precession frequencies, and only certain orientations are carried on through
to the next steps of the experiment. Between the repetitions of the single experiments,
however, the evolution time t1 increases in regular intervals from scan to scan. In this
way the magnetisation is labelled by the chemical shifts or couplings of spins. During
the following mixing period the magnetisation is transferred between spins. This could
be a simple delay (NOESY) or a repetitive train of pulses (TOCSY) or a single 90◦ pulse
on one (COSY) or two (HSQC) channels. The mixing period is typically followed by the
acquisition period.
1.8.2 The INEPT and HSQC sequences
The INEPT (I nsensitive N uclei Enhanced by Polarization T ransfer) sequence (Fig.
1.14) is a central building block in many bioNMR applications.
The pulses and delays used on the proton channel form a spin echo as described above.
The effect of the first pulse on the proton channel is the creation of −Iy magnetization
from the initial Iz state. The J-coupling that evolves during the entire period τ trans-
forms the −Iy term into 2IxSz if τ equals 1/(2JIS). Two centred 90◦ pulses on both
channels transform this proton antiphase term into 2IzSy. This term corresponds to S-
antiphase magnetization, i.e. a doublet with a 180◦ phase shift between the two peaks.
The centre of the doublet corresponds to the S resonance frequency and its separation
in Hz equals JIS.
In order to acquire decoupled signals refocussing must be applied via an additional spin
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Figure 1.14: INEPT pulse sequence. I denotes the proton channel, S the insensitive nucleus.
Taken from [205].
echo (Fig. 1.15). This sequence yields a decoupled in-phase signal that is enhanced in
intensity by a factor of γI/γS for IS moieties in comparison to direct S detection.
Figure 1.15: Refocussed INEPT pulse sequence. I denotes the proton channel, S the insen-
sitive nucleus. Taken from [205].
The main use of INEPT is the detection of insensitive nuclei in an indirect yet more
sensitive manner, namely via protons which are directly bound to insensitive nuclei
(i.e. 15N or 13C) [206]. In 15N-labelled proteins, the scalar coupling between protons
and adjacent nitrogen nuclei can be used for H eteronuclear S ingle Quantum C oherence
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(1H, 15N-HSQC) experiments. In this experiment, magnetisation is transferred from the
proton to the adjacent nitrogen nucleus using the INEPT pulse sequence. The scalar
coupling constant between amide 1H and 15N, JNH is around 90 Hz, and the INEPT
transfer is optimised when τ=1/(2JNH). The magnetisation is then labelled with the
nitrogen chemical shift and, in a reverse INEPT step, transferred back to the proton
before detection takes place. Thus, the directly detected dimension contains the proton
chemical shifts while the nitrogen shifts are displayed in the indirectly detected dimension
(Fig. 1.16). Likewise, this experiment can be conduced on 13C-labelled proteins to
transfer magnetisation between protons and adjacent carbons, giving rise to the 1H,
13C-HSQC experiment.
Figure 1.16: Overlay of the 1H, 15N-HSQC spectra of 15N-fH∼7,8Y (blue) and 15N-fH∼7Y
(red) with inlayed structures of the two proteins (same colour coding, PDB 2JGX for
fH∼7 and derived from PDB 2UWN for fH∼7-8).
While in a 1H, 15N-HSQC experiment amide NH resonances are monitored, 1H, 13C-
HSQC spectra contain in principle all CH correlations. In practice, separate versions
of the 1H, 13C-HSQC experiment are typically recorded for aliphatic and aromatic reso-
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nances of proteins. 1H, 15N-HSQC experiments are usually optimised for protein back-
bone amides but also contain the glutamine and asparagine sidechains. Additionally, the
arginine ε and, in exceptional cases, lysine ζ sidechain amine resonances can be observed
at favourable pH values.
The 2D HSQC experiments form the basis of many techniques used in protein NMR
spectroscopy. The 1H, 15N-HSQC spectrum is often the first experiment that is collected
for a 15N-labelled protein and used to judge if the protein is folded and monomeric.
If the 1H, 15N-crosspeaks are well dispersed and deviate significantly from the random
coil values, and if the number of crosspeaks corresponds well with the number that is
expected for the protein sequence, the chosen buffer and temperature conditions can be
maintained for further NMR studies. For backbone assignment, the 2D 1H, 15N-HSQC
experiment is used to link a number of different 3D spectra which each other: each 3D
spectrum uses the 1H, 15N-HSQC plane for the first two dimensions and adds a third
dimension which varies between experiments. In this manner, further carbon and pro-
ton chemical shifts are linked to the backbone 1H, 15N-resonances of the HSQC-plane
for each amino acid.
1.8.3 Sequential backbone assignment of proteins
For protein structure determination, 15N, 13C-labelled protein samples are routinely used
in order to obtain almost complete chemical shift information of the individual amino
acids, allowing a large number of NOE-restraints to be used. Structures of small pro-
teins and peptides with molecular weights < 6 kDa can be determined without isotope
labelling using homonuclear TOCSY, COSY and NOESY experiments. These tech-
niques are especially useful in the case of proteins which can not readily be produced by
micro-organisms, for example in the case of bactericidal activity - isotope labelled amino
acids for peptide synthesis are expensive. For the range of approximately 6-12 kDa 15N
labelling is sufficient for structure determination. During the sequential assignment,
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chemical shift values of individual amino acids are used to identify residues as belonging
to a certain amino acid type.
For 13C/15N labelled proteins so-called triple resonance experiments link the resonance
frequencies of different atoms to the backbone amide proton and nitrogen chemical shifts
that are displayed in the 1H, 15N-HSQC experiment. In the third dimension, chemical
shift information from the Cα and Cβ atoms can be gained as well as the resonance
frequencies of the backbone carbonyl groups and those of Hα and Hβ atoms. Triple reso-
nance experiments are usually acquired in pairs: in one of the pairwise collected spectra
the magnetisation transfer is directed through the carbonyl group, linking the amide NH
frequencies exclusively to the chemical shift information of the preceding amino acid. In
the second spectrum the magnetisation transfer occurs via Cα atoms of the n and n-1
residue, linking each NH crosspeak to both the chemical shift of its own and the preced-
ing Cα. Using both spectra simultaneously allows assignment of each peak in the third
dimension as belonging to the nth or (n−1)th amino acid, allowing unambiguous sequen-
tial assignment of the polypeptide chain. In practice, several pairs of triple resonance
experiments are combined to determine the sequential connectivity in order to overcome
difficulties arising from spectral overlap or low signal-to-noise ratios. Depending on the
atom type in the third dimension, these pairs are denoted CBCA(CO)NH/HNCACB
[207, 208], HAHB(CO)NH/HAHBNH [209] and CONH/(CA)CONH [210] (Fig. 1.17).
When all expected signals are present, the spectra pairs can be used independently to
establish the connectivity, otherwise they can complement each other. Programs for
automated backbone assignment facilitate the assignment process [211]. Due to the lack
of a secondary amide in the proline backbone the sequential assignment of backbone
resonances is interrupted since these residues are not visible in the 1H, 15N-HSQC ex-
periment. The carbon resonances of proline residues can, however, be determined on the
following residue during the sequential assignment.
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Figure 1.17: Magnetisation transfer during the CBCA(CO)NH (red) and CBCANH (red
and green) experiments. The CBCA(CO)NH experiment transfers resonances from
the n-1 residues to the backbone NH of the n residue only, the CBCANH experiment
additionally transfers resonances from the n residue. Excitation takes place on the
aliphatic protons and is detected on the amine NH, or both excitation and detection
take place on NH-protons (out-and-back experiments).
1.8.4 Relaxation and correlation times
After bringing the nuclear magnetic moments out of their thermal equilibrium orien-
tations in the static magnetic field, one can measure the time constants with which
they return to the thermal equilibrium, the so-called relaxation rates. Because differ-
ent processes are responsible for the evolution of the magnetic components that are
perpendicular and parallel to the external field, the time constants with which these
components return to equilibrium are determined separately. In order to return to the
thermal equilibrium, the spins interact in multiple ways with the surrounding environ-
ment. The longitudinal relaxation time constant T1 is used to describe the return to
thermal equilibrium populations along the z-axis, while processes leading to the decay
of single-quantum coherences in the xy-plane are described by the transverse relax-
ation time constant T2. Small fluctuating magnetic fields caused by molecular tumbling
are the source for relaxation processes. For spin 1/2 the most prominent sources of
fluctuating fields are through space dipole-dipole (DD) interactions and chemical shift
anisotropy (CSA) of nuclei. When several relaxation mechanisms are present these can
cross-correlate because they have a common origin: thermal motion. Pulse sequences
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which remove the cross-correlation between dipolar and CSA relaxation must be used
to determine the DD relaxation. The suppression of cross-correlation can be achieved
by a train of 180◦ degree pulses during the 15N relaxation period [212]. Additionally,
selective inversion of the NH protons is applied in the centre of this period which has the
double advantage of suppressing both cross-correlation and exchange broadening caused
by water. The relaxation then becomes monoexponential and the decay of magnetisation
can be expressed as
M(t) = M0 ∗ exp(−R ∗ t), (1.4)
where R is either the longitudinal or the transverse relaxation rate, R1 or R2 respectively,
depending on the experiment. Relaxation is often reported by using longitudinal (or
spin-lattice) and transverse (or spin-spin) relaxation times T1 and T2 (T1 = 1/R1 and
T2 = 1/R2).
In proteins, the measurement of T1 and T2 is commonly performed in a residue-dependent
manner. Because relaxation times reflect local as well as global mobility, relaxation mea-
surements are used to investigate site-specific flexibility and dynamics but also overall
molecular size. For example, backbone amide groups are often used for relaxation mea-
surements to determine flexible loops and rigid structure elements. T1 and T2 measure-
ments can also be used to estimate a protein’s overall rotational correlation time (τc)
because both T1 and T2 depend on the overall frequency with which the protein tumbles
in solution. For macromolecules in solution, T1 increases beyond a certain molecular
weight with increasing molecular size, while T2 decreases monotonically (Fig. 1.18).
The correlation time estimated from the R2/R1 ratio are proportional to the protein
size, and thus to the molecular weight, making relaxation measurements a convenient
tool for investigation of self-association processes [213].
2D 1H, 15N-HSQC like relaxation spectra, acquired using different 15N relaxation delays,
yield accurate relaxation times through fitting the decay of intensity for each residue as
a function of the delay time. In small peptides where little overlap between the amide
signals exists 1D spectra recorded with different 15N delays can be used to estimate
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Figure 1.18: Schematic representation of the change in relaxation time constants with in-
creasing correlation time τc. Taken from [205].
relaxation times. The peak intensity I decays exponentially with the relaxation time
constant T , thus with the intensities Ix and Iy belonging to the two different delay
times the time constant can be estimated from just two measurements (though precision
















this is equally valid for T1 and T2, depending on which NMR experiment is chosen. For T1,
the so-called inversion recovery sequence is used which inverts the 15N magnetization to
−Iz. After this point increasing the relaxation delay allows sampling of the exponential
decay through recording the magnetisation after the transfer to protons.
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To determine T2 the
15N spin echo pulse sequence 90◦-τ -180◦-τ with τ < < 1/2 1JNH
is applied. This effectively removes the 1JNH coupling evolution. However, in order to
suppress the effects of cross correlation between dipolar and CSA relaxation mechanisms
every 5-10 ms the multiplet components are exchanged by the action of a 1H 180◦ pulse
[212]. Plotting the intensities as a function of τ and fitting an exponential function yields
the decay constant T2.
Because signal detection can only take place in the xy-plane, every NMR signal is in-
evitably affected by T2. Since T2 gets shorter with increasing τc (and thus with increasing
molecular weight) (Fig. 1.18), and because the linewidth is proportional to 1/T2, NMR
spectroscopy generally suffers from increased line broadening with increasing molecular
weight, restricting routine INEPT-based NMR spectroscopy to molecules of up to around
30 kDa. For larger proteins, the different relaxation properties of different spin states
are used. For a given spin, the doublet in which its resonance is split by the scalar cou-
pling with a neighbouring spin is non-symmetric, i.e. for an amide proton spin the 15Nα
and 15Nβ states of the neighbouring amide nitrogen have different relaxation properties.
This effect becomes more pronounced with large molecular weights. Instead of mixing
the different spin states and yielding one relative broad signal, decoupling is avoided
and the spectral analysis focussed on the sharper signal of the in-phase doublet (Fig.
1.19). This concept is used in T ransverse Relaxation-Optimised SpectroscopY (TROSY)
and Cross Relaxation-Enhanced Polarization Transfer (CRINEPT) Spectroscopy [214].
TROSY is based on constructive interference between DD coupling and CSA in the
absence of decoupling [215]. While DD coupling is field-independent, CSA increases
proportionally to the field strength, and at 900 MHz both effects almost cancel for
15NH-groups. In TROSY, the compensation of DD couplings and CSA is active during
the 15N chemical shift evolution and the 1H acquisition. For large proteins with molec-
ular weights > 100 kDa for which TROSY is already used, transverse relaxation during
the magnetisation transfers becomes limiting. The CRINEPT sequence combines the
cross-relaxation transfer with the coherent J-transfer. The implementation used in this
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work, CRINEPT-HMQC-TROSY, removes the effective coupling evolution in F1 but
relies on relaxation to remove the fast relaxing component prior to the t2 acquisition
period [216]. For our system this process was not fully effective and asymmetric 1H-15N-
doublets were observed in the F2 dimension. Both TROSY and CRINEPT, however, do
not eliminate DD couplings between NH groups and remote protons - therefore, both
techniques achieve their maximum potential only for deuterated proteins.
Figure 1.19: Comparison of 1H proton traces extracted from 2D amide spectra with and
without decoupling (red: decoupled HSQC, black:CRINEPT-HMQC-TROSY without
decoupling). The different intensities of the doublet components in the spectrum
acquired without decoupling are averaged in the decoupled HSQC spectrum. The red
trace was acquired on a ca. 15 kDa 15N labelled protein, the black trace after addition
of a second protein of ca. 185 kDa, forming a protein-protein complex of ca. 200 kDa
with the smaller labelled protein.
1.8.5 1H, 15N-HSQC monitored titrations
Following the backbone assignment, binding studies can be conducted using the 1H,
15N-HSQC, TROSY or CRINEPT experiments. The chemical shift changes that are
observed during a titration with a small ligand are used to determine the ligand binding
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site on the protein. This so-called chemical shift mapping is a common application of
bio-NMR spectroscopy and can, if the kinetics of the binding are favourable, be used to
determine the dissociation constant of the complex which forms during the titration. A
gradual chemical shift change can be observed for residues in the fast chemical exchange
regime, i.e. when the interconversion between free and bound protein is fast compared
to the difference between the Larmor frequencies of the free and bound state. In this
case, the obtained spectrum represent the population-weighted average of the resonance
frequencies of the bound and unbound species (Fig. 1.20), and with higher ligand con-
centration the averaged peak moves further towards the chemical shift of the bound
species. In the case of slow exchange, both the bound and free protein are observed
simultaneously, giving rise to two peaks for a single amide group. The most inconve-
nient case is, however, exchange on the intermediate timescale: in this exchange regime,
intermediate broadening of peaks is observed which can lead to complete “bleaching”
and disappearance of cross peaks during the titration. Because the difference in Larmor
frequencies depends on the field strength and temperature, varying these two parameters
can improve the spectral quality by changing the exchange regime.
Figure 1.20: Schematic representation of 15N-HSQC shift changes during fast exchange:
V445 in 15N-fH∼7,8Y upon titration with fully sulfated heparin tetrasaccharide. Mo-
lar ratios are protein:ligand 1:0 (red), 1:0.4 (green), 1:0.8 (orange) and 1:1.5 (blue).
Vertical dimension: ppm(15N), horizontal dimension: ppm(1H).
In 1H, 15N-HSQC titrations the effect of ligand binding on the protein backbone is
monitored, whilst in the 1H, 13C-HSQC experiment usually the sidechains can be in-
vestigated. It is noteworthy that one interaction can exhibit different exchange regimes
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in both HSQC-experiments because the difference between the bound and free state
resonance frequencies (in Hz) can be different for NH and CH protons. In the fast ex-
change regime, the chemical shift differences during a titration are usually reported as










is used, where ∆δH and ∆δN are the chemical shift differences between each titration
point and the ligand-free reference spectrum for 1H and 15N, respectively.
1.8.6 NMR studies of glycosaminoglycans
Because no method for homogeneous isotope labelling in carbohydrates exists to date,
homonuclear NMR is used for glycosaminoglycan characterisation. A large emphasis
is on J-couplings and chemical shifts and common NMR experiments are 1H-COSY
(COrrelation Spectroscopy), TOCSY (TOtal C orrelation Spectroscopy) and NOESY
experiments. With the COSY and TOCSY experiments single hexoses are identified, and
NOEs between the rings are used to establish the primary sequence. Natural abundance
13C NMR can also be used if sufficient quantities of the GAG can be produced.
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2.1 Protein production and purification
2.1.1 Fermentation for production of isotope labelled proteins
For production of 15N fH∼7 (Y402), 15N fH∼7-8 (H402), 15N fH∼7-8 (Y402) and 15N
fH∼19-20 fermentation of the respective Pichia pastoris (P. pastoris) clones was con-
ducted. The clones were provided by Dr. Christoph Schmidt and Dr. Andrew Herbert
and contained the expression vector pPICZαB with the human fH residues 386-446
(fH∼7), 386-507 (fH∼7-8) and 1107-1231 (fH∼19-20) where the amino acid in position
402 is a tyrosine residue in fH∼7Y and fH∼7-8Y and a histidine in fH∼7-8H. (The
complete sequences can be found in the Appendix.) With respect to residue 402 both
fH variants are commonly found but Y402 is the prevalent form and H402 has been
suggested as a risk factor for age related macular degeneration. The vector conveys
resistance against the antibiotic Zeocin. The protein genes had been placed upstream
of the Saccharomyces cervisiae α-factor secretion sequence, directing the proteins to the
secretory pathway and thereby facilitating purification. Short cloning artefacts between
the protein sequence and the secretion signal where present in these clones, facilitat-
ing the cleavage of the secretion signal by Kex2 endopeptidase. These artefacts are
subsequently subject to partial proteolysis, resulting in a mixture of protein with and
without the cloning artefact. Ion exchange or heparin affinity chromatography at mildly
acidic conditions (pH 5.0-6.0) allowed separation of the two species. For the fH∼7Y and
fH∼7-8Y/H constructs, the cloning artefact comprised of the additional sequence EAAG
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at the N-terminus. For fH∼19,20, the cloning artefact was EAEF. Mutant proteins of
fH∼19,20 were provided by Dr. David Kavanagh and Dr. Andrew Herbert and have, in
general, been produced in a similar manner.
Previously, the vectors had been transformed into the P. pastoris strain KM71H. Clones
were streaked from glycerol stocks on YPD-agar containing Zeocin (100 µg/mL) and
incubated at 30◦C for 48 h. Single colonies were used to inoculate 10 mL of buffered
minimal glycerol (BMG). After shaking at 200 rpm for 48 h at 30◦C the 10 mL cultures
were combined with 200 mL of fresh BMG and left shaking at 30◦C for another 48 h,
after which the inoculant (ca. 300 mL, OD600 of 20) was spun down (10 min, 1,500 g)
to separate the cells from the 14N-containing media. Pellets were resuspended in 20 mM
sterile potassium phosphate, pH 6.0 and used to inoculate 600 mL of Minimal Media
(MM) for fermentation at 30◦C.
A New Brunswick Bioflow3000 system fitted with a pH probe (Mettler Toledo), a dis-
solved oxygen (DO) probe (Mettler Toledo), a stainless steel stirrer and a sterile filter
(0.2 µm) air inlet were used for the fermentation. The fermentation was controlled and
recorded using an AFS Bio Command Interface. 2.6 mL PTM1 trace salts and 0.5 mL
antifoam were added to the MM prior to inoculation. The temperature was set to 30◦C
until the glycerol from the initial media and additional 10 mL of glycerol had been
metabolised. The DO level served as a general measure of metabolic activity. The pH of
the culture was regulated with 2 M KOH to stay above 4.5, and air was pumped through
the culture at a constant flow rate of 0.5 units. The pH probe was calibrated prior to
autoclaving using reference solutions of 7.0 and 4.0 pH units. For DO probe calibration,
a value of 100% was set to equal the DO level in the MM before inoculation, at 30◦C,
200 rpm and 0.5 air flow, and a DO level of 0% was set after deconnecting the probe for
30 s. The agitation was coupled to the DO value via a control circuit in order to keep
the DO level at 40 % during the fermentation. Additionally, oxygen air enrichment was
used if at top agitation a DO value of 40% was still not reached, as a constant DO level is
believed to be critical for protein expression. The lower and upper value for the agitation
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were 200 and 1000 rpm, respectively. A second control circuit was used to maintain a
pH of around 5.0 by adding small amounts of 2 M KOH. Before induction with methanol
(enriched with 4.4 PTM1 salts/mL methanol) the culture was cooled down to 15 ◦C to
limit proteolysis. Methanol feeding periods were manually adjusted to match the level of
adaptation to methanol, leading to ever increasing amounts of injected methanol. The
estimated total amount of methanol in the cell culture was kept below 1.5 % at any
time to avoid intoxication. After 4 days of induction the cells were removed from the
fermenter, spun at 5,000 rpm for 10 min (centrifuge Sorvall RC3B plus) and discarded.
The supernatant was spun at 10,000 g for 30 min (centrifuge Sorvall RC26 plus) and
filtered through a 0.2 µm filter to cut off any remaining cells. 5 mM ethylendiamin
tetraacetic acid (EDTA), 0.5 mM phenylmethyl sulfonyl fluoride (PMSF) and 0.002%
(v/v) sodium azide were added to the filtered supernatant to inhibit proteolysis and
bacterial growth.
For production of 13C,15N-fH∼7-8Y, the initial fermentation media did not contain glyc-
erol but 15 g of 13C-D-glucose as the sole carbon source. An additional feed before
induction consisted of 1 g of 13C-glycerol. For induction, overall 20 g of 13C-methanol
was used.
The production of 15N-NK1 followed a generally similar procedure. The clone was pro-
vided by Jon Deakin, Paterson Institute for Cancer Research, Manchester University,
and contained the expression vector pPIC-9K with the human HGF/SF residues 28-
210 and the mutation A29V. An initial colony was grown on YPD agar containing the
antibiotic G418 (10 µg/mL) against which pPIC-9K conveys resistance. The overall
amount of methanol used during the induction phase was much higher than for the fH-
producing clones to account for the intact Alcohol Oxidase 1 (AOX1) promotor in the
NK1-producing clone. This gene is disrupted in the pPICZα vector, leaving only the
AOX2 gene intact and resulting in a slower methanol metabolism in the latter case.
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2.1.2 Shaker flask expression of unlabelled proteins
For the expression of unlabelled fH-constructs, shaker flasks were used instead of fer-
mentors. Cultures were inocculated using BMG, 30 ◦C and 250 rpm and transferred to
BMM for induction at 15-20◦C. 0.5-1.5% (v/v) methanol was added twice a day and the
cells were harvested 4 days after transfer to BMM.
2.1.3 Ion Exchange and Heparin Affinity Chromotography
Following the addition of protease inhibitors and sodium azide, the supernatant was
diluted with the 4 fold volume of distilled water and an initial purification step using
a self-packed 5 mL column of SP-Sepharose (Sigma) or Heparin-Sepharose (Amersham)
was conducted at gravity flow and 4◦C. The bound protein was washed with 20 mM
potassium phosphate pH 6.0 until the absorbance at 280 nm (A280) had reached a value
below 0.1, then step-eluted with NaCl. For factor H constructs 1 M NaCl, 20 mM potas-
sium phosphate pH 6.0 were used for elution, for NK1 1.5 M NaCl, 20 mM potassium
phosphate pH 6.0. 0.5 -1 mL fractions were collected until the A280-value levelled close
to 0. The fractions were screened for the protein of interest using SDS-Polyacrylamide
gelelectrophoresis (SDS-PAGE), combined accordingly and desalted by buffer exchange
or dialysis.
For the second purification step another cation exchange or heparin affinity chromatog-
raphy was applied using either a 1 mL MonoS column (General Electrics) or a Poros
20HE (0.46 x 10 cm, Applied Biosystems) heparin-affinity column and Äkta FPLC sys-
tem (Amersham) for both factor H modules and NK1. The column was equilibrated
with 20 mM potassium phosphate (plus 100 mM NaCl for NK1), pH 5.0-6.0. Desalted
protein was injected and a linear gradient to 1 M or 1.5 M NaCl (NK1) was applied.
The elution of protein was followed by the A280-value and fractions with high absorbance
values were subject to SDS-PAGE. Clean fractions were combined and - depending on
their further usage - concentrated, buffer exchanged or frozen in liquid nitrogen and
stored at -80◦C.
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2.1.4 SDS-Polyacrylamide Gel Electrophoresis
Protein molecular weights were estimated and the purity of protein samples assessed
using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Protein
amounts ranged between ca. 1-5 µg per lane. Protein samples were mixed with 0.5
equivalents (v/v) of 1:2 reducing or non-reducing loading buffer (2x sample buffer ac-
cording to Lämmeli, Fluka) and heated at 80◦C for 3 min. Total sample volumes were
around 20 µL. Each sample was loaded into an individual well on a prepacked polyacry-
lamide gradient gel (NuPAGE 4-12% (w/v) Bis-Tris, Invitrogen). For small molecular
weights MES buffer was used, for large molecular weights MOPS buffer (20x NuPAGE
MES or MOPS SDS running buffer, Invitrogen). For referencing, a protein standard mix
(Precision Plus Unstained Standard, BioRad) was loaded into one of the wells. Elec-
trophoresis was persued for about one hour at 150 V. Afterwards, the gel was washed
several times with dH2O for 30 min, then Coomassie-stained (EZblue, Sigma) for about
one hour. For destaining, the gel was left in dH2O over night.
2.1.5 Mass spectrometry
Spectra were acquired on a Voyager-DE STR MALDI-TOF (Applied Biosystems) instru-
ment with a nitrogen LASER in negative mode. Matrices used were sinapinic acid for
protein samples and α-cyano-4-hydroxy-cinnamic acid (CHCA) for peptides. Matrices
were obtained by mixing 15 mg sinapinic acid or 10 mg CHCA, respectively, with 400 µL
ddH2O, 100 µL 3% (v/v) TFA and 500 µL acetonitrile, followed by sonication for 3 min.
Generally, 0.5 µL protein or peptide samples were mixed with 0.5 µL of the appropriate
matrix directly on the MALDI-TOF plate. The LASER intensity was adjusted manually
for each sample. For analysis of peptides obtained during the microwave assisted TFA




2.2.1 Size exclusion chromatography
Heparinase I digested heparin from bovine intestines was provided by Jon Deakin. 50 mg
of digested heparin was dissolved in 1 mL 250 mM ammonium bicarbonate and applied
to a Bio Gel P-10 gel filtration column (120 x 1.5 cm, Bio-Rad) in 250 mM ammonium
bicarbonate under gravity flow conditions. The A232 of each fraction was measured and
the major species, disaccharide (dp2), tetrasaccharide (dp4), hexasaccharide (dp6) and
octasaccharide (dp8) were isolated. For dp2, dp4 and dp6 the size-separated oligosaccha-
rides were subsequently subject to anion exchange chromatography in order to achieve
separation according to sulfation levels/overall charge.
2.2.2 Ion exchange chromatography
A strong anion exchange chromatography (SAX) column (AS-17 Ionpac, Dionex) on a
HPLC system (Waters, 600 controller and 486 detector) was used to further purify the
size-fractionised oligosaccharides. Distilled water, titrated with HCl to a pH of 3.5, was
used as running buffer and a salt gradient to 1 M NaCl was applied. The elution was
followed by A232 and fractions were collected manually. Purified oligosacchrides were
freeze-dried and concentrated.
2.2.3 Desalting
Desalting of dp4 and dp6 was accomplished on the same Waters HPLC system using
a Superdex Peptide 10/300 GL column (General Electrics) with 250 mM ammonium
bicarbonate as running buffer and following the A232-trace or, for dp8, using a PD-
10 desalting column (General Electrics) and dH2O. For the PD-10 columns, 0.5 mL
fractions were collected and the A232-value was measured for each fraction on a UV/vis
spectrometer (Lambda, HP) using quartz cuvettes. Fractions with low A232-values on
the later end of the A232 peak were omitted due to overlap with the salt elution. This
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overlap was found to be too large for oligosaccharides smaller than dp8, hence the two
different desalting methods.
2.3 Concentration measurements for proteins and GAGs
Protein concentrations were determined by using the A280 values. Concentrations were
calculated using the Beer-Lambert equation with the following values for extinction co-
efficients at 280 nm (ε280):
Table 2.1: Calculated extinction coefficients at 280 nm







fH∼19,20 mutant proteins containing an additional tryptophan 21930
NK1 26630
C3b 176700
as obtained from the Swiss-Prot database for the respective amino acid sequences. HBD2
samples were obtained from Dr. Emily Seo who used the Bradford assay for concentra-
tion measurements. All oligosaccharide concentrations were determined using A230 values
and ε230=5200 M
−1cm−1 [198]. The absorbtion at 230 nm is due to the double bond and
neighboring carboxyl group at the non-reducting end of the oligosaccharide and largely




2.4.1 Preparation of protein and GAG samples for NMR
Purified protein was buffer exchanged using Vivaspin concentrators (Satorius, with PES
membranes) or overnight dialysis (Tube-O-DIALYZERS, GBiosciences). The molecular
weight cutoff for concentrators (MWCO) was 3, 5 or 30 kDa, depending on the protein
size, and 1 kDa for overnight dialysis. For 5 mm (outer diameter, O.D.) NMR tubes, the
concentration of the sample and its volume (≤ 550 µL) were adjusted and 5-10% (v/v)
of D2O as well as 0.01% (w/v) sodium azide were added. Samples for lysine sidechain
experiments were not directly supplemented with D2O. Instead, the sample volume was
adjusted to 400 µL and a capillary (Norell, 2 mm O.D.) was filled with D2O and inserted
into the sample in the 5 mm O.D. tube. For 3 mm NMR tubes, the sample volume
was 200 µL and the D2O concentration was 10% (v/v). Protein concentrations varied
between 50 µM (for HSQC-titrations) and 0.8 mM (for triple resonance experiments).
Oligosaccharides were, after desalting, repeatedly freeze-dried and dissolved in 500 µL
ultrapure D2O (Deuterium oxide “100”, Sigma). Prior to NMR spectra collection the
sample pH was measured using a Hamilton Minitrode and, if necessary, adjusted with
small amounts of the buffer’s conjugated acid or base (0.1 M stocks). NMR samples
were stored at 4◦C.
2.4.2 NMR spectrometers
A Bruker AVANCE 14.1 T spectrometer (600 MHz proton Larmor frequency) and
a Bruker AVANCE 18.8 T spectrometer (800 MHz proton Larmor frequency), both
equipped with a 5-mm triple resonance cryoprobe, were used throughout the project.
For the C3b binding study, a 3-mm sample tube was used which was inserted in the




2.4.3 Backbone assignment of fH∼7-8Y
Spectra for the backbone assignment of fH∼7-8Y were aquired at 600 MHz field strength
using 5 mm sample tubes at 310 K on a 0.8 mM 15N-protein sample in 20 mM sodium ac-
etate pH 5.0 containing 5% (v/v) D2O. For backbone assignment, the CBCA(CO)NH/CB-
CANH [217, 218, 219] pair as well as the NH(CA)CO/NHCO [220, 221, 222, 223] and
HBHA(CO)NH/HBHANH [217, 218] pairs were acquired. Chemical shift labelling peri-
ods were typically set to 8-12 ms for 1H, 4-6 ms for 13C and 15-20 ms for 15N. 1D spectra
were acquired in between 3D spectra to confirm the stability of the sample. Gener-
ally, the focus during the sequential assignment was on the CBCA(CO)NH/CBCANH
spectra; the other two spectra pairs were used to complete the assignment where severe
overlap or sparse data made the assignment of the CBCA(CO)NH/CBCANH pair am-
bigous. Spectra were processed using the process program from the AZARA program
suite (v2.7, copyright (C) 1993-2002 Wayne Boucher and Department of Biochemistry,
University of Cambridge) and assigned using CcpNmr Analysis [224]. The AZARA code
can be obtained from http://www.ccpn.ac.uk/azara/. After grouping resonances in the
three experiments as Cα, Cβ, Hα and CO-resonances and identifying glycine residues
as far as possible, the peaks were exported into the semi-automated backbone assign-
ment program MARS [211]. Further information required by MARS were the primary
sequence and a secondary structure prediction, which was obtained using PSIRED (Po-
sition Specific Iterated Prediction) [225]. Glycine residues needed to be identified prior
to MARS because a missing Cβ entry in the MARS input list is treated as a poten-
tially larger amino acid whose Cβ resonance could not be identified. Glycine residues
therefore have to be denoted as such in the MARS input file. The assignment predic-
tions obtained by MARS were imported into Analysis via a Format Converter (CcpNmr




15N relaxation measurements were performed at 283 K or 298 K on 600 MHz (Bruker
AVANCE) or 800 MHz (Bruker AVANCE) spectrometers equipped with cryprobes as
1D or 2D experiments. 1D measurements were found to be sufficient in the case of
HBD2 (283 K, 600 MHz AVANCE) due to little overlap in this relatively small peptide.
1D spectra with different delay times for T1 and T2 measurements were collected, the
intensity decrease was measured for amide signals and the relaxation times were cal-
culated using eq. 1.6. Delay times for the free HBD2 peptide were 11.1, 201.1, 301.1,
401.1, 501.1, 601.1, 701.1 and 801.1 ms for T1 and 16.0, 48.0, 80.0, 96.0, 112.0, 128.0,
160.0 and 192.0 ms for T2 measurements. For a sample of HBD2 with a 4 fold excess
of DS-dp6, 50.1, 201.1, 301.1, 401.1, 501.1, 601.1 and 701.1 ms were used for T1 and
16.0, 48.0, 80.0, 112.0, 144.0, 160.0 ms for T2 measurements. For a sample of HBD2
with a 16 fold excess of the pentasaccharide Fondaparinux (a commercial name for the
thrombin/antithrombin binding sequence in HS). The following delays were used: 11.1,
201.1, 401.1, 601.1, 701.1 and 801.1 ms for T1 and 16.0, 48.0, 80.0, 96.0, 112.0, 128.0 ms
for T2 measurements.
Six delay times for T1 (51.0, 301.0, 501.0, 601.0, 751.0 and 851.0 ms) and six delay times
for T2 (16.0, 32.0, 48.0, 64.0, 80.0 and 96.0 ms) were used for 2D experiments on factor H
constructs. Relaxation rates for each of the chosen signals were obtained by exponential
decay fitting in gnuplot (1D, after deconvolution using TOPSPIN) or CcpNmr Analysis
(2D). Correlation times τc were calculated from the obtained R1- and R2-values and the
spectrometer frequency using the program R2R1 tm (A. G. Palmer III, Columbia Uni-
versity). In the case of the 1D spectra, only 8-10 peaks in the amide region were selected
and the values obtained for T1 and T2 were averaged before calculating the correlation
times using R2R1 tm. Sidechain amides were excluded from both 1D and 2D relaxation
analysis as they might be very flexible. For analysis of 2D spectra the relaxation times




2.4.5 1H, 15N-HSQC titration experiments
Following the backbone assignment of fH∼7-8Y several 1H, 15N-HSQC spectra were mea-
sured between 310 and 298 K and a pH-titration was conducted at 298 K between pH
5.0 and 7.4. Using both temperature and pH dependency, the backbone assignments
were transferred from 310 K, pH 5.0 to 298 K, pH 7.4 with the help of these titrations
using CcpNmr Analysis. The oligosaccharide titration experiments on fH∼7-8Y and
fH∼7-8H were done at the latter conditions with protein concentrations around 50 µM
and varying ligand concentrations. Overlays of 1H, 15N-HSQC spectra of 15N-fH∼7-8Y
and 15N-fH∼7-8H showed only very few differences in chemical shifts, implying only
limited local changes around the SNP. The assignment of the fH∼7-8H-1H, 15N-HSQC
spectrum was therefore done based on chemical shift similarities with the Y-form. The
largest chemical shift difference between both isoforms was found to be experienced by
the SNP-neighbouring residue 403.
Titration conditions for NK1 were 303 K, 20 mM sodium acetate pH 6.0, 100 mM NaCl.
No double labelled sample was prepared and assignments were not available for this
protein. A few crosspeaks of residues that are involved in GAG binding could, however,
be assigned on the basis of previously published spectra [125].
Analysis of chemical shift changes during titrations was facilitated by CcpNmr Analysis,
which includes macros for assignment transfer during titrations and the calculation of
chemical shift differences between different spectra.
2.4.6 CRINEPT-HMQC-TROSY experiments on the fH19-20-C3b
complex
CRINEPT-HMQC-TROSY spectra were acquired on samples containing 15N fH19-20
and C3b. The samples were prepared in 3 mm tubes to yield higher concentrations and
to minimize sensitivity losses due to relatively high salt content of the samples (100 mM
64
2.4 NMR
potassium chloride and 50 mM potassium phosphate). 10% (v/v) D2O was added to the
NMR samples. The relaxation delay was shortened to 0.9 s (instead of 1.5 s used for
smaller proteins) and acquisition times were 46 ms in the directly detected dimension
and 12.5 ms in the indirectly detected dimension. The CRIPT transfer delay was varied
and the intensities of the first acquired FIDs were compared in order to determine the
optimal delay, which was found to be 5 ms (for the dependence of CRIPT transfers on
correlation times see Fig. 5 in [214]).
2.4.7 NMR experiments for structure determination of GAG
oligosaccharides
1D proton spectra of oligosaccharides were acquired at 298 K, at different pH values and
with different degrees of water suppression, depending on the size of the residual water
signal after repeated freeze-drying and resuspension in D2O.
The general approach for the determination of oligosaccharide sequences was largely
based on proton 1D spectroscopy because these substances were only available at nat-
ural abundance of 13C. In 1D spectra soft water supression was used to suppress the
residual HDO signal without affecting oligosaccharide signals. The resonance frequen-
cies obtained from this experiment were then used for selective excitation of protons
in 1D TOCSY and 1D COSY experiments [226]. Since the hexose rings in GAG-
oligosaccharides are separated by glycosidic linkages, which interrupt the J-coupling
based TOCSY transfer, this strategy allowed the characterisation of one hexose at a
time; occasionally peak overlap would result in simultaneous excitation of two hexose
rings. By varying the TOCSY mixing times between 60 and 120 ms and thereby mod-
ulating the transfer efficiency, the proton assignments of individual hexose rings were
obtained. The length and power of the selective pulse were varied in order to enhance
its selectivity where peak overlap was a problem. Comparison of chemical shifts and
J-couplings with literature values [227] aided the proton assignment and the analysis of
the sulfation pattern. In the second step of the GAG characterisation, 1D ROESY and
65
2.5 Binding studies
NOESY experiments [228, 229, 230] were used to establish the connectivity of individ-
ual hexose rings. This step was facilitated by the fact that heparin is an unbranched
oligosaccharide, limiting the number of NOEs between different rings. In cases of se-
vere overlap in the proton dimension or inefficient TOCSY transfer, natural abundance
2D 13C,H-HSQC spectra were collected to help the assignment by the addition of 13C
chemical shift information. In case of the fully sulfated hexasaccharide, dp6C, a 2D
homonuclear TOCSY spectrum was also acquired [231].
2.5 Binding studies
2.5.1 Preparation of fluorescent GAGs for gel mobility shift assay
Fluorescent labelling of purified oligosaccharides was achieved using 2-aminoacridone
(AMAC) essentially as described in [232]. Freeze-dried oligosaccharides were dissolved
in 40 µL of a solution of 85% (v/v) dimethylsulfoxide (DMSO) and 15% (v/v) acetic acid
containing 0.1 M AMAC. The mixture was incubated at room temperature for 15 min
before 40 µL of 1 M aqueous sodium cyanoborhydride was added. Further incubation
at 37◦C for 16 hrs followed after which the reaction mixture was freeze-dried. In order
to separate labelled oligosaccharides from unreacted AMAC, the dried mixture was re-
dissolved in 5-10 mL pre-chilled (-20 ◦C) ethanol and left at -20◦C for 30 min before
centrifugation at 12,000 rpm for 5 min. The ethanol was discarded and the procedure
repeated until the superantant was colourless and did not emit under UV-excitation,
signalling that all excess AMAC had been removed.
2.5.2 Gel mobility shift assay
The Gel Mobility Shift Assay (GMSA) was conducted as described in [233]. Protein
was buffer exchanged to phosphate buffered saline (PBS) and mixed with fluorescently
labelled oligosaccharides at different concentrations to a total volume of 10 µL PBS
containing 25% (v/v) glycerol and a trace of phenol red. The samples were incubated
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at room temperature for 15 min and subsequently loaded on a 1% (w/v) agarose gel
in 10 mM tris(hydroxymethyl)-aminomethane-HCl, pH 7.4, and 1 mM EDTA. Elec-
trophoresis was performed for 8 - 15 min at 200 V in a horizontal agarose electrophoresis
system using 40 mM Tris-HCl, pH 8.0, and 1 mM EDTA acid as electrophoresis buffer.
The fluorescent oligosaccharides were visualised under UV-light using an excitation wave-
length of 230 nm. The AMAC emission maximum is in the visible region, at 550 nm.
2.5.3 Heparin affinity chromatography
Buffer exchange to PBS was conducted as described for NMR samples. A sample con-
taining both isoforms of fH∼7-8 (0.05 mM in 1 mL) was prepared and loaded onto a
Poros 20HE heparin-affinity column (0.46 x 10 cm, Applied Biosystems) that had been
equilibrated with PBS. A gradient reaching to 1 M NaCl was applied and the elution
was followed by means of the A280-value .
2.5.4 Isolation of sheep erythrocytes
Sheep erythrocytes were washed from defibrinated sheep blood (TCS Biosciences). 1 mL
blood was transferred to a 15 mL falcon tube and diluted with 10 mL of buffer containing
20 mM HEPES, 145 mM NaCl, 0.1 % (w/v) gelatin (from pork skin, Fluka) and 10 mM
EDTA, pH 7.3 at 25◦C. The cell suspension was mixed gently and spun for 10 min at
500 g and 4◦C. The supernatant and a slim white layer of leucocytes were discarded and
the procedure was repeated two times. Subsequently, the washing buffer was replaced
by the same buffer but without EDTA. Three more washing steps were done with the
EDTA-free buffer and at 1,000 g. The washed cells were stored on ice up to one week.
Prior to use the cells were washed once more in EDTA-free buffer to remove lysed cells
and haemoglobin. For concentration measurements cells were lysed with distilled water
and the absorbance at 412 nm (A412) was measured. An A412 value of 0.87 at 1 cm
pathlength corresponds to a cell concentration of 5*108 cells/mL (personal information
from Dr. Kerry Pangburn, Complement Technology). EDTA in the first washing buffer
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had the function of removing calcium ions from the cell suspension in order to inhibit
the calcium-dependent classical pathway during the haemolytic assay.
2.5.5 Haemolytic complement assay
This assay was originally outlined in [95] and applied to investigations on the recombi-
nantly expressed C-terminus of fH by [69]. 20 µL of normal human serum (NHS) were
mixed with 1.25 µL 0.1 M MgEGTA (1:1 MgCl2 and ethylene glycol-bis(2-aminoethyl)-
N,N,N’,N’-tetraacetic acid), 2.5 µL sheep erythrocytes stock solution and 1.25 µL haem-
olytic assay buffer (20 mM HEPES, 141 mM NaCl, 5 mM MgEGTA, 0.1% (w/v) gelatin,
pH 7.3). EGTA had the function to selectively bind calcium, not magnesium (a cofactor
to factor B) from NHS. The concentration of sheep erythrocytes in the cell stock was
adjusted to give an A412 of 0.5-0.6 units at the conditions used for the assay. In prac-
tice, 2.5 µL of different concentration of cell solutions were lysed through addition of
197.5 µL distilled water. 100 µL of the lysed solutions were transferred to separate wells
of a 96 well plate and the A412 was measured for each well. A cell stock yielding a A412
of 0.5-0.6 units in this setup was then chosen for the actual assay. To the 25 µL solution
containing buffer, NHS and erythrocytes 25 µL of different concentrations of fH19-20
WT in haemolytic assay buffer was added. For comparison of several mutant fH19-20
proteins, a range of concentrations of fH19-20 WT (0.2-10 µM) was first used in order
to determine the concentration at which 50% lysis was observed. This concentration
was subsequently used with each of the mutant proteins for comparison with the WT.
In the case of the fH19-20 mutant D1119G and proteins encompassing fH7 a range of
protein concentrations was used (0.2-10 µM for D1119G and 0.2-67 µM for fH7 and
encompassing constructs) because at the 50%-lysis value for fH19-20 WT no significant
lysis was observed for any of these proteins. The 50 µL reaction mixture was incubated
at 37◦C for 20 min and quenched by addition of 150 µL cold quenching buffer (20 mM
HEPES, 145 mM NaCl, 5 mM EDTA, pH 7.3). Remaining cells were spun down for 5
min at 1,500 g and 4◦C in a round bottom 96 well plate and 100 µL of supernatant was
transferred from each well to a fresh 96 well plate, which was then used for A412 readings.
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Each experiment was repeated at least four times and a standard error was calculated
for each sample. As a negative control a well was filled with the same reaction mixture
but serum which had been heat-inactivated at 56◦C for 30 min [234]. In practice, stock
solutions containing buffer, cells and NHS were made up for a whole plate at a time and
supplemented with the protein solutions in order to minimize pipetting errors.
2.6 GAG-protein cross linking
For cross linking of dp4C to fH∼7Y, a method generally based on [235] was used. 0.2
mg desalted dp4C was added to a mixture of 22 mM 1-Ethyl-3-[3-dimethylaminopropyl]-
carbodiimide hydrochloride (EDC) and 30 mM sulfo-NHS (N-Hydroxysuccinimide) in 50
mM 2-(N-morpholino)ethanesulfonic acid (MES), pH 6.0. The total reaction volume was
1 mL. The mixture was incubated for 15 min at 25◦C and excess reagent was removed
by rapid passing through a PD-10 desalting column using the same buffer. Recovered
activated dp4C was combined with 400 µL of 750 µM fH∼7Y (2.3 mg) for further
incubation at 25◦C for 3 hrs. Subsequently, the reaction mixture was passed over a 1 mL
MonoS column equilibrated with 20 mM potassium phosphate pH 5.0 and eluted with
a linear gradient to 20 mM potassium phosphate, 400 mM NaCl pH 5.0. Fractions were
checked for the cross linked complex using matrix-assisted laser desorption/ionization-
time of flight mass spectrometry (MALDI-TOF). Fractions which contained a species
with the expected mass were found in the flow through, signalling changed electrostatic
characteristics of the protein after cross linking. The fractions containing fH∼7Yxdp4C
were combined, freeze-dried and desalted using two 1 mL HiTrap desalting columns
(Amersham) in a row. 20 mM potassium phosphate, pH 6.0 and a flowrate of 3 mL/min
was used in this step. The injection volume was 0.5 mL, and the A280 was monitored to
follow the protein elution. Fractions containing the cross linked complex (fH∼7Yxdp4C)
were identified using MALDI-TOF mass spectrometry and subjet to dialysis into 50 mM
ammonium acetate for tandem mass spectrometry (MS-MS).
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2.6.1 Trypsin digestion
Prior to digestion with trypsin, fH∼7Y (87 µL, 105 µM) and fH∼7Yxdp4C (100 µL,
91 µM) were incubated with 8 M urea and 250 mM DTT at 75◦C for one hour and
subsequently with 125 mM iodoacetamide for 30 min in the dark at room temperature.
To remove the denaturing reagents the samples were subject to overnight dialysis into
50 mM ammonium acetate, pH 7.4. For the digest, trypsin (Promega, sequencing grade)
was pre-incubated at 30 ◦C for 15 min and 5 µg added to each sample. A small amount
of trypsin was subject to autodigestion for comparison. All three samples were incubated
for 6 hours at 37 ◦C and subject to mass spectrometry.
2.6.2 Microwave assisted TFA digestion
Since conventional trypsin digestion did not prove successful for the cross linked complex,
a more radical approach was followed to obtain peptides from the complex [236]. 30 µL
of 80 µM fH∼7Yxdp4C was mixed with 100 mM Dithiothreitol (DTT) and 20% (v/v)
trifluoro acetic acid (TFA) in a 1.5 mL Eppendorf container. The sample was placed
within a glass beaker in a domestic microwave along with a second glass beaker containing
roughly 100 mL water (for absorbance of excess radiation). The sample was heated at
950 Watt for 6 min in 2 min steps. After each step, the sample was opened to release
pressure and avoid violent opening of the container during microwaving. The sample was
then subject to MALDI-TOF mass spectrometry. For peptide analysis the web server
ProSight PTM (https://prosightptm.scs.uiuc.edu/) was used.
2.7 Media and buffers
YPD-Agar for growth of P. pastoris :




2.7 Media and buffers
1.5% (w/v) agar
BMG (buffered minimal glycerol) for P. pastoris growth:
100 mM potassium phosphate pH 6.0
1.34% (w/v) yeast nitrogen base (Sigma)
4 x 10−5% (w/v) biotin
1% (v/v) glycerol
BMM (buffered minimal methanol) for P. pastoris expression:
as BMG but no glyerol and 0.5% methanol
PTM1 trace salts for isotope labelled P. pastoris expression:
6.0 g cupric sulfate pentahydrate
0.08 g sodium iodide
3.0 g manganese sulfate monohydrate
0.2 g sodium molybdate dihydrate
0.02 g boric acid
20.0 g zinc chloride
65.0 g ferrous sulfate heptahydrate
0.5 g cobalt chloride
0.2 g biotin
5.0 mL sulfuric acid
in 1L distilled water
Buffers for erythrocyte isolation and haemolytic assay:
1st erythrocyte washing buffer: 20 mM HEPES
145 mM sodium chloride
10 mM EDTA
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0.1 % (w/v) gelatin (from pork skin, Fluka)
pH 7.3 at 25◦C.

















3 Oligosaccharide preparation and
characterisation
3.1 Preparation of heparin-derived oligosaccharides
3.1.1 Differences between heparin and heparan sulfate and their
relevance for this study
Heparin binding to fH was investigated because several studies conclude that the in-
teraction of fH and heparan sulfate (HS) could be at the center of the host-recognition
process of fH [69, 74]. HS is more heterogeneous and therefore isolation of pure species
is more difficult than for heparin, making the latter a common replacement for HS. This
approach seems reasonable on the basis of the common carbon skeleton. The main chem-
ical difference between heparin and HS is the level of sulfation which is higher in heparin.
Sulfated domains in HS are, however, more often involved in protein binding than unsul-
fated domains, lending justification for the use of heparin in place of the physiological HS.
It should be noted that the oligosaccharides used in this study were all desalted in
0.25 M ammonium bicarbonate buffer after ion exchange chromatography. This buffer
was chosen due to the voltile nature of its components, most of which were lost in
subsequent freezdrying steps with D2O. However, due to this procedure the counterion
for carboxyl and sulfate groups in the NMR samples was likely ammonium. The available
literature values which are quoted in this chapter, however, were obtained mostly on
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samples containing potassium or sodium counterions. This difference might explain a
few resonances for which the chemical shifts were notably different from literature values.
3.1.2 Purification of heparin-derived oligosaccharides
Heparinase I-digested heparin was supplied by Jon Deakin (Paterson Institute, Univer-
sity of Manchester). An initial gel filtration yielded separation of disaccharide, tetrasac-
charide etc. up to decasaccharide fractions (Fig. 3.1). The different size oligosaccharides
are labelled as dp2, dp4, dp6 etc. throughout this work, where dp stands for degree of
polymerisation.
Figure 3.1: Gel filtration chromatogram of 50 mg bovine intestinal heparin digested with
heparinase I. The labelling refers to disaccharide (dp2), tetrasaccharide (dp4) etc.
The subsequent strong anion exchange (SAX) chromatograms of different size fractions
became more complex with increasing molecular weight as a consequence of the hetero-
geneous nature of heparin (Fig. 3.2, 3.3). Pure species were obtained for dp2, which
is almost pure after the gel filtration, and dp4, but no attempt was made to isolate
chemically pure species from crude dp8 and dp10 fractions. Fully sulfated dp6 was
also prepared but no further hexasaccharide species were isolated. Differently charged
oligosaccharides of defined length were labelled alphabetically according to the order in
which they eluted from the anion exchange column, starting with the lowest salt con-
74
3.1 Preparation of heparin-derived oligosaccharides
centration. The fully sulfated tetrasaccharide containing six sulfate and two carboxyl
groups is therefore labelled dp4C throughout this report.
Figure 3.2: SAX chromatogram of heparin tetrasaccharides from heparinase I digestion of
bovine intestinal heparin. The absorbance (AU) was measured at 230 nm. A, B and
C refer to the three prevalent tetrasaccharide species with C being the fully sulfated
tetrasaccharide.
For dp2 and dp4 fractions PD-10 desalting columns did not yield sufficient separation
of the oligosaccharides from the salt as determined by the length of the 90◦ pulse on
a 800 MHz NMR spectrometer (14.8 µs at a power level of -0.5 dB, when the default
pulse length at this power level for a salt free sample was 8 µs). The dp2-dp6 fractions
were therefore desalted again using a Sephadex column which yielded better separation.
The desalted samples were freeze-dried and re-dissolved in D2O several times before
NMR spectra were collected for primary structure determination. It was found that
the use of high-grade D2O and a repetition of at least three freeze-drying steps were
necessary for sufficient exchange of water with D2O. The primary structures of dp4A-
C obtained by the digestion of bovine intestinal heparin had been established prior to
this work [237, 238]. The three tetrasaccharides in Fig. 3.4 are representative of the
oligosaccharide variety obtained by enzymatic digestion of heparin, though percentages
vary depending on the heparin source, i.e. organism and tissue. dp4C is fully sulfated
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Figure 3.3: SAX chromatogram of heparin hexasaccharides from heparinase I digestion of
bovine intestinal heparin. The absorbance (AU) was measured at 230 nm. In analogy
to the tetrasaccharide nomenclature C refers to the fully sulfated hexasaccharide dp6C.
heparin tetrasccharide while dp4A and dp4B each contain one sulfate less. In dp4A, the
sulfate group at position 6 of the reducing end glucosamine is missing, while in dp4B
the internal IdoA2S is replaced by unsulfated GlcA.
Following purification, 1D 1H NMR spectra were recorded to verify the primary struc-
tures of the obtained oligosaccharides. A detailed 1H NMR analysis of the three main
tetrasaccharide species obtained by heparinase I digestion of heparin had been carried
out previously in our group and served as a control for fully sulfated tetrasaccharide
dp4C, the most frequently used species (Fig. 3.5).
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Figure 3.4: Different tetrasaccharides obtained from heparinase I digestion of bovine in-
testinal heparin. From top to the bottom dp4C (∆UA2S-(1→4)-α-D-GlcNS6S-(1→4)-
α-L-IdoA2S-(1→4)-α-D-GlcNS6S), dp4A (∆UA2S-(1→4)-α-D-GlcNS6S-(1→4)-α-L-
IdoA2S-(1→4)-α-D-GlcNS) and dp4B (∆UA2S-(1→4)-α-D-GlcNS6S-(1→4)-β-D-
GlcA-(1→4)-α-D-GlcNS6S). Varying structural elements are highlighted in green.
Figure 3.5: 1H NMR spectrum of tetrasaccharide dp4C at 298 K and 600 MHz.
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3.2 Characterisation of two new heparin
tetrasaccharides
During a heparin digestion carried out by Liu Chong in our group (using heparin from
porcine intestinal mucosa and heparinase I from Grampian enzymes) two new tetrasac-
charide species were isolated that had not been present in previous heparin digestions, or
only as very minor components (compare Fig. 3.6 with Fig. 3.2). The characterisation
of these compounds became part of the presented work. The two tetrasaccharides, which
eluted from a SAX column at lower salt concentrations than dp4A-C, were desalted, re-
peatedly freeze-dried and dissolved in D2O, and subjected to NMR analysis at 800 MHz.
The two species were labelled dp4D and dp4E.
Figure 3.6: The SAX chromatogram of the tetrasaccharide fraction from porcine intestinal
mucosa heparin digested by heparinase I showed two additional species D and E. The
absorbance (AU) was measured at 230 nm. A higher flowrate was used than in Fig. 3.2.
3.2.1 Characterization of dp4D
The primary sequence of dp4D was determined by NMR to be ∆UA2S-(1→4)-α-D-
GlcNS-(1→4)-α-L-IdoA2S-(1→4)-α-D-GlcNS (Fig. 3.7). It is presented at the start of
this chapter to facilitate understanding of the subsequently presented spectra.
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Figure 3.7: Scheme of ∆UA2S-(1→4)-α-D-GlcNS-(1→4)-α-L-IdoA2S-(1→4)-α-D-GlcNS
(dp4D). Carbon positions are numbered in red.
Sufficient separation of the anomeric signals allowed efficient assignment of proton reso-
nances of individual rings in this tetrasaccharide using 1D TOCSY experiments. Selec-
tive excitation of individual anomeric protons was followed by varying the length of the
mixing time. Signals of all four rings were assigned in this way (Fig. 3.8).
Signals from the unsaturated D-ring appeared at positions corresponding to documented
∆UA2S frequencies. The small chemical shift of the B-ring anomeric proton indicated
that this ring was IdoA rather than GlcA. The signals of protons H2-H4 in the B-
ring were characteristic for IdoA2S, with the H5 peak likely suppressed along with the
water signal. The chemical shifts and the coupling constants of the two remaining rings
generally exhibited features that were in agreement with GlcNS. Significantly smaller
chemical shifts of H5 and H6 protons in comparison with the protons in fully sulfated
GlcNS6S rings suggested that both rings were missing sulfate groups at the C6 postion.
Thus, analysis of 1D TOCSY spectra of dp4D yielded the primary sequence ∆UA2S-α-
D-GlcNS-α-L-IdoA2S-α-D-GlcNS (Fig. 3.7). In order to establish which of the GlcNS
rings was ring A and which one was ring C 1D ROESY spectra were recorded. The
anomeric proton of the D- and B-rings were excited, respectively, and ROE transfers to
protons of ring C (from D-H1) or ring A (from B-H1) were observed (Fig. 3.9). From
the anomeric proton of the D-ring ROE transfers were observed to H2 of the same ring
as well as to H4 and H6 in GlcNS-1. No transfer to protons from GlcNS-2 was observed
in this spectrum, strongly indicating that GlcNS-1 is ring C. Similarly, ROE transfer
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Figure 3.8: 1D 1H NMR spectrum of dp4D (bottom) and 1D TOCSY spectra of the in-
dividual rings (α-D-GlcNS1, α-D-GlcNS2, B=α-L-IdoA, D=∆UA from top to bottom,
120 ms mixing time). The B-H5 proton frequency is suppressed along with the water.
However, TOCSY excitation at 4.77 ppm lead to transfer to all remaining protons of
the B ring (not shown), indicating the position of B-H5.
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from H1 in the B-ring to H2 and H3 of the same ring were observed and to H4 as well
as H6 in GlcSN-2, confirming GlcNS-2 as the reducing end ring A.
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Figure 3.9: (a) ROE analysis of the linkage between ring B and A. Bottom: ROESY spec-
trum with excitation at 5.19 ppm (H1 of ring B) and 60 ms mixing time yielded ROE
transfer to GlcNS2 (green circles), middle: TOCSY spectrum of GlcNS2, top: TOCSY
spectrum of ring B. (b) ROE analysis of the linkage between ring D and C. Bottom:
ROESY spectrum with excitation at 5.50 ppm (H1 of ring D) and 60 ms mixing time
yielded ROE transfer to GlcNS1 (green circle), middle: TOCSY spectrum of GlcNS1,
top: TOCSY spectrum of ring D.
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To complete the assignment of dp4D through addition of 13C chemical shift information,
a 13C natural abundance 2D 1H, 13C-HSQC spectrum was recorded. Cross peaks of the
anomeric CH groups and the allylic CH group D4 were well separated from the remaining
signals due to their high 1H and 13C chemical shifts. A1 is the only anomeric CH group
which does not participate in a glycosidic linkage, resulting in an upfield shift of its 13C
resonance (Fig. 3.10).
Figure 3.10: 1H, 13C-HSQC spectrum of dp4D (anomeric region). F2 (the directly detected
dimension) corresponds to 1H, F1 (the indirectly detected dimension) to 13C.
The cross peaks of the remaining CH and CH2 groups resonate between 3.0 and 5.0
ppm in the 1H dimension and between 60 and 85 ppm in the 13C dimension (Fig. 3.11).
As expected for two GlcNS residues, the CH groups attributed to the A and C rings
resonate at very similar frequencies in both dimensions, with the exception of the above
mentioned anomeric groups. The low 1H and 13C chemical shifts of the A6 and C6
groups are additional indicators for the absence of sulfate groups at position C6 in both
GlcNS rings. The HSQC spectrum also confirmed the existence of a strong coupling
between protons H5 and H6 in both the A- and the C-ring which distorted the shape of
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Figure 3.11: 1H, 13C-HSQC spectrum of dp4D (non-anomeric region). F2 (the directly
detected dimension) corresponds to 1H, F1 (the indirectly detected dimension) to 13C.
proton multiplets seen in 1H TOCSY spectra. As part of glycosidic linkages A4, B4 and
C4 all show relatively high 13C chemical shifts of around 80 ppm. This supports the H3
and H4 assignment in GlcNS rings A and C as deduced from the analysis of 1D TOCSY
spectra (see above).
A comparison of the measured 1H chemical shifts together with literature values is pre-
sented in Table 3.1. The data are in good agreement, supporting the analysis of the
dp4D primary structure.
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Table 3.1: Measured 1H and 13C chemical shifts in ppm for dp4D (dp4D (exp)) and 1H
literature values for the same pyranoses in similar chemical environments (Lit).
Resonance 1H Lit [237] 1H dp4D (exp) Resonance 13C dp4D (exp)
∆UA2S-H1 5.50 5.50 ∆UA2S-C1 99.70
∆UA2S-H2 4.61 4.58 ∆UA2S-C2 76.73
∆UA2S-H3 4.31 4.21 ∆UA2S-C3 65.19
∆UA2S-H4 5.98 5.98 ∆UA2S-C4 108.23
αGlcNS-2-H1 5.43 5.33 αGlcNS-2-C1 99.67
αGlcNS-2-H2 3.22 3.25 αGlcNS-2-C2 60.46
αGlcNS-2-H3 3.67 3.61 αGlcNS-2-C3 71.95
αGlcNS-2-H4 3.70 3.76 αGlcNS-2-C4 81.12
αGlcNS-2-H5 3.92 3.85 αGlcNS-2-C5 73.35
αGlcNS-2-H6 3.86 3.86 αGlcNS-2-C6 62.50
αGlcNS-2-H6’ 3.86 3.85
αIdoA2S-H1 5.20 5.19 αIdoA2S-C1 101.83
αIdoA2S-H2 4.29 4.28 αIdoA2S-C2 78.04
αIdoA2S-H3 4.22 4.21 αIdoA2S-C3 70.96
αIdoA2S-H4 4.07 4.03 αIdoA2S-C4 78.65
αIdoA2S-H5 4.80 4.77 αIdoA2S-C5 71.39
αGlcNS-1-H1 5.43 5.40 αGlcNS-1-C1 93.73
αGlcNS-1-H2 3.22 3.21 αGlcNS-1-C2 60.86
αGlcNS-1-H3 3.67 3.67 αGlcNS-1-C3 72.13
αGlcNS-1-H4 3.70 3.68 αGlcNS-1-C4 80.19
αGlcNS-1-H5 3.92 3.91 αGlcNS-1-C5 73.20
αGlcNS-1-H6 3.86 3.85 αGlcNS-1-C6 62.81
αGlcNS-1-H6’ 3.86 3.85
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3.2.2 Characterization of dp4E
The primary sequence of dp4E was found to be ∆UA2S-(1→4)-α-D-GlcNS-(1→4)-β-D-
GlcA-(1→4)-α-D-GlcNS6S (Fig. 3.12). It is presented at the start of this chapter to
facilitate understanding of the subsequently presented spectra.
Figure 3.12: Scheme of ∆UA2S-(1→4)-α-D-GlcNS-(1→4)-β-D-GlcA-(1→4)-α-D-
GlcNS6S (dp4E). Carbon positions are numbered in red.
The strategy employed for the characterisation of dp4E was generally the same as for
dp4D. First, a 1D 1H NMR spectrum and a series of 1D TOCSY spectra for the individual
rings were recorded (Fig. 3.13), followed by a more detailed analysis of the individual
rings using 1D TOCSY spectra with different mixing times and different excitation
frequencies as explained for dp4D. The linkages were again established using 1D ROESY
experiments. The absence of a peak at 5.2 ppm indicated that this compound did not
contain an IdoA ring but the IdoA C5-epimer, GlcA, the anomeric proton of which
resonates at a lower frequency. In GlcA the anomeric proton resonates at around 4.6
ppm, partially overlapping with the H2 of the unsaturated ring D (Fig. 3.13).
The 1D proton spectrum of dp4E displays the β-anomer of the reducing end ring as
a minor species (Fig. 3.14). It is characterised by the high field shift of the anomeric
proton in this ring (from 5.45 ppm in the α-anomer to 4.7 ppm in the β-anomer). The
presence of weak signals from H6 and H6’ at relatively high frequencies for the β-anomer
suggest that the reducing ring is a GlcNS6S residue, but ROESY spectra were recorded
to further test this hypothesis.
Analysis of 1D TOCSY spectra of dp4E confirmed the assumption that the B-ring was
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Figure 3.13: 1D 1H spectrum of dp4E (bottom) and 1D TOCSY spectra of the individual
rings (A, C, B, D from top to bottom) acquired using a 120 ms mixing time. The B5
proton signal is suppressed along with the water.
a GlcA, not a IdoA residue. Furthermore, due to the low chemical shifts of the H5
and H6 protons in one of the GlcN rings, it became clear that either ring A or ring C
would have to be a GlcNS residue, the other one a GlcNS6S residue. The D-ring was
found to be the expected ∆UA2S residue that is inherent to oligosaccharides produced
by enzymatic digestion with heparinase. In order to establish which of the rings was the
GlcNS residue 1D ROESY spectra were recorded. The anomeric proton of the D- and B-
rings were excited, respectively, and ROE transfers to protons of ring C (from D-H1) or
ring A (from B-H1) were observed (Fig. 3.15). From the anomeric proton of the D-ring
ROE transfers were observed to H5 and H6 in the GlcNS residue, indicating that GlcNS
is ring C. ROE transfers from H1 in the B-ring were observed to H4 and H3 as well as
H6 in GlcSN6S, confirming it as the reducing end ring A. Thus, the sequence of dpE
was found to be ∆UA2S-(1→4)-α-D-GlcNS-(1→4)-β-D-GlcA-(1→4)-α-D-GlcNS6S.
A detailed comparison of the resonance frequencies with literature values is presented in
Table 3.2. Good agreement between experimental and literature values was observed.
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Figure 3.14: 1D 1H TOCSY spectra of ring A of dp4E. Excitation at 5.435 ppm, 4.307
ppm and 3.007 ppm from bottom, mixing time 120 ms. The proton at 3.007 ppm
belongs to the β-anomer of ring A. Top: 1D spectrum at slightly lower pH than Fig.
3.13 displays clearer peaks of the β-anomer.
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Figure 3.15: (a) ROE analysis of the linkage between rings B and A. Top: TOCSY spec-
trum of the GlcNS6S residue, middle: TOCSY spectrum of ring B, bottom: ROESY
spectrum with excitation at 4.57 ppm (H1 of ring B) and 60 ms mixing time yielded
ROE transfer to GlcNS6S (green circles), establishing this residue as ring A. (b) ROE
analysis of the linkage between rings D and C. Top: TOCSY spectrum of the GlcA
residue, middle: TOCSY spectrum of ring D, bottom: ROESY spectrum with excita-
tion at 5.49 ppm (H1 of ring D) and 60 ms mixing time yielded ROE transfer to GlcA
(green circles), establishing this residue as ring C.
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Table 3.2: Measured 1H and 13C chemical shifts in ppm for dp4E (dp4E (exp)) and 1H
literature values for the same pyranoses in similar chemical environments (Lit).
Resonance 1H Lit [237] 1H dp4E (exp) Resonance 13C dp4E (exp)
∆UA2S-H1 5.50 5.50 ∆UA2S-C1 99.60
∆UA2S-H2 4.61 4.57 ∆UA2S-C2 76.74
∆UA2S-H3 4.31 4.21 ∆UA2S-C3 65.15
∆UA2S-H4 5.98 5.97 ∆UA2S-C4 108.18
αGlcNS-2-H1 5.43 5.54 αGlcNS-2-C1 100.26
αGlcNS-2-H2 3.22 3.25 αGlcNS-2-C2 60.54
αGlcNS-2-H3 3.67 3.59 αGlcNS-2-C3 72.01
αGlcNS-2-H4 3.70 3.75 αGlcNS-2-C4 80.86
αGlcNS-2-H5 3.92 3.78 αGlcNS-2-C5 73.29
αGlcNS-2-H6 3.86 3.79 αGlcNS-2-C6 62.39
αGlcNS-2-H6’ 3.86 3.81
βGlcA-H1 4.59 4.57 βGlcA-C1 105.77
βGlcA-H2 3.37 3.35 βGlcA-C2 75.55
βGlcA-H3 3.84 3.81 βGlcA-C3 78.60
βGlcA-H4 3.77 3.74 βGlcA-C4 79.86
βGlcA-H5 3.81 3.78 βGlcA-C5 79.16
αGlcNS6S-1-H1 5.43 5.44 αGlcNS6S-1-C1 93.65
αGlcNS6S-1-H2 3.25 3.24 αGlcNS6S-1-C2 60.13
αGlcNS6S-1-H3 3.68 3.70 αGlcNS6S-1-C3 72.02
αGlcNS6S-1-H4 3.73 3.68 αGlcNS6S-1-C4 81.38
αGlcNS6S-1-H5 4.12 4.13 αGlcNS6S-1-C5 70.76
αGlcNS6S-1-H6 4.29 4.31 αGlcNS6S-1-C6 69.33
αGlcNS6S-1-H6’ 4.35 4.31
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The here presented NMR studies led to the conclusion that both dp4D and E contained
four sulfate groups. As in the case of the two tetrasaccharides with 5 sulfates, dp4A
and B, the later eluting compound was found to contain a GlcA rather than an IdoA
ring: dp4B binds with higher affinity to the SAX column than dp4A, and dp4E binds
stronger than dp4D. A possible reason for the sudden occurance of these two less sulfated
species in this particular heparin digestion could be a sulfatase impurity in the heparinase
batch used for this digestion. The heparin which was used in this particular digestion
originated from porcine, not bovine like the previously used heparin. The different source
is, however, unlikely to be the reason for the observed differences as both porcine and
bovine heparin are common sources for heparin oligosaccharide preparations and such a
difference has not been described in the literature.
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3.3 Characterization of fully sulfated hexasaccharide
Fully sulfated hexasaccharide was isolated by purifying the hexasaccharide fraction from
the initial gel filtration (Fig. 3.1) using SAX chromatography (Fig. 3.3). Only the
tightest binding fraction, dp6C, was kept since it was assumed that it would be the fully
sulfated species. Homonuclear 1D and 2D NMR was employed to verify this assumption.
The 1D 1H spectrum showed the expected anomeric protons for three GlcN residues and
the unsaturated non-reducing end ring (Fig. 3.16). Only one anomeric signal was found
at the resonance frequency of the IdoA, but a 1D TOCSY (not shown) clarified that
this anomeric signal was indeed made up of the signals of two different IdoA rings. The
unsaturated ring and the two IdoA rings were identified in a 2D TOCSY spectrum (Fig.
3.17).
Figure 3.16: 1D 1H NMR spectrum of hexasaccharide dp6C at 298 K and 600 MHz.
The sequence in which the rings are linked was established by comparison of 2D TOCSY
and 2D ROESY spectra. It was found that the anomeric protons of the GlcN residues
posed a useful starting point because two of the GlcN H1 strips in the ROESY showed
cross peaks with the H3 and H4 resonances of the IdoA residues. This link also allowed
grouping of the resonances of the two IdoA residues, whose H3, H4 and H2 protons
resonate at different frequencies. The GlcN H1 which resonates as the middle of the
three GlcN H1 signals was thus linked to the IdoA with the higher resonance frequency
for H4 and the lower resonance frequency for H3 (Fig. 3.18). The H2 of this IdoA (IdoA1)
was found to overlap with the H3 signal of the unsaturated ring. Analogously, the GlcN
H1 with the lowest resonance frequency among the three anomeric GlcN protons showed
cross peaks with the H3 and H4 resonances of the second IdoA ring (IdoA2) (Fig. 3.18).
In this IdoA residue the H5 proton could also be assigned.
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Figure 3.17: Homonuclear 1H 2D TOCSY spectrum of fully sulfated heparin derived hexas-
accharide. Proton strips of the unsaturated ring D are labelled black. The peaks that
are linked by red lines belong to two IdoA residues with overlapping anomeric proton
shifts. The IdoA H5 protons are supressed along with the water signal. F2 corresponds
to the 1H, F1 to the 13C dimension, respectively.
Figure 3.18: Homonuclear 1H 2D TOCSY (blue) and ROESY (red) of fully sulfated hexas-
accharide. The ROESY peaks which were used to establish the link between IdoA1 and
GlcN2 (A) and between IdoA2 and GlcN3 (B) are highlighted (circles). F2 corresponds
to the 1H, F1 to the 13C dimension, respectively.
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The remaining GlcN residue was identified as the reducing monosaccharide because its
anomeric proton (the one with the highest frequency) did not show cross peaks with
protons from other rings (Fig. 3.19). The anomeric proton of the unsaturated non-
reducing end ring showed cross peaks with the H4 resonance of the GlcN3 ring ( circled
cross peaks in Fig. 3.19).
Figure 3.19: Homonuclear 1H 2D TOCSY (blue) and ROESY (red) of fully sulfated hex-
asaccharide. H1 of GlcN1 shows ROESY cross peaks (red) only with protons which
belong to the same ring and are present in the TOCSY spectrum (blue). The anomeric
proton of the unsaturated ring is linked to the H4 of GlcN3 in the ROESY spectrum
(circles, for assignment of GlcN3 see Fig. 3.18). F2 corresponds to the 1H, F1 to the
13C dimension, respectively.
Comparison of the chemical shifts of the H2-IdoA groups with literature values [239]
confirmed that both IdoA1 and IdoA2 were IdoA2S residues. The six H6-GlcNS res-
onances cluster between 4.2 and 4.4 ppm, which confirmed sulfation in the 6 position
for all three rings. The H2-∆UA resonance frequency was above 4.6 ppm, identifying
the unsaturated non-reducing end ring as ∆UA2S. N-sulfation of the GlcN-rings is more
difficult to judge from NMR spectra because of the larger distance from the CH skeleton.
The high salt concentration which was necessary for elution of the hexasaccharide does,
however, suggest that these positions in the GlcN rings were sulfated as well, so that
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the hexasaccharide was found to be fully sulfated (∆UA2S-(1→4)-α-D-GlcNS6S-(1→4)-
α-L-IdoA2S-(1→4)-α-D-GlcNS6S-(1→4)-α-L-IdoA2S-(1→4)-α-D-GlcNS6S). This com-
pound was further titrated into fH∼7-8Y and monitored by 1H, 15N-HSQC spectra (see
below). A detailed comparison of 1H chemical shifts of dp6C with literature values is
presented in Table 3.3.
Generally, the obtained resonances are in good agreement with the literature. An excep-
tion are the H5 resonances in both IdoA2S rings. Another literature source, however,
reports the IdoA2S H5 resonance in dp4C to be 4.765 [237], which is much closer to the
value obtained for the two IdoA2S H5 resonances in dp6C in this work. 1H resonances
do not seem to be very sensitive to the length of the oligosaccharide under observation
but rather to the degree of sulfation. Thus, it is reasonable to assume that specific res-
onances found in dp4C and dp6C residues do not differ significantly and that the dp4C
resonance frequencies listed in [237] are relevant for this comparison.
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Table 3.3: Measured dp6C (∆UA2S-(1→4)-α-D-GlcNS6S-(1→4)-α-L-IdoA2S-(1→4)-α-
D-GlcNS6S-(1→4)-α-L-IdoA2S-(1→4)-α-D-GlcNS6S) resonance frequencies in ppm
(dp6C (exp)) and literature values (Lit).
Resonance Lit [239] dp6C (exp) Resonance Lit [239] dp6C (exp)
∆UA2S-H1 5.519 5.501 αGlcNS6S-2-H1 5.439 5.423
∆UA2S-H2 4.612 4.616 αGlcNS6S-2-H2 3.289 3.30
∆UA2S-H3 4.317 4.315 αGlcNS6S-2-H3 3.645 3.563
∆UA2S-H4 6.053 5.982 αGlcNS6S-2-H4 3.715 3.672
αGlcNS6S-3-H1 5.402 5.399 αGlcNS6S-2-H5 3.956 4.844
αGlcNS6S-3-H2 3.273 3.301 αGlcNS6S-2-H6 n.d 4.045
αGlcNS6S-3-H3 3.661 3.657 αGlcNS6S-2-H6’ n.d 4.262
αGlcNS6S-3-H4 3.840 3.835 αIdoA2S-1-H1 5.23 5.222
αGlcNS6S-3-H5 3.976 4.050 αIdoA2S-1-H2 4.30 4.344
αGlcNS6S-3-H6 n.d. 4.263 αIdoAS2-1-H3 4.27 4.230
αGlcNS6S-3-H6’ n.d. 4.371 αIdoAS2-1-H4 4.14 4.089
αIdoA2S-2-H1 5.17 5.222 αIdoAS2-1-H5 5.12 4.829
αIdoA2S-2-H2 4.33 4.325 αGlcNS6S-1-H1 5.446 5.446
αIdoAS2-2-H3 4.33 4.194 αGlcNS6S-1-H2 3.257 3.262
αIdoAS2-2-H4 4.10 4.116 αGlcNS6S-1-H3 3.735 3.705





4 Studies on fH∼7 and fH∼7-8
4.1 Protein production
4.1.1 Fermentation and purification of 13C, 15N-fH∼7-8Y
In order to collect triple-resonance NMR experiments for the backbone assignment ex-
periments a 0.7 mM sample of 13C,15N-fH∼7-8Y NMR sample was produced. The P.
pastoris clone (strain KM71H, expression vector pPICZα) containing the DNA sequence
coding for fH∼7-8Y was grown and induced in a Bioflow3000 fermentor (Fig. 4.1). The
fermentation temperature was set to 30 ◦C before the induction phase but due to techni-
cal problems with the water supply the temperature was fluctuating until the induction
phase, when the water regulation was altered and the temperature was set to 15 ◦C. Small
increases in temperature after each methanol feed reflected the increasing metabolic ac-
tivity of the cells. The pH was initially set to 5.0 and was maintained by a control
circuit. This circuit could, however, only act by adding 2 M KOH to correct for the
metabolic production of acid. As can be seen from the fermentation record (Fig. 4.1),
injection of 13C-glucose (injection 1) and 13C-methanol (injections 2-8) led to production
of acid which was compensated for by the automated addition of 2 M KOH. As a result
of a relatively slow pH control circuit the pH had a tendency to overshoot through the
addition of too much KOH. Occasionally a small amount of concentrated phosphoric
acid was added manually to the batch in order to decrease the pH to the setpoint before
induction. As a positive side effect the addition of phosphoric acid increased the buffer
capacity of the batch.
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Figure 4.1: Fermentation of 13C,15N-fH∼7-8Y. The spikes in the agitation curve (dark blue)
reflect metabolic activity, i.e. oxidation of initial 13C-glycerol (1) and 13C-glucose (2)
and, during induction, of 13C-methanol (3-8). The starting point of the induction period
is marked with an asterisk.
The reaction of the cells to 13C-methanol feeds reflects an adaptation process: the first
injection of 4 mL (injection 3 in 4.1) was slowly oxidised, as can be seen by both the low
absolute value to which the agitation rose and the long time it took for it to drop back
to the baseline. The second injection of another 4 mL of methanol was oxidised faster
(injection 4), and the two following injections of 6 mL each were again digested quickly
(injections 5 and 6). The small agitation peak before the last methanol injection is due
to a small volume of methanol that had been gained from washing the empty methanol
vials (injection 7). The last injection consisted of 5 mL of methanol (injection 8). Thus,
a total volume of 31 mL methanol was used.
The overall yield was 60 g cells/800 mL fermentation volume. After separation of the
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supernatant and addition of protease inhibitors 2.5 mL of the supernatant were diluted
with 10 mL of dH2O to perform a small-scale initial purification test on 0.7 mL SP-
Sepharose (Amersham) and gravity flow conditions. The bound protein was washed with
20 mM potassium phosphate and eluted with 1 M NaCl in 20 mM potassium phosphate.
A SDS-gel of the flow through, washing and elution fractions showed a single band of
ca. 15 kDa in the elution fractions and no concentrated protein in the flow through or
washing fractions (Fig. 4.3). The test was repeated using 1.5 M NaCl for elution to
obtain a sharper elution profile (Fig. 4.2). The purification was then scaled up to 7 mL
of SP-Sepharose and the whole supernatant was processed in one step, giving similar
results.
Figure 4.2: Small scale test purifications of 13C,15N-fH∼7-8Y on SP-Sepharose. Shown are
step elutions with 1.5 M (blue) and 1 M NaCl (green). Fractions were collected manually
and the fraction size was 0.5 mL.
After elution the protein was frozen in liquid nitrogen and stored at -80 ◦C until further
purification. During the next purifcation step, MonoS cation exchange chromatography
at pH 6.0, two peaks eluted at similar salt concentrations (Fig. 4.4).
Since no mass difference was observed for these two peaks on a SDS-PAGE gel (Fig. 4.5)
it was assumed that the acidic cloning artefact EAEAAG had partially been removed
from the protein (corresponding to the later peak) and that the resolution of SDS-PAGE
was not sufficient to resolve the two species. The second species was more abundant
and could be separated from the first species using small protein loads and shallower
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Figure 4.3: SDS-gels for small scale test purifications of 13C,15N-fH∼7-8Y. A) elution with
1 M NaCl, B) elution with 1.5 M NaCl. SN: supernatant, FT: flow through, W: wash, 1)
- 7) fractions corresponding to Fig. 4.2. A protein ladder with individual bands in kDa
for comparison is included in each gel. The molecular weight of fH∼7-8Y is 13 kDa.
salt gradients. Partial proteolysis of similar cloning artefacts had been observed when
using the same cloning method in the past. 1H, 15N-HSQC spectra of both proteins
displayed two additional 15NH cross peaks for the earlier eluting species (Fig. 4.6).
These additional cross peaks and the backbone assignment of fH∼7-8Y accomplished on
the later eluting species led to the conclusion that the protein belonging to the later peak
contained the slightly truncated cloning artefact EAAG, while the earlier eluting peak
contained the full-length cloning artefact EAEAAG. One additional negatively charged
sidechain in the N-terminus seems thus sufficient to lower the affinity of the 13 kDa
protein for a cation exchange column.
Despite the lower theoretical pI of fH∼7-8Y (8.76 with the artefact EAAG and 8.61
with the artefact EAEAAG) when compared to fH∼7Y (9.24 with the artefact EAAG,
all values obtained from SwissProt) an overlay of the purification chromatograms of both
proteins at pH 6.0 shows that fH∼7-8Y elutes at a higher salt concentration than fH∼7Y
(Fig. 4.4).
Comparison of the 1H, 15N-HSQC spectra of fH∼7Y and fH∼7-8Y showed that fH∼7-8Y
was well folded and that most residues in module 7 experience no or only relatively small
chemical shift changes in the presence of module 8 (Fig 4.7).
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Figure 4.4: Purification of 13C,15N-fH∼7-8Y (solid line) on a MonoS cation exchange col-
umn. The two peaks correspond to proteins with the artefact EAEAAG (earlier peak)
and EAAG (later peak). For comparison the purification of fH∼7Y is overlayed (dashed
lines, cloning artefact EAAG).
Figure 4.5: SDS-PAGE of purified 13C,15N-fH∼7-8Y after cation exchange on a MonoS
column. Shown are fractions between 40 and 50 mL of the chromatogram shown in Fig.
4.4 as well as a protein ladder with individual bands in kDa for comparison. No mass
difference can be seen between the two peaks in Fig. 4.4 signalling only a small difference
in mass or different oligomeric states or different conformations for both peaks.
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Figure 4.6: Overlay of 1H, 15N-HSQC spectra of the first (red) and second (blue) peak
of fH∼7-8Y-elution from a MonoS column (Fig. 4.4). The asterisks denote the two
15NH-cross peaks that are only present in the earlier eluting protein. F1 refers to 15N,
F2 to the 1H dimension.
4.1.2 Fermentation and purification of unlabelled and 15N-labelled
proteins
In principle, fermentations of 15N-fH∼7Y, 15N-fH∼7-8Y/H, 15N-fH∼19-20 and 15N-NK1
were conducted in a similar manner but unlabelled glycerol was used instead of 13C-
glycerol and 13C-glucose. 30 mL glycerol was present in the minimal media and further
10 mL of glycerol were added for the additional feeding step. Unlike the clones contain-
ing the fH∼7-8 and fH∼19-20 sequences the NK1-clone belonged to a Mut+-strain with
an intact AOX1 gene. As a result, this clone oxidised methanol at a much higher rate.
Ca. 110 g of cells were obtained from a 960 mL fermentation of 15N-NK1 and yields
were similar for the other 15N-labelled protein expressions. The supernatants of different
expressions were processed in the same way as the 13C,15N-fH∼7-8Y-containing super-
natant with the exception of 15N-NK1 which was purified on Heparin-Sepharose during
the initial purification step since a small scale test showed better purification results
than when using SP-Sepharose. 15N-fH∼7-8H, 15N-fH∼7-8Y and 15N-fH∼19-20 were
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Figure 4.7: Overlay of the 1H, 15N-HSQC spectra of 15N-fH∼7,8Y(blue, later eluting peak
from MonoS) and 15N-fH∼7Y (red) with inlayed structures of the two proteins (same
colour coding, PDB 2JGX for fH∼7 and derived from PDB 2UWN for fH∼7-8).
purified like 13C, 15N-fH∼7-8Y and gave similar results with minor peaks corresponding
to complete cloning artefacts and major peaks corresponding to truncated cloning arte-
facts. 15N-NK1 was produced as one uniform protein but, unlike the fH modules, suffered
from degradation if stored at room temperature or 4 ◦C. For production of unlabelled
fH constructs (fH∼7Y and fH∼19-20) shaker flask expressions were sufficient. Yields
were lower when compared to the fermentor expressions but still several mg/1L culture.
Similar distributions of cloning artefacts were observed for shaker flask and fermentor
expressions.
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4.2 Backbone assignment of 13C,15N-fH∼7-8Y
Binding experiments with fH∼7 and dp4C showed significant chemical shift changes for
K446, the C-terminal residue of fH∼7. Consequently, in order to assess possible binding
contributions from module 8 (which had not previously been implicated in heparin bind-
ing), the 13C, 15N labelled double module fH∼7-8 was prepared and its backbone was
assigned. The backbone assignment was achieved using the CBCA(CO)NH/CBCANH
(Fig. 4.8) pair of 3D triple resonance experiments as well as the NH(CA)CO/NHCO
and HBHA(CO)NH/HBHANH spectral pairs, as described in section 1.8. MARS [211],
a software package for semi-automated backbone assignment, assigned about 50% of the
backbone resonances in the HSQC spectra, using as input a list containing the Cα, Cβ,
CO, Hα and NH resonance frequencies as well as assignments of the glycine residues.
Importing these assignments into CCPN Analysis and manually checking for mistakes
led to only 2-5% disagreement with the automated assignment. The rest of the backbone
was assigned manually; 97% of the 15NH backbone resonances were identified.
During the assignment it was found that the protein contained the artificial cloning
sequence EAAG at the N-terminus. Residues which did not give peaks in the 1H, 15N-
HSQC spectra (Fig. 4.9) were N396, N399, C442 and D497, the first three of which
belong to module 7. Severe overlap occurred between the backbone amide signals of
C448 and C389, D413 and V445 as well as K474 and Y465, making temperature- and
pH-titrations in small steps necessary to transfer the assignments for conditions used
for oligosaccharide titrations (i.e. from 310 K, pH 5.0 to 298K, pH 7.4). Spectra were
collected at pH 5.0 and 310 K, 307 K, 304 K, 301 K and 298 K as well as at 298 K and
pH-values 5.0, 5.9, 6.4, 6.9 and 7.4. The backbone signals of K474 and Y465 remained
unresolved under titration conditions, but the D413 and V445 pair separated and both
peaks could be followed during the titrations.
The backbone 15NH signals of K472, C477 and H417 only showed small overlap at as-
signment conditions but merged into one broad peak during the temperature titration.
However, H417 could be followed under the ligand-titration conditions since it showed
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Figure 4.8: Example of two 1H, 13C-planes at two different 15N frequencies in the overlaid
CBCANH (purple/red) and CBCA(CO)NH (green) spectra, showing the stretches linked
to the backbone 15NH-resonance frequencies of Ile506 (left) and Cys505 (right). Cross
peaks occurring in both spectra in the Ile506 stretch belong to residue Cys505, while cross
peaks which are only present in the CBCANH spectrum belong to residue Ile506. Equally,
cross peaks in both CBCANH and CBCA(CO)NH spectra in the Cys505 stretch belong
to residue Thr504. The sequential order can be established because the CBCANH cross
peaks in the Cys505 strip align with cross peaks in both CBCANH and CBCA(CO)NH
in the Ile506 strip.
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Figure 4.9: Assigned 1H, 15N-HSQC spectrum of 13C,15N-fH∼7-8Y at 310 K, 20 mM potas-
sium phosphate, pH 5.0. Sidechain resonances are denoted by asterisks and connected
by horizontal lines for Gln and Asn residues. Peaks with dashed crosses and colored
green are folded and not displayed at their real 15N frequency.
characteristic large chemical shift changes during the pH-titration that were also ob-
served for this residue during pH-titrations of fH∼7Y/H where the H417 15NH cross
peak did not overlap with other residues.
Other 15NH cross peaks that could not be unambiguously assigned under the conditions
used for oligosaccharide titrations (mostly due to excessive broadening at pH 7.4) be-
longed to residues L386, E395, G397, K424, S463 and K496. In total, information of
chemical shift perturbation for the backbone NH cross peaks of about 10 non-Proline
residues in fH∼7-8Y could not be given due to missing/unassigned peaks in the reference
spectra. This represented about 8% of the total backbone signals. However, the peaks
that remained unassigned because of spectral overlap (in particular the C448/C389 and
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K472/C477) were still visible during the ligand titrations and did not experience sig-
nificant shift changes during the titrations, implying that none of these residues were
involved in binding.
A comparison of the assigned 1H, 15N-HSQC spectra of fH∼7Y and fH∼7-8Y showed
that the biggest chemical shift movements are experienced by residues at the C-terminus
of CCP 7 as would be expected from the end-to-end arrangement of the two modules.
However, residues in the strand which contains a helical loop did also exhibit signifi-
cant shift changes, suggesting small local structural changes (Fig. 4.10 and 4.11) upon
addition of CCP 8.
Figure 4.10: Overlay of 1H, 15N-HSQC spectra of fH∼7Y (red, PDB 2JGX) and fH∼7-8Y
(blue, prepared from PDB 2UWN (fH∼6-8H)). K446 is the N-terminal residue in the
fH∼7Y construct. The labels highlight residues in CCP 7 which experience combined
chemical shift changes larger than the standard deviation of 0.03 ppm in the presence
of CCP 8.
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Figure 4.11: Visualization of chemical shift changes experienced by CCP 7 in the presence of
CCP 8. Cross peaks of the residues highlighted in blue experience backbone combined
chemical shift changes larger than the standard deviation of 0.03 ppm in the presence
of CCP 8 (see Fig. 4.10).
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4.3.1 Titrations of fH∼7 and fH∼7-8 with heparin tetrasaccharide
and sucrose octasulfate monitored by 1H, 15N-HSQC
The first oligosaccharide-protein titrations were done using 15N-fH∼7Y and 15N-fH∼7H,
which were provided by Dr. Andrew Herbert. The conditions used were 20 mM potas-
sium phosphate, pH 7.4 and 298K, the protein concentration was 50 µM and the initial
ligand concentrations were between 13 and 25 µM, respectively. First, a reference spec-
trum without the ligand was recorded to account for small differences in pH and salt
concentrations that could lead to small chemical shift changes compared to the spectra
used for the assignment. This spectrum was also used to transfer the assignments ob-
tained at more acidic conditions by Andrew Herbert for both variants of fH∼7. Titration
points with increasing ligand concentrations were recorded, chemical shift differences
were calculated and histograms showing these differences were produced (Fig. 4.12).
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Residue 402, linked to AMD, appeared to be at the edge of the heparin binding site:
while this residue’s cross peak did not show significant chemical shift changes, residues
405 and 406 experienced large chemical shift changes.
Figure 4.12: Combined amide chemical shift changes in 15N-fH∼7Y (solid) and 15N-fH∼7H
(faint) upon titration with dp4C (see the inset) at 298 K, 20 mM potassium phosphate,
pH 7.4. Residues with chemical shift changes >0.06 ppm (green) and chemical shift
changes of 0.04-0.06 ppm (yellow) are mapped onto the fH∼7Y-structure and drawn in
stick presentation (PDB 2JGX). Basic residues are also drawn in stick representation.
Proline residues and other non-observable residues are omitted from the sequence.
Residues most affected by the binding are K405, F406 and K446 which experience chem-
ical shift changes >0.06 ppm (larger than 3 times the average chemical shift change).
Residues R404 (in the Y-form), S411, I412, D413, V414, Y390 and F391 also shift sig-
nificantly (with chemical shift changes larger than 2 times the average chemical shift
change). The region on CCP 7 which comprises all these residues except for K446 is
denoted site 1 in the following text. When these residues were mapped onto the NMR
structure of fH∼7Y [240] it became obvious that binding site 1 is in proximity to residue
402 and is orientated towards the N-terminus and module 6 rather than towards the
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C-terminus and module 8. However, a large chemical shift change was also observed for
the most C-terminal residue of the fH∼7-construct, K446, which is located in the linker
region between fH∼7 and fH∼8. (The linker region is generally referred to as the amino
acid sequence between the last Cys residue of one module and the first Cys residue in
the following module, in this case 442C-IRVKT-448C). It was assumed that this sec-
ond binding site (site 2) could be due to the artificial absence of module 8 in the fH∼7
constructs and an increased flexibility of the C-terminus. Consequently, fH∼7-8Y and
fH∼7-8H were expressed and labelled with 15N. Titrations under the same conditions as
used for 15N-fH∼7 showed that site 2 resonances exhibited larger chemical shift changes
than those in site 1 (Fig. 4.13).
Judged by the chemical shift changes, the primary binding site in the double module
therefore seemed to be located in the linker region and the hypervariable loop close to
the C-terminus of module 7 (Fig. 4.13). The presence of CCP 8 completes the binding
site in the linker between CCP 7 and CCP 8. Even more unexpected was the finding that
the double module fH∼7-8 (neither the H- nor the Y-form) does bind dp2, while in the
case of fH∼7 dp2 and dp4 showed very similar binding results. This behaviour, observed
using 1H, 15N-HSQC titrations, was supported by GMSA data acquired by Jon Deakin
and Dr. Malcolm Lyon (see below). More binding studies with sucrose octasulfate
(SOS) were conducted and compared with the results obtained from the dp4C titrations
as part of our collaboration with an x-ray group [241]. 15N fH∼7-8 rather than fH∼7
was used in these studies since the titrations with dp4C suggested contributions from
the linker region between CCP 7 and CCP 8. SOS is often employed as a heparin
mimic in x-ray crystallography but a comparison with the more physiological heparin-
derived tetrasaccharide dp4C was required, given the large chemical differences between
both compounds (structures inserted in Fig. 4.13). The titration of 15N-fH∼7-8Y was
repeated using SOS instead of dp4C (Fig. 4.13, 4.14). No significant differences in
the binding sites of these two ligands were found despite large differences in size and
primary structure, suggesting that both molecules bind to the same regions of fH∼7-
8Y and that charge density rather than subtle structural features is responsible for the
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Figure 4.13: Combined amide chemical shift changes in 15N-fH∼7-8Y upon titration with
dp4C (red) and the heparin mimic sucrose octasulfate (SOS, blue) at 298 K, 20 mM
potassium phosphate, pH 7.4. Site 1 observed in the single module fH∼7 (Fig. 4.12)
shows smaller chemical shift changes than the double module. Concentrations used: 50
µM protein with 75 µM dp4C and 60 µM protein with 500 µM SOS. Missing residues
are either proline residues or residues whose amide cross peaks were lost in the presence
of the ligand due to line broadening.
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binding. Chemical shift changes upon binding of the two ligands are quantified in the
next section.
Figure 4.14: 1H, 15N-HSQC spectra of 15N-fH∼7-8Y titration with sucrose octasulfate
(SOS) at 298 K, 20 mM potassium phosphate, pH 7.4. Concentrations were 60 µM
protein (ref) and 15.5, 31, 62, 124, 248 and 496 µM SOS.
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4.3.2 Evaluation of the effects of Y402H SNP on the binding of
dp4C and SOS to fH∼7-8
A direct comparison of the 1H, 15N-HSQC titrations of both fH∼7-8 variants with both
dp4C and SOS shows that only small differences are observed between the protein vari-
ants and dp4C/SOS binding sites (Fig. 4.15). Subtle differences are found at the N-
terminus of CCP 7. The chemical shift changes seem to be larger when using the H402
variant but it is possible that this is caused by slightly varying protein or GAG concen-
trations. During HSQC titrations samples are repeatedly taken from their NMR tubes,
mixed with small volumes of ligand stock and, after pH adjustment, transferred back.
This procedure leads to errors in concentration as the sample volume is permanently re-
duced. In complementary experiments like gel mobility shift assays and heparin affinity
chromatography no significant differences in binding affinities were observed between the
two fH∼7-8 variants. Both proteins eluted in one peak from a heparin affinity column
after simultaneous injection. Thus, using the fH∼7-8 construct neither changes in the
position of the binding site nor significant reduction in affinity were observed as a result
of the Y402H SNP.
113
4.3 Binding studies of fH∼7 and fH∼7-8
Figure 4.15: Comparison of the effect of SOS (top) and dp4C (bottom) fH∼7-8Y (blue)
and fH∼7-8H (red).
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4.3.3 Titration of fH∼7-8Y with dp6C
An attempt was made to titrate dp6C in fH∼7-8Y in order to answer two questions:
whether the binding site for the hexasaccharide is larger and whether it binds more
strongly than dp4C to the protein. While mainly the same residues seemed affected by
the complex formation the binding affinity was higher as judged by intermediate broad-
ening and disappearance of cross peaks (Fig. 4.16 and 4.17). At large excess of dp6C
some cross peaks which had been broadened during early titration points sharpened,
signalling saturation. Other peaks, however, did not re-appear during the last points
of the titration (Fig. 4.17). The effect which temperature and field strength have on
the exchange regime was not investigated further in this titration. During the titration
of HBD2 with Fondaparinux, however, these two parameters were found to be impor-
tant tools that allowed the chemical shift changes to be followed during intermediate
exchange broadening (see below).
A comparison of the fH∼7-8Y titrations with dp4C and dp6C revealed similar binding
sites for both oligosaccharides (Fig. 4.18). The largest chemical shift changes were still
observed in the linker region between CCP 7 and CCP 8. The binding affinity of fH∼7-8Y
for dp6C can be judged to be higher than the affinity for dp4C because the titration
with dp6C showed signs of intermediate broadening. However, the N-terminal binding
site in CCP 7 which was more pronounced in the dp4C titration of fH∼7 than in fH∼7-8
did become more prominent in this titration with dp6C. A possible interpretation of this
observation is that with dp6C both binding sites can be bridged while with dp4C they
compete for oligosaccharide binding. This observation matches the hypothesis that for
dp6C the two binding sites termed site1 and site2 above simultaneously contribute to
the complex, while dp4C is only able to contact one of them at any time. The length
of a free tetrasaccharide is ca. 17 Å[165], which is not sufficient to span a whole CCP
module of about 30-35 Å. dp6C is significantly longer (ca. 25 Å) than dp4 and almost
as long as a CCP module, it might therefore be able to contact both site1 and site2
simultaneously. dp6C does also carry a larger negative charge (eleven anionic groups
instead of eight in dp4C), although the charge density is the same. Physiological NS
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Figure 4.16: Titration of 25 µM fH∼7-8Y with dp6C at 298K, 20 mM potassium phos-
phate, pH 7.4, 800 MHz. Ligand concentrations were: 0 µM (blue), 12.5 µM (red),
37.5 µM (green), 50 µM (yellow), 100 µM (blue). The region of the spectrum within
the black square is enlarged in Fig. 4.17. The asterisk denotes residue V445, whose
shift changes follow a curved rather than a straight line, indicating that this residue
experiences two different events during the titration. F2 refers to the 1H, F1 to the
15N dimension, respectively.
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Figure 4.17: Enlargement of Fig. 4.16. Cross peaks undergo intermediate exchange broad-
ening but sharpen at high ligand concentrations. FH∼7-8Y: 25 µM, dp6C: 0 µM
(blue), 12.5 µM (red), 37.5 µM (green), 50 µM (yellow), 100 µM (blue). F2 refers to
the 1H, F1 to the 15N dimension, respectively.
domains in HS comprise 8-9 disaccharide units, dp6 is therefore still short in comparison
to physiological HS chains and the length of one CCP module could easily be spanned
by physiological HS chains.
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Figure 4.18: Comparison of the effect of dp4C (blue, protein:GAG ratio 1:3.5) and dp6C
(red, protein:GAG ratio 1:4) on fH∼7-8Y.
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4.3.4 Gel mobility shift assay and heparin affinity chromatography
on fH∼7-8
The GMSA data, obtained by Jon Deakin, led to the same result as the titration ex-
periments monitored by HSQC spectra (Fig. 4.19): the migration of dp2 in the electric
field is not hindered by either of the fH∼7-8 mutants, implying that dp2 is not bound
by these proteins and in the buffer usually employed in GMSA (PBS).
Figure 4.19: GMSA on fH∼7-8Y/H (top) and fH∼7Y/H (bottom, taken from [240]) with
different length oligosaccharides. Free ligand migrates to the anode (+). Oligosaccha-
rides which are are hold back by the proteins and do not migrate out of the wells.
This assay did not exhibit significant differences in the binding affinities for the same
length oligosaccharides between the two isoforms fH∼7-8Y and fH∼7-8H. This result is
in line with the titration results which showed that the main binding site in fH∼7-8 is
located at the C-terminus of CCP 7, well away from residue 402.
Injection of a solution containing both fH∼7-8Y and fH∼7-8H in PBS onto a heparin
affinity column (Poros HE20) followed by elution with a salt gradient resulted in a single
peak, again implying that in the double module residue 402 is not part of the major
heparin binding site (the same experiment yields separation of the two variants of the
fH∼7 single module, [240]).
119
4.4 Oligomerisation of fH∼7 upon addition of dp4C
4.4 Oligomerisation of fH∼7 upon addition of dp4C
In many cases heparin binding proteins dimerise upon heparin binding [242, 243, 244].
This dimerisation slows down the molecular tumbling which is reflected in the change of
15N relaxation times. The rotational correlation time, τc, can be determined from the
ratio of the 15N T1 and T2 relaxation times [245]. Chemical exchange can influence the
results. However, in the cases presented here the majority of residues experience no or
marginal chemical shift changes and can safely be described as being in the fast exchange
regime in which no peak broadening is observed. In this case the resulting relaxation is
given by the weighted average of the relaxation times of individual species [246]. The
15N T1 and T2 relaxation times were measured based on 1D experiments sampling the
envelope of NH resonances. A comparison with 2D 15N relaxation data obtained for
fH∼7Y showed good agreement with the 1D data. Therefore, the 1D method was used
for this study. The measurement of 15N T1 and T2 for different samples led to the fol-
lowing results:
sample method T1 / ms T2 / ms T1/T2 τc / ns
fH∼7Y 25 µM 1D, 800 MHz 712 145 4.9 4.7
fH∼7Y 25 µM 2D, 600 MHz 462 151 3.0 4.6
fH∼7Y 25 µM + dp4C 40 µM 1D, 800 MHz 981 74 13.3 8.4
fH∼7H 600 µM 1D, 800 MHz 662 121 5.5 5.0
fH∼7H 25 µM + dp4C 40 µM 1D, 800 MHz 1140 85 13.4 8.5
The drastic increase in the protein τc values in the presence of dp4C clearly imply that
some form of oligomerisation (most likely dimerisation) is caused in both fH∼7Y and
fH∼7H by the addition of the heparin-derived oligosaccharide dp4C. Large excess of
dp2 caused some dimerisation of fH∼7Y (data not shown), however to a much smaller
degree, which might be related to its size and the fact that it contains only three sulfate
groups as opposed to six sulfate groups in dp4C. The measurements were all done using
samples with pH values around 5, and it remains to be seen if this trend is also observed
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at physiological pH. Practically identical rotational correlation times of the two proteins
imply that their dimerisation in the presence of dp4C does not depend on the 402Y/H
polymorphism. Sedimentation studies of fH∼6-8Y and H in the presence of heparin
decasaccharide have recently been carried out and in these experiments a slightly larger
self-association tendency was observed for the H402 form when compared to the Y402
form [247].
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4.5.1 The HISQC experiment
1H, 15N-HSQC titrations are commonly used to monitor chemical shift changes of back-
bone NH signals induced by increasing ligand concentrations. In the context of heparin
binding proteins, however, lysine and arginine sidechains are of central importance. Due
to the long sidechains of these two basic amino acids it does not seem ideal to observe
backbone resonances only, as the backbone NH of a lysine residue whose ζ-NH+3 -group
is involved in an interaction does not necessarily undergo large chemical shift changes
(and vice versa). The 1H, 15N-HSQC experiment alone does not confer the degree of
atomic resolution that NMR is capable of. This work demonstrates how monitoring the
backbone resonances can be complemented by sidechain experiments both in the non
covalent protein heparin complex (H2CN) and after chemical cross linking (HISQC).
One reason for the absence of arginine- and lysine sidechains in the HSQC experiment
is the fast exchange of sidechain NH protons with bulk water. For arginine Hε signals
this exchange is slow enough at pH values below 6, thus arginine NεHε cross peaks can
be observed under slightly acidic conditions and are usually assigned during structure
determination. For lysine Hζ protons the exchange rate is even faster, and at pH 6
and room temperature NζHζ resonances are not observed unless they belong to buried
sidechains or are protected from exchange by complex formation/oligomerisation. Ad-
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ditionally, the 1H, 15N-HSQC experiment is usually performed with a nitrogen offset
of around 110 ppm which is far away from the resonance frequency of Nζ nitrogens at
around 33 ppm. Consequently, ζ-NH+3 groups do not usually appear in
1H, 15N-HSQC
spectra. These limitations are overcome by the HISQC pulse sequence (for Heteronu-
clear In-phase Single Quantum Coherence), which is optimised for lysine ζ-NH+3 -groups
rather than backbone NH groups [248]. The key of the HISQC experiment is the fact
that during the nitrogen chemical shift labelling period the 15N transverse coherence
is kept in-phase with respect to the the attached protons via proton decoupling, hence
the name of the sequence. The development of the HISQC experiment was motivated
by a tight DNA-protein complex in which a lysine NζHζ cross peak was protected from
exchange with water by the tightly bound ligand [248]. Here, it was investigated if a
similar protection could be observed for the fH∼7Y-heparin interaction. Spectra were
recorded at different temperatures and pH values to determine conditions that could be
used for the assignment of all lysine NζHζ cross peaks in fH∼7Y. Only at 283 K and pH
3.0 was the water exchange sufficiently slow to observe and assign all NζHζ resonances,
conditions which can hardly be used for physiological meaningful ligand titrations. This
problem was overcome by covalent cross linking of the fH∼7Y-GAG complex and use of
the H2CN pulse sequence, as desribed in this section.
4.5.2 Preparation of a covalent GAG-protein complex
Standard 1H, 15N-HSQC titrations of proteins with GAGs follow the movement of back-
bone NH resonances. Out of nine basic residues (five lysines and four arginines) only
three were among the residues that displayed significant movement of NH cross peaks
during the titration of fH∼7Y with dp4C. The positions of the five lysine residues in
the structure of fH∼7Y are indicated in Fig. 4.20. Three are in the N-terminal part
of the protein (K388, K405 and K410) while two are in the C-terminal half (K424 and
K446). In order to characterise the contributions from these lysine sidechains to binding
of dp4C a zero-length cross linking strategy was applied. dp4C contains two carboxyl
groups which can be activated with carbodiimides. Subsequently, a peptide bond can be
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formed with protein lysine sidechains if the activated oligosaccharide forms a complex
with the protein. A similar strategy was developed previously to characterise protein-
protein complexes through cross linking of lysine and aspartate/glutamate sidechains,
followed by tryptic digestion and mass spectrometry [249].
Figure 4.20: Position of the five lysine residues on fH7Y (PDB 2JGX).
Prior to cross linking, the purity of fH∼7Y was checked using cation exchange chro-
matography (Fig. 4.21). The activated dp4C was separated from excess cross linking
reagent using a PD-10 desalting column. The products of the cross linking reaction
were also loaded onto a MonoS column in order to separate free protein, whose binding
properties should be unchanged, from the cross linked species. The cross linked protein,
fH∼7Yxdp4C, was expected to bind with much lower affinity to the cation exchange
column due to the negative charges of the dp4C moiety. Different fractions were subject
to MALDI-TOF mass spectrometry and it was found that the cross linked protein did
not bind to the MonoS column at all (Fig. 4.22). The masses of several minor species
which bound better than fH∼7Yxdp4C but less well than the free protein were also
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measured. It was concluded that they corresponded to species arising from chemical
modifications of fH∼7Y with the cross linking reagents and dimerisation caused by cross
linking of two protein molecules without a dp4C molecule. Thus, separation of activated
dp4C from the cross linking reagents prior to addition of the protein appears to have
been incomplete. Further purification of the MonoS column flow through using HiTrap
desalting columns also revealed the presence of remaining cross linking reagents (Fig.
4.23). An accurate mass measurement after this desalting step and dialysis confirmed
that the protein-GAG hybrid recovered from the MonoS flow through contained only
mono-cross linked species (Fig. 4.24).
Figure 4.21: Purity check of fH∼7Y on a MonoS column prior to cross linking with dp4C,
pH 6.0.
4.5.3 HISQC spectra of fH∼7Y and fH∼7Yxdp4C
The HISQC sequence is a variant of the HSQC sequence which is optimised for lysine
ζ-NH+3 sidechains [248]. The presence of 5-10% deuterium for the lock signal as usu-
ally used in protein NMR can lead to complications in HISQC spectra because proton-
deuterium exchange in ζ-NH+3 -groups produces NH2D and NHD2 species which display
isotope shifts in both dimensions and deuterium spliting in the 15N dimension. These
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Figure 4.22: Purification of fH∼7Yxdp4C on a MonoS column at pH 6.0. The cross linked
protein does not bind to the cation exchange column due to the presence of the neg-
atively charged tetrasaccharide. Free protein elutes at the same salt concentration as
previously (Fig. 4.21). A range of minor species was detected, corresponding to chem-
ically modified fH∼7Y. The masses are approximate as they were acquired without
previous calibration of the MALDI-TOF mass spectrometer.
Figure 4.23: Desalting of fH∼7Yxdp4C on two consecutive HiTrap Desalting columns. The
first peak corresponds to fH7Yxdp4C while the large second peak most likely contains
remaining cross linking reagents.
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Figure 4.24: Accurate mass measurement of fH∼7Yxdp4C using tandem mass spectrome-
try. The simulation of a species with five postive charges (red triangles) corresponds
well to the measured spectrum.
satellite peaks surround the main NH3 cross peaks. While the NHD satellites that
are usually observed for glutamine and asparagine sidechains in protein 1H, 15N-HSQC
spectra aid in identifying sidechain signals, such satellites cause intensity loss and in-
convenient overlap in HISQC spectra because the chemical shift dispersion of the NζHζ
cross peaks is generally very small. Additionally, peak intensities can vary widely due to
different proton exchange rates making the distinction between the satellites of strong
peaks and the weak peaks problematic. To achieve satellite-free NζHζ cross peaks com-
mon 5 mm NMR tubes were replaced by capillary tubes (Norell). These consist of a
5 mm NMR outer tube and a smaller inner tube with an outer diameter of 2 mm and
a volume of 60 µL. This capillary was filled with D2O for the lock signal and no D2O
was added to the actual sample. This setup allows for the necessary number of deu-
terium spins for the lock signal while preventing proton-deuterium exchange. It should,
however, be noted that if free hydrogen/deuterium exchange is allowed the relative in-
tensities of the NH3, NH2D and NHD2 peaks can be used to determine the flexibility of
lysine sidechains, as proposed recently [250]. A practical solution to the problem can be
achieved by using deuterium decoupling during the t1 period. This removes the splitting
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caused by deuterium but not the isotope shifts.
A 15N-fH∼7Yxdp4C sample which had been prepared by Jon Deakin from 15N-fH∼7Y
and dp4C was subject to HISQC spectroscopy at pH 3.0 and 283 K. These conditions
were found to be suited for the free fH∼7Y, i.e. the protein appeared to be folded at
this pH as judged from the 1H, 15N-HSQC spectrum. At higher pH or temperature at
least one of the five sidechain NζHζ cross peaks disappeared due to fast exchange with
water. Overlay of the free and cross linked samples showed that only two of the five
lysine residues were not affected by the cross linking (Fig. 4.25).
Figure 4.25: Overlay of the assigned HISQC spectra of free fH∼7Y (black) and cross linked
fH∼7Yxdp4C (green). The two most C-terminal lysines, K424 and K446 seem unaf-
fected by the cross linking.
Assignment of the HISQC spectrum was accomplished using a 13C,15N-sample of fH∼7Y
and recording an (H)CCENH3 spectrum [248]. This pulse sequence directs the TOCSY
magnetisation transfer in the opposite direction compared to the flow of magnetisation in
the C(CO)NH-TOCSY experiment, linking the Cα - Cε resonances to the ζ-NH+3 group
rather than to the backbone NH atoms. The spectrum was recorded using the free pro-
tein and the same pH and temperature conditions as used for the HISQC spectra. It was
then compared to the conventional sidechain C(CO)NH-TOCSY spectrum of fH∼7Y,
which had been assigned in our group prior to the start of this project (Fig. 4.26). The
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Cα - Cε chemical shifts for all lysine sidechains in the assigned C(CO)NH-TOCSY were
compared to the Cα - Cε chemical shifts for all residues in the unassigned (H)CCENH3
spectra and lysine residues in the latter were identified based on the similarity of the
five carbon chemical shifts in each sidechain. Comparison of the 13C chemical shifts
allowed transfer of the assignments despite the large difference in pH and temperature
under which the original TOCSY had been recorded (pH 5.0, 298K). The similarity of
the carbon chemical shifts does again point to the stability of the protein fold at pH 3.0.
K446 was not present in the C(CO)NH-TOCSY spectrum because in this experiment
lysine sidechain resonances are detected on the C-terminal neighbour, which is lacking
for K446 in the fH∼7 construct. However, since the remaining four lysine sidechains
could be unambiguously assigned using the described strategy the only remaining lysine
sidechain in the (H)CCENH3 could be positively identified as belonging to the remaining
K446.
Based on the assigned HISQC spectrum of fH∼7Y the conclusion was drawn that neither
K424 nor K446 was cross linked to dp4C in fH7Yxdp4C (Fig. 4.25). This result was
surprising as K446 showed the largest movement of its backbone NH cross peak during
the titrations with dp4C and SOS. An accurate mass measurement of 14N-fH7Yxdp4C
had shown that the mass of the cross linked protein corresponded to the linkage with
one dp4C molecule only, thus the disappearance of the three N-terminal lysine sidechain
15NH cross peaks in the HISQC spectrum could only be explained with exchange broad-
ening. An 1H, 15N-HSQC spectrum of the cross linked sample did indeed exhibit large
perturbations and bleaching of resonances in the whole N-terminal region of the pro-
tein (Fig. 4.27). It was therefore concluded that the tetrasaccharide was bound either
to K388, K405 or K410 and that its proximity to the remaining two N-terminal lysine
residues caused intermediate exchange broadening of their sidechain and backbone 15NH
cross peaks.
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Figure 4.26: Example of the comparison of different fH∼7Y TOCSY spectra. The 13C-
resonances of the lysine sidechain are linked to the backbone 15NH of the preceding
residue in the CCONH-TOCSY (red) or the 15NζHζ of the lysine sidechain in the
(H)CCENH3 (green). The magnetisation transfer is shown schematically for both
experiments in the respective color.
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Figure 4.27: 1H, 15N-HSQC spectrum of free fH∼7Y (black) and cross linked fH7Yxdp4C
(green). Many of the broadened and shifted NH cross peaks belong to residues in the
N-terminal region of the protein (red boxes).
4.5.4 Trypsin digestion of fH∼7Y and fH∼7Yxdp4C
The analysis of the cross linked fH∼7Yxdp4C with the HISQC experiment had not un-
ambiguously answered the question to which lysine sidechain dp4C was covalently linked,
mass spectrometry and trypsin digestion were employed as complementary techniques.
The protease trypsin is widely used as a biochemical tool for protein identification. It
cleaves peptide bonds which lie C-terminal of arginine and lysine residues. Trypsin
digestion of free fH∼7Y should thus yield two very short peptides (E382AAGLR and
CIRVK446) for both the N- and C-terminus. These could not readily be identified by
MALDI-TOF mass spectrometry due to increased noise levels below 1 kDa and small
molecule impurities which made small peptide identification unreliable. Additionally,
the middle stretch following residues K405 is also too short for reliable detection by
MALDI-TOF (K405FVQGK410). These limitations also apply to fragments obtained
through trypsin digestion of fH7Yxdp4C as long as they are not cross linked to dp4C,
which would increase the molecular weight by more than 1 kDa. However, four large
130
4.5 Cross linking of dp4C to fH∼7Y
peptides could clearly be identified in both samples after denaturation/reduction, alky-




Figure 4.28: MALDI-TOF spectrum after fH∼7Y trypsin digestion. Horizontal arrows in-
dicate alkylation products.
The presence of the first and the last cysteine residue in these peptides confirmed suc-
cessful reduction. Since all three peptides were also found in the digestion of fH7Yxdp4C
it was clear that neither the N-terminal lysine residue, K388, nor the hypervariable loop
residue K424 was cross linked to dp4C. K410 was very likely also not cross linked because
the presence of the second fragment starting with S411 proved that this residue was still
recognized as lysine by the protease, which is unlikely for a lysine residue carrying a
large covalent modification.
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Figure 4.29: MALDI-TOF spectrum after fH7Yxdp4C trypsin digestion. Fragments which
could be identified and which are not modified are highlighted in cyan, red, and blue.
The framed numbers refer to the lysine residues which were identified as not cross
linked on the basis of the presence of the respective fragment. The light stretches in
the sequence (top) were not identified.
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4.5.5 Microwave-assisted acid hydrolysis
As the last analytical step in the fH7Yxdp4C analysis microwave-assisted acid hydrol-
ysis coupled with mass spectrometry (MAAH-MS) was used. This method provides an
alternative route to protein sequencing where tandem mass spectrometry fails (which is
often the case for membrane proteins). The sequence coverage was much better for the
C-terminus of the cross linked protein than for the N-terminus (Fig. 4.30). The identi-
fied fragments included both the first and the last cysteine residue, again signalling that
both disulfide bonds had been reduced under the drastic conditions of acid, DTT and
microwave irradiation.
Figure 4.30: MALDI-TOF spectrum after microwave-assisted TFA hydrolysis of
fH7Yxdp4C. Several C-terminal fragments (blue and cyan) and one N-terminal
fragment (red) were identified. The C-terminal stretch that was contained in every
single C-terminal fragment is highlighted in blue, the ”growing” amino acid sequence
in cyan. The framed numbers refer again to lysine sidechains present in the respective
fragments and not modified.
Prolonging the time the cross linked protein was exposed to microwave irradiation did
not improve the sequence coverage but increased the amount of small peptides below
1 kDa. The microwave-assisted TFA hydrolysis confirmed that residue K446 was not
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linked to the tetrasaccharide, nor was residue K388. The first result confirmed the re-
sults of the NMR analysis but could not be obtained from trypsin digestion, while the
latter result was in agreement with the trypsin digestion data but could not be obtained
from the NMR analysis. Thus, the partial TFA-hydrolysis complemented the NMR and
trypsin digestion data. Together the results from these three technique leave only one
residue as the possible cross linked lysine: K405.
In the crystal structure of fH∼6-8H in complex with SOS [241] the Nζ atom of K405
is in relative proximity (4.5 and 4.3 Å) to two sulfate groups of the only well-defined
SOS molecule in the deposited PDB file (Fig. 4.31). Cross linking, on the other hand,
requires a carboxyl group of dp4C to be in the vicinity of the lysine sidechain. SOS does
not have any carboxyl groups, our results therefore hint to the existence of different
binding modes for SOS and dp4C.
Figure 4.31: Residue 405 in the x-ray structure of fH∼6-8H in complex with SOS. Prepared
from PDB 2UWN.
Trypsin cleavage before the modified residue K405 was possible because the protease
identified the N-terminal neighbour, R404. The modified peptide, K405(dp4C)FVQGK410,
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was not detected in the MALDI-TOF analysis of the digested fH7Yxdp4C and thus only
indirect evidence leads to the conclusion that K405 was the cross linked residue. It is,
however, not surprising that this fragment was not detected because of its large negative
charge. After the cross linking seven negative charges remain in the dp4C moiety. This
high number cannot be compensated by the positive charges which the short peptide
K(dp4C)FVQGK adopts even in the presence of TFA (which is part of the MALDI-TOF
matrix).
4.5.6 Titration of fH∼7Y with dp4C monitored by H2CN
experiments
During the titration of fH∼7Y with dp4C at pH 7.4 and 298 K none of the NH+3 cross
peaks was detectable by the HISQC experiment. At lower pH addition of dp4C caused
sample precipitation. A way around this problem was the usage of double labelled pro-
tein which allowed following the 15N chemical shift changes during the titration using
the H2CN pulse sequence with the excitation and detection of H
ε protons [251].This
pulse sequence links the Nζ chemical shift to the Cε and Hε chemical shifts of lysine
sidechains. This procedure allowed use of physiological conditions for the binding exper-
iments. 13C,15N-fH∼7Y was titrated with dp4C and 2D planes of the H2CN sequence
were recorded. The assignment was transferred on the basis of the known Nζ and Cε
chemical shifts. The results of this titration are displayed in Fig. 4.32. It can be seen
that the HεCε cross peaks of K446 and K424 did not change position during the titration.
This is consistent with the results of the cross linking and the HISQC experiments. The
chemical shifts of the remaining three residues were affected, starting with the smallest
to the largest change in the order K410 < K388 < K405. A mutational study conducted
on the N-terminus of fH found that the mutations K405A and R404A in fH∼6-8 each
had a significant effect on binding to different heparin affinity columns, while K388A
resulted in only a small decrease in this affinity for certain heparin preparations [252].
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This study thus supports our observation that K405 is a central player in the N-terminal
heparin binding site in CCP7 and validates the use of the H2CN pulse sequence for the
analysis of protein-GAG complexes.
Figure 4.32: H2CN titration of fH∼7Y with dp4C (CH-planes). The ratios given in the
respective colours are protein:ligand. The least affected peaks are again K424 and
K446.
The analysis of the cross linked complex, together with the presented 1H ,15N-HSQC
and H2CN titrations of fH∼7Y, lead to the conclusion that the backbone NH but not
the sidechain NH+3 group of K446 contributes to heparin binding. It cannot be entirely
excluded that K446 does not directly contribute to heparin binding at all and that the
chemical shift changes observed in the 1H ,15N-HSQC titration are due to an allosteric
effect. This is, however, an unlikely scenario because of the role of the nearby R444
sidechain in the crystal structure of fH∼6-8H in complex with SOS. Titrations have been
conducted in our group using a TEMPO-radical labelled heparin disaccharide which
caused paramagnetic relaxation enhancement of the K446 backbone NH cross peak,
indicating the binding of the oligosaccharide at this position.
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4.6 Discussion of heparin binding to the fH∼6-8 region
4.6.1 NMR methods for monitoring of lysine sidechains
It was found that the HISQC sequence was not useful for the monitoring of lysine
sidechains in the non-covalent fH∼7Y:dp4C complex, possible due to unsufficient su-
pression of exchange with water. Spectra were recorded at different temperatures and
pH values to determine conditions that could be used for the assignment of all lysine
NζHζ cross peaks in fH∼7Y. Only at 283 K and pH 3.0 was the water exchange suffi-
ciently slow to observe and assign all NζHζ resonances. The fact that none of the lysine
sidechains was observed in the HISQC experiment of the non-covalent fH∼7Y:dp4C com-
plex at pH 7.4 and room temperature underlined the weakness of the interaction, which
was found to have a Kd around 40-50 µM in the
1H, 15N-HSQC titration of fH∼7Y with
dp4C. The conditions under which all lysine sidechain resonances were observed using
the HISQC sequence were too acidic to be used for any physiological interpretation of the
complex and where thus only used for the characterisation of the cross linked complex.
In addition, protein precipitation was observed upon addition of the dp4C at pH 3.0.
In order to follow the sidechain signals during titrations at more physiological conditions
another lysine sidechain experiment was employed, the so-called H2CN experiment. This
is an out-and-back type experiment which does not rely on the exchanging protons for
excitation or detection but - unlike the HISQC experiment - requires 13C labelling. In
this experiment the aliphatic sidechain protons Hε are excited and the magnetization
is transferred to 13C in an INEPT step, followed by a second INEPT transfer to 15N.
Nitrogen chemical shift labelling takes place while proton and carbon couplings do not
evolve due to decoupling pulses on both the 1H and 13C channels. Following the t1
period the magnetisation is back transferred to 13C via another INEPT step, labelled
with the 13C chemical shift and eventually transferred back to the Hε protons where
the detection takes place. By leaving out the incrementation during the t1 or t2 pe-
riod this experiment can be set up as a 2D 13C,H- or 15N,H-experiment, respectively
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(dubbed H2C(N) and H2(C)N). Comparison of the N
ζ chemical shifts in the 2D H2(C)N
experiment with the previously assigned HISQC experiment allowed assignment of the
Nζ signals in the H2(C)N spectrum. Several H2(C)N spectra were recorded at different
temperatures and pH values in order to transfer the assignment to physiological con-
ditions, where a heparin titration was performed. The Cε resonances in the H2C(N)
spectrum were assigned based on the Hε shifts in the H2(C)N spectrum. While they
served as an additional assignment test via comparison of Cε resonances in (H)CCENH3
and CC(CO)NH spectra they cannot be relied on as a sole instrument for the assign-
ment of the Nζ resonances because of their generally very small chemical shift dispersion.
4.6.2 Heparin binding to the fH∼6-8 region
During this study it was found that heparin derived fully sulfated tetrasaccharide (dp4C)
initiates similar chemical shift changes when titrated into fH∼7-8 (both variants) as the
synthetic heparin mimic sucrose octasulfate. This finding served as justification for its
use in a crystallographic study of fH∼6-8H in complex with SOS by our collaborators
[241]. The backbone NH chemical shift changes during the titrations were almost indis-
tinguishable for both ligands and both protein variants, fH∼7-8Y and fH∼7-8H. While
on the first glance these findings seem surprising - given the large structural differences
between dp4C and SOS - they are not incompatible with a model in which the heparin
protein complex is dominated by charge-charge interactions: SOS has the same number
of negative charges as dp4C, and because of its smaller size the charge density in SOS is
even higher. It should not be forgotten that the possibility of binding non-physiological
ligands to proteins is the basis of a large branch of pharmaceutical research and drug
development, and that the binding affinity of SOS to fH∼7-8 is significantly lower than
the affinity of dp4C, i.e. a larger amount of ligand is needed to achieve similar chemical
shift changes.
A number of findings and conclusions from the x-ray study of fH∼6-8H with SOS were
not supported by the previous work from our laboratory and or results obtained during
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this project. One conclusion that was drawn from the crystal was a possible steric clash
between the tyrosine sidechain of residue 402 and a SOS molecule [241]. In the crystal,
the histidine sidechain of residue 402 in fH∼6-8H directly coordinates a SOS molecule.
The hypothesis that a tyrosine sidechain could not maintain this interaction and would
even sterically hinder the SOS binding to this particular binding site (there are several
SOS binding sites in the x-ray structure) seemed supported by the failure of crystalliza-
tion trials with fH∼6-8Y and SOS. Only the H402 variant was successfully crystallized
and only in the presence of SOS, leading to the conclusion that a “stiffening” effect of
SOS was needed for crystallization and that this effect could not be obtained in the
tyrosine variant. We used the Y402 variant in the NMR and cross linking studies, yet
the results of these experiments suggested binding of dp4C in the vicinity of 402, the
critical tyrosine residue. If the isolated CCP 7 module alone (as used in the cross linking
and H2CN titration study) is able to hold a ligand molecule in place at the N-terminus
of CCP 7 this binding site should also be occupied in the presence of CCP 6, which -
according to the crystal structure - contributes to this binding site via a histidine residue
in the C-terminal half of CCP 6. The assumption that binding to the binding site ob-
served in the crystal structure of fH∼6-8H with SOS could not be accomplished by the
tyrosine variant seems thus questionable. A binding study with different types of hep-
arin/HS observed that each isoform of fH∼6-8 exhibits a higher affinity than the other
one, depending on the type of heparin/HS that was used [252]. The solution structures
of both fH∼7 variants [240] show that the overall structure of CCP 7 is not disturbed by
the SNP Y402H. The lack of a single salt bridge from residue H402 to the ligand in the
tyrosine variant might reduce the affinity of the tyrosine variant for SOS and heparin
but most likely does not exclude formation of the complex, as proven by the experiments
presented in this thesis.
More open questions surround the role of CCP 6 in the binding of heparin to fH. Un-
fortunately, fH∼6-7 proved to be too unstable for NMR spectroscopy. Thus, we were
unable to conduct NMR studies on this construct in order to clarify the contributions
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of CCP 6. In the crystal structure, this module seems to contribute more to the SOS
binding than CCP 7 or CCP 8: one entire SOS binding site is contained in CCP 6, and
the binding site involving the critical residue H402 is completed by a second histidine
residue in CCP 6, H360. However, the binding studies which were presented along with
the x-ray structure do, to some degree, contradict the conclusions drawn from the fH∼6-
8H:SOS structure. The constructs fH∼5-6 and fH∼6-7 elute at lower salt concentrations
from a heparin column than fH∼7-8, and the latter elutes at approximately the same
salt concentration as fH∼6-8 (Fig. 3 in [241]). This behaviour points to larger binding
contributions from CCP 8 than CCP 6. Additionally, a titration of partially deuterated
15N-fH∼6-8Y with SOS in our laboratory did not find evidence for the large binding
contributions of CCP 6 that were observed in the crystal. While CCP 6 was not as-
signed in this NMR study a comparison with the fH∼7-8Y titration revealed that most
unassigned amide cross peaks (i.e. resonances from CCP 6) remained in place, confining
the binding amides to CCP modules 7 and 8 (data not shown). Additional experiments
using both heparin (in form of a heparin affinity column) or SOS (in the 1H, 15N-HSQC
titration with fH∼6-8) do not therefore fully support the interpretation of the x-ray
structure. A possible explanation for the potentially over rated involvement of CCP 6
in the binding is the particular orientation of protein molecules relative to each other
seen in the protein crystal. While protein-ligand interactions in [241] are displayed and
analysed using an isolated protein molecule in fact several protein molecules contribute
to the binding of each SOS molecule in this crystal: the overall ratio of protein:ligand
is 1:1, despite the observation of several SOS binding sites per protein molecule. This
arrangement potentially allows minor contributions to the SOS binding from residues
outside of the binding site(s) as observed in the liquid phase.
These arguments touch the fundamentals of x-ray crystallography - molecules need to
interact in a network-like fashion to form crystals, and such contacts cannot simply be
avoided in protein crystallography. In many cases, some of the interactions seen in crys-
tals are representative of physiological interactions, e.g. in cases where proteins need to
self-associate to be functional. Growth factors and virus capsid proteins, for example,
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are known to self-associate (to dimers and multimers, respectively) in their physiological
environment and crystal structures are representative of these interactions. Generally,
by measuring the buried surfaces in protein crystals and with the help of complementary
techniques it is possible to differentiate between physiological protein oligomerisation and
additional contacts between multimers which only reflect crystal packing. This process
is, however, often disputed in protein-ligand complexes and even more difficult when
the ligand binds in a superficial manner, i.e. does not enter a binding pocket. The
fH∼6-8H-molecules are “glued” together by SOS molecules in the reported crystal and
the asymmetric unit contains at least three protein molecules. Which of the observed
interactions can be maintained by a monomeric protein in solution need to be answered
by complementary methods.
4.6.3 The protein-heparin cross linking strategy
In this study, a zero-length cross linking strategy previously employed to link protein-
protein or protein-peptide complexes was tested on a protein-heparin complex. Heparin
tetrasaccharide was activated with common chemical cross linking reagents and, after
a basic purification step, mixed with fH∼7Y in a biochemical buffer at pH 6.0. The
resulting hybrid was identified by chromatography (the covalent complex failed to bind
to a cation exchange column) and mass spectrometry. While an accurate mass measure-
ment proved a 1:1 stoichiometry, three lysine sidechain amine cross peaks disappeared
from the HISQC spectrum upon cross linking. In theory, one single cross peak should
disappear from the HISQC spectrum of the cross linked species and an additional peak
should appear in the 1H, 15N-HSQC spectrum due to the creation of a new peptide
bond. Instead, not only did three peaks disappear from the HISQC spectrum, but many
more backbone amide cross peaks were broadened beyond detection in the 1H, 15N-
HSQC spectrum, and additionally distored peak shapes were observed in this spectrum.
Assignment of the HISQC spectrum (the 1H, 15N-HSQC spectrum had been assigned
previously [240]) revealed that the observed changes in both spectra clustered at the
N-terminus of fH∼7Y. Further investigation using mass spectrometry, trypsin digestion
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and microwave-assisted acid hydrolysis yielded the following result: of the five lysine
sidechains, four could unambiguously be identified as not affected in either the HISQC
and/or yielding unmodified peptide fragments in the trypsin digestion/acidic hydrolysis.
The only lysine sidechain which was not identified by either method was K405. These re-
sults are in good agreement with the fH∼6-8H:SOS crystal structure where this sidechain
directly coordinates a SOS molecule. Thus, the techniques presented in this work have
the potential to become useful tools in the characterisation of glycosaminoglycan-protein
interactions. Together with 1H, 15N-HSQC- monitored ligand titrations these techniques
are able to identify and distinguish between binding contributions from lysine sidechain
amines and lysine backbone amides, thus complementing the common chemical shift
mapping approach which relies on the analysis of 1H, 15N-HSQC spectra only.
It should be noted that, despite significant efforts using different mass spectrometry tech-
niques, no fragmentation of the cross linked hybrid was accomplished by tandem mass
spectrometry. The intact hybrid gave a broadened peak in the MALDI-TOF spectrum
which was in fact made up of a number of peaks differing by 80 Da, arising from species
with different numbers of SO3 groups. After trypsin digestion and acid hydrolysis, no
peptide could be identified which contained the heparin tetrasaccharide, and the cross
linked fragment could only be identified in an indirect manner. All these difficulties are
probably due to the large negative charge of the tetrasaccharide. This charge prevents
the intact complex from accumulating enough positive charges to fragment in tandem
mass spectrometry. For small peptides containing the tetrasaccharide the situation is
even worse because the number of residues available for the protonation through the
acidic matrix is smaller. Such fragments are probably not observed in a common posi-
tive mode MALDI-TOF because they cannot adopt a positive net charge. Efforts were
made to use negative mode MALDI-TOF but the signal to noise ratio was worse and no
peptides could be identified at all. Sulfated glycosaminoglycans are challenging targets
for mass spectrometry because of their large negative charge and the lability of sulfate
groups. It remains to be seen if the development of new methods in this field will aid
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the identification of such compounds in the future. Such development would without
doubt open a large range of possibilities for studies of heparin-protein complexes.
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5.1 NMR binding studies of fH∼19-20
FH acts as a cofactor to factor I which proteolytically inactivates C3b covalently bound
to host cell surfaces. Binding sites for C3b have been mapped to both the N- and the
C-terminus of fH. While the N-terminus contains the regulatory domains of fH (CCP
1-4), which provide a platform for factor I binding [253], the C-terminal domains CCP 19
and CCP 20 are not directly involved in the inactivation of C3b. They do nevertheless
play a critical role in the C3b deactivation process because the N-terminal modules of fH
do not contribute to the cell recognition process. Thus, the C-terminus of fH acts as a
sort of anchor for the protein, directing the functional domains CCP 1-4 into proximity
of host cell-surface bound C3b which requires deactivation. This section summarizes
a number of experiments which were conducted in order to elucidate the interplay of
heparin oligosaccharides (which serve as a model for cell surfaces), C3b, and fH∼19-20.
The binding site on C3b for the C-terminal fH modules has previously been shown to
reside in the so-called TED domain [67]. This domain, which contains the covalent at-
tachment point of C3b, remains bound to cell surfaces after proteolytic C3b inactivation.
It is then labelled C3d. Because the TED domain does not significantly alter its struc-
ture during the progression from C3b to C3d [254, 255] C3d was used instead of C3b
in some of the following experiments. C3d is a convenient replacement for C3b because
the latter has a large molecular weight of 175 kDa while C3d is much smaller (35 kDa).
Binding of C3b to 15N-fH∼19-20 caused uniform broadening and disappearance of many
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peaks in the 1H, 15N-HSQC spectrum of fH∼19-20 because of the slow molecular tum-
bling of the resulting complex. This problem was circumvented by the use of C3d in lieu
of C3b.
The backbone assignment of fH∼19-20 was obtained from Dr. Andrew Herbert [79] and
transferred to different pH-values and salt concentrations using a set of pH and salt
titrations. A number of assignments were lost during this procedure due to ambiguity
caused by overlap or peak broadening. Residues whose cross peaks could not be unam-
biguously assigned are omitted in the following histograms.
5.1.1 Binding of C3b and C3d to fH∼19-20
To avoid working with a very concentrated stock of C3b, a 1:1 ratio of C3b and 15N
labelled fH∼19-20 was prepared and subsequently diluted with 15N fH∼19-20. CRINEPT-
HMQC-TROSY was employed during the titration because of the large molecular weight
of the complex (around 200 kDa). Although the sensitivity of the spectra improved when
compared to conventional 1H, 15N-HSQC spectra many peaks remained broadened and
could not be detected. The relative small gain in sensitivity when using CRINEPT-
HMQC-TROSY was likely due to the fact that the used proteins were not deuterated.
In non-deuterated proteins efficient relaxation pathways remain in the form of many
dipole-dipole interactions between NH protons and other proximate protons. CRINEPT
and TROSY experiments are most effective when combined with deuteration [214]. In
general, only cross peaks of the most flexible regions of fH∼19-20 were observed in early
titration points, i.e. sidechains and terminal resonances. Upon dilution with increasing
amounts of 15N fH∼19-20 the peak broadening decreased in a dose-dependent manner
(Fig. 5.1).
This observation is in accordance with a binding equilibrium in which the percentage of
the free (smaller) protein increases, contributing more and more to the intensity of the
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Figure 5.1: CRINEPT-HMQC-TROSY spectra of 15N-fH∼19-20 and C3b. C3b:fH∼19-20
ratios were A) 1:1 (black), B) 1:1.3 (red), C) 1:1.8 (green) and D) 1:2 (blue.)
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cross peaks which represent weighted averages of free fH∼19-20 and fH∼19-20:C3b com-
plex. Because many peaks are only visible at excess of fH∼19-20 meaningful chemical
shift changes, which are also weighted, could not be observed in this titration. Deuter-
ation of 15N-fH∼19-20 would have been needed to improve the spectral quality of the
∼200 kDa complex. A titration with the smaller C3d was conducted instead as C3d’s
molecular weight is not large enough to decrease the molecular tumbling of the protein-
protein complex in the dramatic manner in which C3b does.
In a sample of C3d and 15N fH∼19-20 (ratio 1.6:1) small chemical shift changes and
significant line broadening of a defined set of backbone amide cross peaks were observed.
Several residues could be identified which exhibited larger than average line broaden-
ing (see histogram below) or disappeared completely (highlighted residues in Fig. 5.2,
blue residues in Fig. 5.4). This behaviour is a sign of intermediate chemical exchange
which requires sufficient chemical shift difference between the bound and the free state
and which has been reported before for other macromolecular interactions [256]. The
broadened residues can be assumed to be at the interface of the complex formed between
fH∼19-20 and C3d or to be indirectly affected by structural changes in fH∼19-20 upon
binding to C3d. Residues whose backbone amide cross peak broadening was above the
average broadening are listed in Table 5.1.
To quantify the individual intensity loss due to line broadening in the presence of C3d,
a plot of peak volumes (and, for control, peak heights, which are not shown) for the
individual fH∼19-20 amide backbone residues, compared to the respective values in a
reference spectrum was created (Fig. 5.3). The average loss in peak volume was 85 %.
This large general signal loss was partially due to the decreased concentration of fH∼19-
20 in the sample with C3d. Possibly the larger molecular weight of the protein:protein
complex did also contribute to a general loss in peak volume. Those residues whose
signal loss was above the average value of 85 % are listed in Table 5.1 and highlighted
on the NMR structure of fH∼19-20 (Fig. 5.4).
Generally, residues whose backbone amide cross peaks were significantly broadened (and
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Figure 5.2: Comparison of 1H, 15N-HSQC spectra of fH∼19-20 in the absence of C3d
(green) and with a 1.6fold excess of C3d (red). Cross peaks which exhibit larger than
average line broadening in the complex with C3d are labelled. The grey line connects
the resonances form a diastereotopic sidechain (residue N1117).
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Figure 5.3: Histogram showing the impact of C3d on the signal intensity of amide backbone
cross peaks in fH∼19-20. Cross peaks which are completely lost occur at y-axis value 1.
The C3d:fH∼19-20 ratio was 1.6:1. The average peak volume loss in this experiment
was 85 % between a fH∼19-20 reference spectrum and the complex due to higher protein
concentration in the reference sample. Larger than average broadening was observed for
residues above the cyan line.
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Figure 5.4: NMR structure of fH∼19-20 (PDB 2BMZ) (rotated by 180◦ between both
views) with residues highlighted whose NH backbone cross peaks by broaden more than
the average value in the presence of C3d (dark blue). These residues are also listed in
Table 5.1. For clearness, only a subset of the residues is labelled to facilitate orientation.
Italics type highlights residue which have been linked to aHUS. The C-terminus is at the
top of the structures, the N-terminus at the bottom.
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which, in some cases, experienced chemical shift changes) in the presence of C3d stretch
along the full length of both CCP 19 and 20 but are mainly restricted to one face of the
double module (Fig. 5.4). Interestingly, a number of perturbed residues are part of the
linker between CCP 19 and CCP 20 or located in its close proximity. This could be a
possible hint to a kink in the linker in the C3d-bound form of fH∼19-20 as seen for the
linker between fH modules 3 and 4 in complex with C3b [253]. Unlike the C-terminal
heparin binding site in fH, which is restricted to CCP 20, the C3d binding site covers
both CCP 20 and CCP 19, lending an explanation to the observation of aHUS linked
mutations in CCP 19.
A mutational study [257, 258] found decreased C3b/C3d affinities in the following vari-
ants of fH∼19-20: Q1139A, W1157L, R1182A, W1183L, T1184R (reduced binding to
C3b only), K1188A, R1206A, and R1210A. Of these residues, two main chain NH cross
peaks were not assigned/visible in 1H, 15N-HSQC spectra under conditions used here
(T1184 and R1210). The main chain crosspeak of Q1139 could not be assigned under
titration conditions but its sidechain NH2 peaks were observed. Details of the fH∼19-20
1H, 15N-HSQC spectrum in the presence of 1.6fold excess of C3d are shown for some
of these residues in Fig. 5.5: for Q1139, a slight decrease in intensity was observed
for one of the two diastereotropic sidechain amide protons (Fig. 5.5(c)). The main
chain cross peak of W1157 appears not affected by the presence of C3d, its sidechain
NHε cross peak, however, undergoes a small chemical shift change (Fig. 5.5(b)). R1182
is affected as well as the W1183 main chain peak, which belongs to the significantly
broadened set of cross peaks (Fig. 5.5(a)). K1188 is also among the residues whose
cross peaks are significantly attenuated in the presence of C3d, but K1188 continues to
exhibit chemical shift changes when dp8 is added (Fig. 5.14, 5.5(g)). The R1206 main
chain cross peak undergoes a chemical shift change comparable to the one experienced
by the W1157 sidechain peak (Fig. 5.5(e)). Although R1210 could not be observed in
the 1H, 15N-HSQC spectra the observation that the mutation R1210A leads to a decrease
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Table 5.1: fH∼19-20 residues affected during titrations with C3d. Residues which have
directly been linked to aHUS are highlighted in italics type.
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in C3d/C3b binding is important in the light of our results because the neighbouring
residue, S1209, was found to exhibit line broadening as a result of binding of C3d. On
the other hand, there is a mutation which was not found to have an impact on C3b/C3d
binding in [257] but whose backbone NH cross peak is significantly broadened in the
presence of C3d. This residue is D1119 (changed to G1119 in the mentioned study).
The dramatic effect of C3d on D1119 can be seen in Fig. 5.5(f). R1215Q was described
as a mutation which has no effect on C3b/C3d binding, which is in agreement with the
fact that it is not broadened nor experiences chemical shift changes in the presence of
C3d (Fig. 5.5(d)). The assumption that D1119 is a C3d-binding residues can lend an
explanation to the observation that a mutation in CCP 19, D1119G, is a risk factor for
aHUS [259]. Although no altered affinity had been found for C3d/C3b binding in [257],
the same mutation had dramatic effects in a physiological complement assay [260] (see
below).
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Figure 5.5: 1H, 15N-HSQC spectra of free 15N fH∼19-20 (green) and in the complex with
C3d (red) (Details of Fig. 5.2). The vertical axes correspond to 15N, the horizontal axes
to 1H frequencies in ppm. (a) Backbone NH cross peaks for residues R1182 and W1183,
(b) backbone NH and sidechain NHε (He) cross peaks for residue W1157, (c) sidechain
NH2 cross peaks for Q1139, (d)-(f) backbone NH cross peaks of R1215, R1206 and
D1119, respectively. The mentioned cross peaks are highlighted with asterisks in the
respective spectra.
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5.1.2 1H, 15N-HSQC monitored dp8-titration of fH∼19-20
In order to map the heparin binding site onto fH∼19-20 a titration with heparin derived
octasaccharide, dp8, was carried out. dp8 was chosen in order to judge if the previously
described heparin binding site (from a titration with dp4C, [79]) would turn out to be
more extended when a longer oligosaccharide was used. The titration with dp8 revealed
that this interaction, like the dp4C interaction with CCP 7 and CCP 7-8, falls into the
fast exchange regime (Fig. 5.6, 5.7).
Figure 5.6: 1H, 15N-HSQC monitored titration of fH∼19-20 with dp8. Protein:ligand ratios
are 1:0 (black), 1:0.5 (red), 1:1.1 (orange), 1:2.1 (green), 1:4.3 (blue) and 1:8.5 (purple).
When compared to the previously published chemical shift changes that were observed in
an 1H, 15N-HSQC monitored titration of 15N-fH∼19-20 and dp4C [79] a similar pattern
was observed but the different absolute chemical shift scales are strikingly different (Fig.
5.8). Both oligosaccharides caused significant chemical shift changes in CCP 20 only,
and numerous residues are significantly affected in both titrations, among them residues
1182-1188, 1198-1204, 1215, and 1227-1231. On the other hand, there are also significant
differences in the ranking of affected residues: for dp4C, the C-terminal residue R1231
shows the largest shift changes (∼ 0.18 ppm), followed by T1184, while in the dp8
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Figure 5.7: Detail of Fig. 5.6. Negative (folded) peaks were omitted for clarity.
titration residue Q1187 (∼ 0.42 ppm) is the most affected residue, followed by R1231
and K1188.
A detailed comparison of both oligosaccharide titrations is hindered by the incomplete-
ness of both data sets. It can be seen that both oligosaccharides bind to the same
face on CCP 20, although the same residues contribute differently to binding of the
different oligosaccharides. In this context it should be emphasised that dp4C is a pure
(fully sulfated) tetrasaccharide while for dp8 the heparin octasaccharide fraction was
pooled without further purification. Additionally, different pH and salt conditions were
used for these studies: the dp4C titration was done at pH 4.0 in 8 mM sodium acetate
buffer containing 50 mM sodium chloride while for the dp8 titration pH 7.0 in 20 mM
potassium phosphate was chosen; both titrations were conducted at 298 K. While the
basic sidechains of arginine and lysine residues, which likely contribute most to the hep-
arin binding, are quantitatively protonated at physiological pH subtle local electrostatic
changes can be introduced on the protein by going from one buffer to another, affecting
the chemical shift changes. Such effects have also to be taken into consideration when
comparing the two oligosaccharide titrations. The residues which experience the largest
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Figure 5.8: Comparison of the chemical shift changes induced on 15N-fH∼19-20 by 8 equiv-
alents of dp8 (top) and 12 equivalents of dp4C (bottom). Horizontal lines mark the
average chemical shift changes and twice this value. Red bars indicate the position of
proline residues for which no NH cross peaks are observed. The linker region extends
from C1163 to C1167.
157
5.1 NMR binding studies of fH∼19-20
chemical shift changes in the titration with dp8 are mapped on the NMR structure of
fH∼19-20 in Fig. 5.9 and listed in Table 5.2.
Figure 5.9: NMR structure of fH∼19-20 (PDB 2BMZ)(rotated by 180◦ between both views)
with residues highlighted which experience chemical shift changes of 0.04 - 0.08 ppm
(orange) and > 0.08 ppm (red) during the titration with dp8. Both groups are also
listed in Table 5.2. Bold and italics type are used for residues whose cross peaks are
affected by C3d and which have been linked to aHUS, respectively. The C-terminus is
at the top of the structures, the N-terminus at the bottom.
Among the most affected cross peaks in the dp8 titration is R1231 (Fig. 5.7 bottom).
A Kd value of 4.2 +/- 0.3 µM was calculated for the chemical shift changes observed
for this residue. Similar values were measured for residues E1198 and K1188 (3.2 +/-
1.2 µM and 4.2 +/- 1.3 µM, respectively). The Kd of fH∼19-20 binding to dp4C, for
comparison, has been determined as 9 +/- 2.5 µM in the above mentioned study [79].
These Kd values are in the same range, however, it should be noted that pH and salt
concentration have a significant influence on the affinity of heparin oligosaccharides to
fH∼19-20, making a direct comparison of the Kd values for dp4C and dp8 questionable.
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It should also be taken into consideration that dp4C is a pure, fully sulfated species,
while dp8 is only homogeneous in length and not a pure compound in the sense that its
chemical composition reflects the complex primary structure of heparin. The calculated
Kd is therefore an apparent Kd representing this particular mixture. It is very likely that
the fully sulfated species binds more tightly.
The similarities and differences observed in both titrations are interesting when the
absolute size of the oligosaccharides is compared to the size of the binding interface on
fH∼19-20. dp4C is only ∼ 17 Å long and, if not significantly deviating from its structure
in the free form, too short to cover the mapped binding surface. dp8, on the other hand
( ∼ 34 Å in length) would be able to span the length of a full CCP module (30-35 Å,
Fig. 5.10). It is likely that dp4C binds in multiple ways to the heparin binding site on
fH∼19-20 since a surface area that is effectively larger than the ligand exhibits chemical
shift perturbation upon dp4C binding. Another possibility is the binding of two dp4C
molecules to fH∼19-20 at the same time.
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Figure 5.10: Detail of the NMR structure of fH∼19-20 (PDB 2BMZ) showing the proposed
heparin binding site as delineated from the dp8 titration (same residues highlighted as
red subset in Fig. 5.9). Heparin octasaccharide (PDB 1HPN) is drawn to scale for
comparison of the relative sizes.
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Table 5.2: fH∼19-20 residues affected during titrations with dp8. Residues which are also
affected by C3d are highlighted in bold type, residues which have directly been linked to
aHUS are highlighted in italics type. ppm values refer to combined chemical shift changes
observed in the dp8 titration.
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5.1.3 The ternary mixture of fH∼19-20, dp8 and C3d monitored by
1H, 15N-HSQC spectra
FH∼19-20 interacts in vivo with both cell-surface polyanions and C3b and both inter-
actions are central for the host protection from complement. In an attempt to access
the simultaneous interaction of fH∼19-20 with heparin and C3d a titration with the
octasaccharide fraction of the heparin digestion (dp8) was conducted in the presence of
C3d and the results were compared to titrations with dp8 alone and C3d alone. Ad-
dition of a 1.6fold excess of C3d to free 15N-fH∼19-20 caused only very small chemical
shift changes in the R1231 15NH-cross peak, R1231 is therefore most likely not directly
involved in the binding of fH∼19-20 to C3d. This residue was therefore used as a probe
for fH∼19-20 binding to dp8 in the presence of C3d (and compared to the binding in
the absence of C3d). Interestingly, the chemical shift changes experienced by the cross
peak of residue R1231 and other residues of the heparin binding site were smaller in the
presence of C3d even at a large excess of dp8 (Fig. 5.11, 5.13). For the R1231 backbone
NH cross peak, a plot of chemical shift changes as a function of ligand concentration
highlights the different binding characteristics (Fig. 5.12). Fitting the chemical shift
changes for the R1231 cross peak in absence and presence of C3d led to Kd-values of
4.2 µM +/- 0.3 µM and 44 µM +/- 0.3 µM, respectively. Interestingly, addition of 50
mM potassium chloride to the last titration point of the ternary mixture (containing
fH∼19-20:C3d:dp8 = 1:1.6:15.0) reversed the chemical shift changes significantly (Fig.
5.11). Presumably, this observation is an indicator of the prevalently ionic contributions
to this protein-heparin interaction.
The line broadening of those residues that where involved in the interaction with C3d
was not affected by dp8, notably for the cross peaks of residues W1183, K1188 and
L1189 in Fig. 5.14. This observation together with the conserved chemical shift trend
of the heparin binding residues suggests that both interactions with fH∼19-20 were pre-
served in the ternary mixture. Addition of 50 mM potassium chloride did not have a
visible effect on the peak broadening in fH∼19-20, suggesting that binding of C3d is not
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Figure 5.11: Comparison of chemical shift changes of residue R1231 of fH∼19-20 induced
by dp8 in absence (left) and presence (right) of C3d. The fH∼19-20:dp8 ratios are listed
for each titration point. Addition of 50 mM potassium chloride to the last titration
point in the ternary mixture reversed the chemical shift changes to some degree (orange
cross peak in right spectrum).
Figure 5.12: Combined chemical shift differences (csd) of the R1231 NH backbone cross
peak induced by dp8 in the absence (green) and presence (red) of C3d. Experimental
values: spheres, fitted curves: solid lines.
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susceptible to small changes in ionic strength, while dp8 binding is.
Figure 5.13: 1H, 15N-HSQC monitored titration of fH∼19-20 with dp8 in the presence of
1.6fold excess of C3d. fH∼19-20:dp8 ratios are 1:0 (black), 1:0.3 (red), 1:0.6 (green),
1:7.9 (purple) and 1:15 (cyan).
C3d was found to bind very weakly to a heparin affinity column at the pH used for the
titration experiment (pH 7.0). The interpretation of the ternary interactions is compli-
cated by this fact. The results do, however, exclude cooperativity between both proteins
with respect to dp8 binding. Cooperative binding of C3d and dp8 to fH∼19-20 would,
presumably, result in an apparent decrease in the Kd for the fH∼19-20:dp8 complex
and saturation would consequently be reached at lower dp8 concentrations. Since the
opposite is observed two explanations are possible: competition between fH∼19-20 and
C3d with respect to heparin-dp8 (resulting in an apparent lower concentration of dp8
available for fH∼19-20 since some is bound to C3d) or reduced affinity of fH∼19-20 for
dp8 in the presence of C3d. The latter scenario could be a consequence of partial over-
lap of the binding sites as previously suggested on the basis of mutational studies and
modelling [258].
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Figure 5.14: Detail of Fig. 5.13. The same detail is shown in the absence of C3d in Fig.
5.7.
5.2 Discussion of the NMR binding studies of fH∼19-20
In this study, C3d was titrated into 15N-fH∼19-20 and 1H, 15N-HSQC spectra were
recorded to delineate the binding site using intact wild type fH∼19-20. Decreased peak
intensity and excessive line broadening was obsereved for several residues. Peaks which
underwent excessive line broadening and disappeared or almost disappeared are listed
in Table 5.1 (first column), together with residues whose cross peaks were less dramat-
ically affected but still significantly broadened (second column). A number of residues
in the linker region fall into this second category, and their broadening might arise from
conformational change rather than direct binding of C3d. For example, a change in the
relative orientation of CCP 19 and CCP 20 could cause such effects. It was observed
previously that ligand binding can alter the relative orientation of neighbouring CCP
modules [253]. Addition of heparin-derived octasaccharide (dp8) did not recover the
intensity losses caused by C3d. The implication of this observation is that dp8 did not
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outcompete C3d with respect to fH∼19-20 binding. It was, however, observed that the
chemical shift changes which dp8 caused in free 15N-fH∼19-20 were smaller in the pres-
ence of C3d (Fig. 5.12, 5.11). One residue, the C-terminal R1231, was chosen to monitor
this effect (Fig. 5.11). This residue was chosen because it is one of the most prominent
heparin-binders in CCP 20 and it was not affected by C3d binding. Mapping of the
respective binding sites on the NMR structure of fH∼19-20 shows that this residue is
not part of the C3d binding site (Fig. 5.4).
In separate titration experiments, nine residues in fH∼19-20 were affected by both
C3d and dp8 (bold residues in Table 5.2). This observation and the altered affinity
of fH∼19-20 for dp8 in the presence of C3d could be explained with a mechanism that
has been proposed by [257] in which cell surface polyanions and C3b first form a tran-
sient encounter complex before the stronger C3b-fH interaction is accomplished. The
role of the polyanions would be that of a mediator which brings factor H in proximity
to cell bound C3b. Such a role is not uncommon for HS which acts as a scaffold for two
proteins in a range of protein-protein interactions like the thrombin:antithrombin or the
FGF:FGF-receptor complex.
A large and still growing number of polymorphisms and mutations in fH∼19-20 has been
linked to the rare yet serious kidney disease aHUS (Fig. 5.15). In this study, several of
the residues linked to aHUS were found to be directly affected by binding of C3d (D1119,
W1183 and L1189) and/or dp8 (R1182, W1183, L1189, V1197, E1198, R1215). Many
of the aHUS mutations of fH∼19-20 cluster around the heparin binding site in CCP 20,
but many other aHUS mutations are found in parts of the protein that are relatively
remote from this binding site, spanning almost the full length of both CCP modules
(Fig. 5.15). A direct link between the aHUS mutations and heparin binding alone could
not be established. Similarly, SPR experiments using the same panel of mutants and
C3b failed to establish a correlation between the aHUS mutants and the affinity to C3b
that would have included all aHUS-linked mutations. We have therefore concluded that
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experiments which investigate all three components at the same time are required. As
the first step towards this goal we have monitored the interaction between wild type
fH∼19,20 and dp8 in the presence of C3d. These experiments yielded promising results
and will be extended to the investigation of aHUS mutant proteins in the future.
Figure 5.15: NMR structure of fH∼19-20 (PDB 2BMZ) with residues highlighted which
have been linked to aHUS (source: aHUS mutational database, www.fh-hus.org). Bold
and italics type are used to mark residues which are affected by dp8 and C3d binding
or either of the two, respectively.
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5.3 GMSA of fH∼19-20 aHUS mutants and dp4C/dp6
The interaction between fH∼19-20, C3b/C3d and cell-surface polyanions is of interest
for kidney research because many mutations in CCP 19 and CCP 20 have been identi-
fied as risk-factors for atypical haemolytic uraemic syndrome (aHUS). Most biochemical
research presented so far made use of mutations and subsequent binding experiments as
well as models derived by molecular docking [258, 91, 79]. In particular, we [260] and
others [257] used a large set of aHUS-related and designed mutants to map the binding
sites of both heparin/cell surfaces and C3b/C3d onto fH. Both studies used heparin as
a cell-surface polyanion mimic and [257] compared the results obtained from heparin
binding assays with binding affinities to endothelial cells from mice. The overall rank-
ing of the tested mutant proteins with respect to heparin on one hand and endothelial
cells on the other hand were very similar, supporting the use of heparin as a cell-surface
polyanion mimic.
A gel mobility shift assay (GMSA) was used to assess the relative binding affinities of
fH∼19-20 WT and 13 aHUS mutants for heparin derived oligosaccharides. The mutant
proteins were prepared by Dr. Andrew Herbert and Dr. David Kavanagh. In this assay,
free heparin oligosaccharides migrates in an electric field through an agarose gel because
of its large negative charge. The formation of a neutral/less charged complex in the
presence of a heparin binding protein hinders this migration and retains the oligosaccha-
ride in the well. Fluorescent labelling of the ligand allows localisation of it after short
electrophoresis, leading to an estimate of how much ligand remained free (i.e. migrated
in the electric field) and how much was retained in the well. For these experiments
pure fully sulfated tetrasaccharide dp4C and dp6 fractions from heparinase I digestion
of bovine intestinal heparin were used.
GMSA of fH∼19-20 with dp4C and dp6 yielded very similar results for the WT and
mutant proteins. The GAG:protein ratio were chosen to give an excess of free GAG
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(evident in the WT lanes as a faint band migrating to the anode). In this manner, both
stronger binding (i.e. less free GAG migrating from the well) and weaker binding (i.e.
more GAG migrating to the anode) could be assessed. In general, the addition of a
positively charged residue (K or R) increased affinity to GAGs, while replacement of a
positively charged residue by an uncharged residue weakened the binding (Fig. 5.16).
This trend was observed for both designed non aHUS and aHUS mutants of fH∼19-20.
From a purely biophysical point of view, this trend is consistent with the observation
that heparin binding is mostly dominated by charge-charge interactions. However, from
a medical point of view a coherent trend was not found for the aHUS mutants: R1210C
(which was not misfolded despite the free cystein, as shown by 1H, 15N-HSQC spectra)
and R1182S bound weaker than WT to GAGs, numerous mutants exhibited binding
affinities similar to the WT, and L1189R, T1184R, and W1183R all bound stronger
than WT. In other words, the aHUS linked mutations display either increased, normal
or decreased heparin binding affinities and heparin binding alone cannot be used as an
indicator for the disease risk associated with aHUS mutations. With the exception of
R1210C, R1215G and R1215Q all mutants were tested for a homogeneously sulfated
GAG, dp4C, as well as for a mixture with different sulfation levels, dp6. No striking
difference between the relative affinities for the two GAGs was observed. In conclusion,
the interaction of fH∼19-20 seems to be dominated by charge-charge interactions, and
heparin binding alone does not correlate with the disease as both weaker and stronger
binding was observed for the aHUS mutant proteins.
While some of the results described in the literature for aHUS-linked mutant proteins
are in agreement, others contradict each other [260, 257]. A number of possible reasons
can be found for these contradictions. Firstly, mutations which lead to an increase in
binding affinity (as was observed for several mutations with respect to both C3b/C3d
and heparin) can reflect an artificial enlargement of the natural binding site. In par-
ticular, this seems to be the case for heparin-binding, which is often mediated through
relatively unspecific ionic interactions. Changing an aliphatic residue nearby the heparin
binding site into a basic residue, for example, might lead to an increase in affinity even if
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Figure 5.16: GMSA with dp4C (A and B) or dp6 (C and D) and fH∼19-20 WT and designed
(A and C) and aHUS (B and D) mutants. Cathode and well: top of gels, anode:bottom
of gels. Residues which are were found to be involved in dp8 binding in the 1H, 15N-
HISQC titration are coloured red and orange for combined chemical shift changes
> 0.08 ppm and 0.04-0.08 ppm, respectively (same colour coding as in Fig. 5.9).
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the mutated aliphatic residue was not previously part of the binding site. Secondly, the
choice of the introduced amino acid is as important as the position at which it is intro-
duced as different mutations of the same amino acid can lead to differently modulated
affinities. Mutation of W1157 to a leucine residue, for example, was reported to impair
C3b binding [257] while the choice of an arginine residue resulted in unaltered binding
affinity [260]. Thirdly, a single amino acid change can lead to severe structural changes,
affect the stability and the protein’s tendency to self-associate, parameters which are
often not checked carefully enough (in the case of [260], the structural integrity of all
mutant proteins was checked by NMR). Additionally, binding contributions from main
chain atoms are overlooked completely in cases were mutations do not lead to signifi-
cant structural changes. The C3d-CR2 complex, for example, has been reported to be
mediated by several main-chain carbonyl groups which were not picked up by earlier
mutational studies [261]. Thus, mutant proteins only represent an indirect tool for a
physiological map of the C3b/C3d and HS binding sites on fH and need validation by
complementary techniques. NMR spectroscopy and x-ray crystallography are able to
characterise the interactions of wild type proteins on an atomic level, helping to ratio-
nalize the results observed in functional assays.
5.4 aHUS mutants in a functional haemolytic assay
The ability of recombinantly expressed fH∼19-20 to impede the protective effect of full
length fH in serum was tested using a complement assay for the alternative pathway
[95, 69]. Because the human complement system does not recognize sheep erythrocytes
(RBCs) as foreign such cells are protected from complement mediated lysis when exposed
to human serum. Recombinant WT fH∼19-20 competes with full length fH for cell
binding but is unable to stop the complement cascade because the truncated protein
lacks the regulatory N-terminal domains. Thus, the addition of WT fH∼19-20 to a
serum sample containing sheep RBCs causes dose-dependant cell lysis which can be
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measured via the haemoglobin absorbance. Interestingly, aHUS associated mutants of
fH∼19-20 cause different degrees of lysis. However, all mutant proteins tested - with
the exception of R1210C - compete less effectively with full length fH than the WT
fH∼19-20 (Fig. 5.17).
Figure 5.17: Haemolytic assay of different mutant proteins and WT fH∼19-20 with sheep
and human erythrocytes. Solid bars: sheep RBCs, shaded bars: human RBCs.
An especially dramatic example is the D1119G mutant protein (Fig. 5.18). For compar-
ison, the assay was simultaneously conduced with human RBCs (Fig. 5.17). Because
human cells have additional, membrane-bound complement regulators of the alternative
pathway the concentrations of recombinant protein that were needed to cause a certain
amount of lysis are larger for human RBSc than for sheep cells. In order to compare the
relative effects of the different mutant proteins the data were normalised. The amount
of lysis caused by 2 µM WT fH∼19-20 was set to 100% and the lysis caused by the same
concentration of mutant proteins were calculated with respect to this value.
The results of this functional assay show that all but one (R1210C) of the tested aHUS-
linked variants of fH∼19-20 are less efficient in protecting cell surfaces from the al-
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5.4 aHUS mutants in a functional haemolytic assay
Figure 5.18: Haemolytic assay of D1119G and WT fH∼19-20 with sheep erythrocytes.
Increasing concentrations of WT protein lead to complete lysis of the cells in human
serum while the mutant protein barely causes any lysis of the sheep cells.
ternative pathway of the complement system (the Ca2+-dependent classical and lectin
pathways were silenced by addition of Mg-EGTA in this assay). Our collaborators have
studied the interaction of the same panel of mutants with C3b and neither observed a
clear trend: some aHUS variants bound to C3b with smaller, some with higher affin-
ity [260]. Since no coherent trend was found in binding studies with aHUS variants
and heparin or C3b alone it can be assumed that the reason for the risk associated
with these variants is to be found in the ternary interaction rather than pairwise single
interactions. One possible explanation is a model which has been proposed by [257] in
which cell-bound HS first forms a transient encounter complex with fH∼19-20. In the
proximity of cell-bound C3b this complex is “swapped” for an interaction with the C3b-
TED domain on fH∼19-20 and this protein-protein complex is additionally stabilized
by binding of fH∼1-4 to another face of C3b [253]. In such a scenario both weaker and
stronger binding to HS as well as to C3b would be able to disrupt a fine equilibrium,
giving rise to reduced protection of cell-surfaces.
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6 GMSA study on the middle region of
factor H
A third heparin binding site in fH has been reported previously to reside in CCP 9 [262].
In collaboration with Dr. Christoph Schmidt a set of recombinant proteins encompassing
fH modules 8-15 were tested for heparin binding via GMSA. Fluorescently labelled size-
fractionised heparin decasaccharide (dp10) was used in this study. None of the wide
range of constructs (fH∼8-9, fH∼10-12, fH∼12-13, fH∼13-15, fH∼11-14, fH∼10-15 and
fH∼8-15) bound heparin in this assay in which fH∼6-8 (H402) was used as a positive
control (Fig. 6.1). Additionally, fH∼8-9 with a cloning artefact containing basic residues
(EFTWPSRPSRIGT) was tested for heparin binding because the reported construct
used in [262] contained such an aritfact. The artefact carrying fH∼8-9 construct was
found to be retained by dp10, albeit not strongly. It was thus concluded that this cloning
artefact was at least partially responsible for the previously observed heparin affinity in
this construct. Similarly, no heparin binding was observed that could be attributed to
CCP 13. This module has also been proposed to carry a heparin binding site, mainly
based on indirect evidence [67]. A potential third heparin binding site is thus unlikely
to exist in fH [68].
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Figure 6.1: GMSA using several constructs form the middle region of fH. The numbering
refers to fH modules, i.e. 6-8(H) stands for fH∼6-8 (H402). The construct 8-9* refers to
fH∼8-9 carrying the N-terminal artefact EFTWPSRPSRIGT. 1 µ fluorescently labelled
oligosaccharide and equimolar amounts of protein were used for each lane.
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7 Heparin binding study on NK1
HGF/SF is a multifunctional growth factor which primarily controls epithelial/endothelial
cell behaviour. Its functions are transduced through the single specific tyrosine kinase
receptor Met. Heparin oligosaccharides act as cofactors in this ligand-receptor interac-
tion. The primary heparin binding site of HGF/SF resides in the two most N-terminal
domains, the N and the K1 domain. The construct of these two domains, which is also
a naturally occurring splice variant of HGF/SF, is referred to as NK1. The physiolog-
ical function of this splice variant is, to present, not fully understood. In addition to
high affinity heparin binding it has been demonstrated that NK1 also binds to dermatan
sulfate (DS), albeit with lower affinity [135]. The objective of this investigation was to
determine whether NK1 has distinct or overlapping binding sites for the two GAGs. 15N
NK1 was titrated with heparin dp4C and DS hexasaccharide (DS-dp6) to assess to which
degree both binding sites overlap and to compare the affinities for both oligosaccharides.
These two oligosaccharides had previously been identified as the smallest binding ligands
of either type of GAG [233].
NK1 was expressed and purified as described in section 2.1. The buffer used for NMR
studies was 20 mM sodium acatate, 100 mM sodium chloride, pH 6.0 and spectra were
recorded at 303 K on a 800 MHz Bruker Avance NMR spectrometer. The oligosaccha-
rides were produced by Jon Deakin as described in section 2.2. For DS oligosaccharides,
chondroitinase AC-1 and chondroitinase ABC were used instead of heparinase [172].
Since no assignment of NH signals was available for NK1, a histogram was produced in
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which peaks were ordered according to the combined chemical shift perturbation that
heparin dp4C binding caused. These “book keeping” assignments were transferred to
the DS-dp6 titration in order to compare relative effects. In some regions of the spec-
tra following the chemical shift changes of individual residues during the titrations was
hindered due to overlap and peak broadening. A comparison of peaks which could be
followed unambiguously during both titrations showed that both ligands affect a set of
key residues to a similar degree (Fig. 7.1).
Figure 7.1: Histogram showing the relative effects of heparin dp4C (blue) and DS hexasac-
charide (orange) on NK1 backbone 15NH chemical shifts. The horizontal axis numbering
does not refer to residue numbers because no assignment was available for NK1. In-
stead, the residues are ordered according to the combined chemical shift changes which
heparin dp4C induced in the amide cross peaks (their numbering is thus only for ”book
keeping”). Ratios were 1:1 protein:oligosaccharide in both titrations.
The binding sites were found to be overlapping yet distinct. While some of the most
affected residues in the dp4C titration were also significantly affected in the DS dp6
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titration, some of the most affected residues in the DS dp6 titration were affected to a
smaller extent by heparin dp4C (red exclamation marks in Fig. 7.2). Additionally, dif-
ferences in line broadening were observed: some cross peaks disappeared in the DS-dp6
but not in the heparin dp4C titration (green asterisks in Fig. 7.2). Finally, differences
could also be observed when comparing the directions in which cross peaks of residues
in the overlapping binding site moved. Some cross peaks were affected in both titra-
tions but exhibited different chemical shift trends (red asterisks in Fig. 7.2), pointing
to different chemical environments. Addition of dp4C to NK1 above a ratio of 1:1 did
not cause further chemical shift changes, implying that at this ratio saturation had been
reached. In contrast, a 2.5fold excess of DS-dp6 had to be added to NK1 in order to
reach saturation with this GAG, indicating lower affinity. Subsequently, a titration with
DS tetrasaccharide (DS-dp4) was conducted, yielding very small chemical shift changes
at a large (> 10-fold) excess of GAG (data not shown). Thus, DS oligosaccharides bind
weaker to NK1 than heparin oligosaccharides of similar size, and the binding affinity for
short DS oligosaccharides increases with their length, at least for such small oligosac-
charides as tetra- and hexasaccharides.
Overall, the following observations were made: (i) for the majority of amide cross peaks
the absolute changes were larger for heparin dp4 at equal concentrations, (ii) a similar
trend was observed between the two titrations (i. e. the same set of key residues was
affected), and (iii) a fraction of the movers observed in the DS-dp6 titration exceeded
the chemical shift changes caused by heparin dp4C. This last point can be ascribed to
the different nature and size of the two oligosaccharides. The data support the assump-
tion that both ligands bind to overlapping sites of NK1, with the larger binding site for
DS-dp6. Several NK1 residues of the heparin dp4C binding site are less important for
DS-dp6 binding as judged by smaller movements of their NH cross peaks in HSQC spec-
tra. This is likely caused by the different chemical nature and charge distribution of the
two ligands. The relative binding affinities of NK1 for the three studied oligosaccharides
are: heparin dp4C > DS-dp6 > > DS-dp4.
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Figure 7.2: 1H, 15N-HSQC monitored titration of NK1 (free protein: black) with heparin
dp4C (blue, 1:1) and DS hexasaccharide (orange, 1:1). Red exclamation marks high-
light residues which are more affected by the weaker binding DS hexasaccharide, green
asterisks highlight residues which experience intermediate broadening in the DS hexasac-
charide titration and red asterisks highlight residues which are affected in both titrations
yet cause different chemical shift perturbations.
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A provisional assignment of some of the key residues of NK1 that are involved in DS-dp6
and heparin dp4C binding can be made based on a comparison with NMR data of NK1
published elsewhere [263]. Some of the most affected residues are C70, R73, L80 and,
to a lesser extent, D68. R73 has been described as central in a x-ray structure of NK1
in complex with a heparin 14mer [126]. All of the above residues were affected during
titrations of the N-domain with fractionated heparin (10-15mers) and SOS [263]. Only
a tetrasaccharide moiety within the heparin 14mer establishes well-defined contact with
NK1 residues in the crystal structure of the complex, suggesting that the size of the
heparin binding site is in the range of the GAGs which were used in this work.
The observation that both heparin dp4C and DS-dp6 caused different chemical shift
changes in 1H, 15N-HSQC spectra of NK1 is interesting when compared to the titrations
of fH∼7-8 with heparin oligosaccharides and sucrose octasulfate (SOS). No significant
differences between these two types of ligand were observed when titrated into fH∼7-8
despite the large chemical differences between SOS and heparin. SOS is very short, con-
tains a furanose ring, lacks L-iduronic acid and D-glucuronic acid and has no nitrogen as
well as no carboxy groups. In other words, it differs from the class of glycosaminoglycans
in many ways. The fact that it nevertheless appears to bind in a very similar position
and manner to fH∼7-8 when compared to dp4C while differences are observed between
the two GAG-type ligands binding to NK1 points to a possible difference between the
NK1 and fH∼7-8 GAG-binding sites. A comparison between complexes of SOS and
fractionated heparin with the N-domain (which contributes most to GAG binding in
NK1 and HGF/SF) is available in the literature [263]. While in NMR titrations both
ligands affect overlapping sets of residues, there are notable differences in the chemical
shift changes that the same residue experiences in titrations with different ligands. It
can be concluded that heparin and DS oligosaccharides as well as SOS all bind to the
same face of NK1 but can still be unique on an atomic level. During NMR-monitored
titrations chemical shift changes are only used to identify and rank protein residues while
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the shifts are usually not interpreted in terms of direction, i.e. high- or low-field shift in
the proton or nitrogen dimension. If x-ray structures of NK1 in complex with DS and
SOS were available this system seemed well suited to attempt a more detailed analysis
of what chemical shift changes are able to report.
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8 Relaxation time measurements of
HBD2 and GAGs
The following investigation became part of a study on the human beta defensin 2 (HBD2)
and two types of GAGs which was conducted by Dr. Emily Seo in our laboratory. The
peptide was expressed and 15N-labelled recombinantly by her [264]. Both DS-dp6 and
Fondaparinux, the antithrombin binding heparin pentasaccharide (Fondaparinux is a
commercial name), were found to bind to HBD2 but exhibited different affinities as
judged by 1H, 15N-HSQC monitored titrations. Substantial differences were observed
during these two titrations. The same set of residues was effected but chemical shift
changes could be followed more easily in the complex with DS-dp6 which was charac-
terised by the fast exchange regime. The titration with Fondaparinux, on the other
hand, suffered from excessive line broadening. The conditions improved when a lower
temperature (283 K instead of initially 298 K) and lower field strength (600 MHz in-
stead of initially 800 MHz) were used. Nevertheless, some peaks still remained broadened
in the latter titration. Additionally, some chemical shift changes followed a linear be-
haviour during the first titration points but seemed to report on a second process after
a 0.5:1 ratio of Fondaparinux:HBD2 was reached. In order to clarify the question if
protein oligomerisation could be caused by addition of the GAGs measurements of 15N
T1 and T2 relaxation times for free HBD2 and HBD2 in the presence of DS-dp6 and
Fondaparinux were conducted at 283 K and 600 MHz, giving the following results:
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sample T1 / ms T2 / ms τc / ns
free HBD2 428 +/- 15 163 +/- 6 4.0 +/- 0.2
HBD2 + DS dp6 (1:4) 466 +/- 20 103 +/- 4 5.0 +/- 0.2
HBD2 + Fondaparinux (1:16) 560 +/- 21 131 +/- 5 6.8 +/- 0.2
Deviations in this table reflect uncertainties in the exponential fit. The rotational cor-
relation times, τc, were calculated using the program R2R1 (Arthur G. Palmer III,
Columbia University). Due to the relative small size of HBD2 (41 residues) 1D spectra
were sufficient to estimate relaxation times from non-overlapping backbone amide peaks.
Decays were fitted to a mono-exponential decay using gnuplot. During the titrations the
overlap in the proton dimension worsened and some peaks which had been used for the
relaxation times of the free HBD2 were no longer used. In total, the number of backbone
amides used for each sample were 12 (free HBD2), 10 (DS-dp6) and 9 (Fondaparinux).
Standard deviations were calculated to evaluate how big the differences in the relaxation
times between the different peaks were:
sample σT1 / ms σT2 / ms
free HBD2 10 18
HBD2 + DS dp6 (1:4) 27 8
HBD2 + Fondaparinux (1:16) 32 11
These values suggest that the spread of T1 and T2 is relatively small in all samples
despite complex formation and chemical exchange. HBD2 was reported to have a roughly
globular shape and to be monomeric in solution [117, 265, 266], which fits well with
the narrow distribution of relaxation times - no large flexible features are present in
HBD2. Presumably, such flexible stretches would cause more dramatic deviations in the
individual relaxation times.
Both complexes used in this study were assumed to be close to saturation (despite the
largely varying ratios) as determined by 1H, 15N-HSQC titrations. While the τc of HBD2
in the presence of DS-dp6 might be caused by the increase in mass through presence of
the GAG in the complex, the more dramatic increase in τc for the sample containing
183
Figure 8.1: Individual relaxation times for backbone amide groups in unbound HBD2. Red
residues in the primary sequence (top) were used, black residues were omitted due to
overlap.
Fondaparinux very likely indicates an increased tendency to self-associate. The τc for
free Fondaparinux has been determined elsewhere to be 0.55 ns [267]. It is likely that
both GAGs have similar τc values due to their similar length and shapes [165, 268]. Thus,
the difference in τc values of the complexes must point to different interaction modes.
The assumption that Fondaparinux causes self-association of HBD2 is in agreement
with DOSY measurements which revealed a slightly decreased diffusion coefficient in
the presence of DS hexasaccharide and a larger decrease in the diffusion coefficient in
the presence of Fondaparinux (1.24*10−10 m2/sec for free HBD2, 1.18*10−10 m2/sec for
the complex with DS-dp6, and 1.08*10−10 m2/sec for the complex with Fondaparinux).
Fondaparinux is a highly sulfated pentasaccharide with eight sulfate groups while DS-
dp6 contains only three sulfate groups. The binding site on HBD2 that is identical for
both GAGs is approximately as long as these oligosaccharides. Fondaparinux therefore
presents sulfates on both sites of its heparin helix, opening the possibility of creating a
trans dimer with two molecules of HBD2. Such an arrangement has been observed in
the x-ray structure of FGF2 with dp4C [184].
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9 Conclusions
Glycosaminoglycan (GAG)-protein interactions are involved in a large variety of biologi-
cal processes ranging from the regulation of blood coagulation to cellular communication
and pathogenic invasion of cells. The main subject of this work were GAG-protein com-
plexes that are thought be central to the host cell recognition. The protein studied was
factor H (fH), a crucial fluid phase regulator of the alternative pathway of the com-
plement system, which is part of the innate immune defense. Recombinantly produced
proteins and heparin derived oligosaccharides were used to structurally characterise the
interaction of fH with heparin/heparan sulfate (HS) using NMR spectroscopy, mass spec-
trometry and other biophysical techniques. Complement assays served the purpose of
putting these structural studies in the physiological context.
Two heparin/HS binding sites exist in factor H. One is located in the 20th, C-terminal
module of factor H, CCP 20, the other centers around CCP 7. Two more potential bind-
ing sites proposed previously in CCP 9 and CCP 13 were discarded during the course of
this work [68]. Cloning artifacts were found to be responsible for the previously reported
heparin binding in CCP 9 and this work contributed to this finding by means of gel mo-
bility shift assay (GMSA). The heparin binding of CCP 20 was studied by GMSA and
NMR. Dose-dependent chemical shift changes induced by the octasaccharide fraction of
heparin, dp8, were observed by NMR using a 15N labelled recombinant construct of the
two C-terminal modules of fH, fH∼19-20. The residues of module 20 identified previ-
ously as heparin binding site by using fully sulfated heparin tetrasaccharide, dp4C, were
also found to be interacting with dp8. However, the chemical shift changes of backbone
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NH protons exerted by both oligosaccharides varied dramatically. A comparison of the
relative sizes of dp4C, dp8 and the heparin binding site in CCP 20 revealed that dp4C,
unlike dp8, is not able to span the complete binding site. Multiple binding modes for
shorter heparin oligosaccharides like dp4C might exist, a scenario that is not uncommon
in protein-GAG interactions.
A number of disease related variants of CCP 19 and CCP 20 exist in the context of full-
length fH, many of which have been linked to a severe kidney disease, atypical hemolytic
uremic syndrome (aHUS). Here, some of the disease linked residues of fH are shown
to be directly affected by dp8 binding. Altered heparin binding was confirmed for a
range of aHUS variants of fH∼19-20 using GMSA and heparin oligosaccharides, dp4C
and dp6. These data were in line with the results of heparin affinity chromatography
[260]. Some aHUS mutants were binding more strongly, some more weakly, and some
with affinity comparable to that of the wild type fH. The binding affinity was found to
correlate almost exclusively with the charge density: a higher net positive charge of the
protein led to increased affinity, a smaller net negative charge to decreased affinity. It
was concluded that no casual link exists between the heparin binding strength and the
aHUS linked variants of fH.
The aHUS related variants of fH∼19-20 exhibited non-uniform alterations not only in
their heparin affinities but also with respect to a second binding partner of the C-
terminus of factor H, C3b [260]. The heparin and C3b binding studies conducted in our
laboratory and by our collaborators, respectively, showed that both heparin and C3b
interactions of the aHUS related fH variants need to be investigated simultaneously in
order to explain the molecular mechanism of aHUS. A possible route towards this goal
is a NMR study of a ternary interaction between fH, C3b and heparin. As the first step,
the complicated interplay of the three molecules was assessed in this work by using 15N
fH∼19-20 (wild type), C3d and dp8 [269]. The binding of C3b to fH∼19-20 was also
monitored by NMR, but the size of C3b prevented its use in the study of the ternary
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complex. C3d was used instead, as it is the part of C3b that interacts with fH∼19-20.
It was observed that an overlap of the heparin and C3d binding sites exists on CCP
20. The C3d binding site was found to span almost the full length of fH∼19-20. A
number of NH cross peaks belonging to residues in the linker region between modules 19
and 20 were found to be broadened in the presence of C3d making it likely that a kink
in the linker region exists in the fH∼19-20:C3d complex. The affinity of fH∼19-20 for
dp8 is reduced in the presence of C3d, matching the observation that both binding sites
overlap. Binding of dp8 but not C3d to fH∼19-20 could be reduced by a small increase
in the buffer ionic strength, demonstrating that the heparin but not the C3d interaction
of fH∼19-20 is dominated by charge-charge interactions [269].
While the heparin binding site in the C-terminus of factor H is contained within a sin-
gle CCP module, CCP 20, the situation is more complicated for the second heparin
binding site of fH centered in CCP 7. This module was thought to be surrounded by
non-heparin binding modules prior to the onset of this work. Since then CCP 6 was im-
plicated through the work of others, while we have shown that the linker region between
modules 7 and 8 is the dominant heparin binding of the fH∼7-8 construct. Towards
this end we have over expressed and 13C, 15N labelled fH∼7-8, assigned its back bone
resonances and performed titrations with dp4C and the heparin mimic sucrose octasul-
fate (SOS). No contributions from CCP 8 to heparin binding were found beyond the
linker region. A collaboration with an x-ray crystallography group during the course of
this work confirmed that a residue in the linker region, R444, coordinates SOS in the
crystal of fH∼6-8 (Y402 H) with SOS. Large contributions of CCP 6 to SOS binding
were also observed in this crystal. These contributions were not matched by heparin
binding affinities of protein constructs comprising different modules between CCP 6 and
CCP 8. These results were corroborated by heparin titration of deuterated fH 6-8 triple
module.
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A substantial part of our efforts was dedicated to exploring the role of lysine side chains
in protein GAG interactions [270]. Large chemical shift changes that we observed for the
NH backbone cross peak of K446 in 1H, 15N-HSQC monitored titrations of fH∼7 and
fH∼7-8 with dp4C, which would traditionally be interpreted as a strong indication of
the interaction of this residue with heparin, were not confirmed by the x-ray data. The
side chain of K446 does not interact with a SOS molecule. In order to better charac-
terize the contributions of individual lysine residues to the binding, their side chain NH
resonances were inspected during the titration experiments. The HISQC experiment,
which monitors lysine NζHζ resonances, was found to have a limited use for the study of
weak fH-heparin complexes as it requires low pH and low temperature, conditions that
caused precipitation of our complex. Instead, a triple resonance H2CN experiment that
monitors Hε, Cε, and Nε resonances was performed using double-labelled samples and
physiological conditions. This experiment confirmed that the side chain of K446 is not
involved in the interaction of fH∼7 with dp4C. This methodology is applicable to the
study of GAG-protein complexes in general. It complements the routinely performed
1H, 15N-HSQC experiments that do not report on the behaviour of lysine side chains
during the GAG titrations.
Using physiological conditions and zero cross linking methodology chemically activated
dp4C was cross linked with a lysine side chain of unlabelled and 15N labelled fH∼7. Ac-
curate mass measurements confirmed that one tetrasaccharide was linked to one molecule
of fH∼7. The low overall positive charge of this covalent complex was a likely reason
for insufficient fragmentation by MS-MS experiments aimed at identifying the point of
attachment. While this technique failed to identify the modified lysine, chemical and
enzymatic degradation analysed by MALDI-TOF MS proved more informative. The
combination of NMR (HISQC experiments) and MS data allowed the identification of
K405 as the residue that was cross linked to the heparin tetrasaccharide.
Y402H is a single nucleotide polymorphism in CCP 7 which significantly increases the
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risk of age related macula degeneration (AMD). For heparin binding studies with fH∼7
and fH∼7-8 two protein variants were produced and tested for each construct, Y402 and
H402. No significant difference in the binding affinities of dp4C or SOS between the two
variants was found during this study. We therefore suggest that heparin binding to CCP
7 is not affected by the 402 polymorphism, contrary to a hypothesis that was based on
the x-ray structure of fH∼6-8 (H402) in complex with SOS. This conclusion is further
supported by the result of our cross linking study in which the Y402 isoform was used.
In this study a residue in close proximity to Y402, K405, was found to be cross linked
to dp4C. While this result confirms the proximity of residue 402 to the heparin binding
site it does not confirm the crystallographers’ assumption that only a histidine residue
in position 402 would allow heparin binding.
Further studies included in this thesis centered on the GAG binding characteristics of
another protein of the innate immune system, human β-defensin 2 (HBD2), and the
heparin binding domain of hepatocyte growth factor/scatter factor, NK1. For NK1,
1H, 15N-HSQC monitored titrations showed that the binding sites for heparin tetrasac-
charide and dermatan sulfate hexasaccharide are overlapping, yet not identical [172].
The oligosaccharides used for the HBD2 study were the antithrombin binding heparin
pentasaccharide Fondaparinux and dermatan sulfate hexasaccharide. T1 and T2 relax-
ation measurements revealed that Fondaparinux but not (or to a much smaller degree)
dermatan sulfate likely initiates dimerisation of HBD2. This result was consistent with
DOSY experiments conducted by Dr. Emily Seo [271].
The methods presented here, ranging from different NMR and MS techniques to chemical
cross linking and physiological assays, can aid structural investigations in the growing
field of GAG-protein interactions. This work contributes to the analysis of the interplay
of factor H with a range of different binding partners, a complex equilibrium which allows




Sequences in brakets are cloning artefacts.
fH∼7Y (Uniprot database entry P08603):
390 400 410 420
(EAAG)LRKCY FPYLENGYNQ NY GRKFVQGK SIDVACHPGY
430 440 450
ALPKAQTTVT CMENGWSPTP RCIRVK
fH∼7-8Y (Uniprot database entry P08603):
390 400 410 420
(EAAG)LRKCY FPYLENGYNQ NY GRKFVQGK SIDVACHPGY
430 440 450 460
ALPKAQTTVT CMENGWSPTP RCIRVKTCSK SSIDIENGFI
470 480 490 500




fH∼19-20 (Uniprot database entry P08603):
1110 1120 1130 1140
(EAEF)GKCG PPPPIDNGDI TSFPLSVYAP ASSVEYQCQN
1150 1160 1170 1180
LYQLEGNKRI TCRNGQWSEP PKCLHPCVIS REIMENYNIA
1190 1200 1210 1220
LRWTAKQKLY SRTGESVEFV CKRGYRLSSR SHTLRTTCWD
1230 1240
GKLEYPTCAK R
NK1 (sequence from [127], WT Uniprot database entry P14210):
30 40 50 60
YV(A in WT)E GQRKRRNTIH EFKKSAKTTL IKIDPALKIK
70 80 90 100
TKKVNTADQC ANRCTRNKGL PFTCKAFVFD KARKQCLWFP
110 120 130 140
FNSMSSGVKK EFGHEFDLYE NKDYIRNCII GKGRSYKGTV
150 160 170 180
SITKSGIKCQ PWSSMIPHEH SFLPSSYRGK DLQENYCRNP
190 200 210
RGEEGGPWCF TSNPEVRYEV CDIPQCSEVE
HBD2 (Uniprot database entry O15263):
30 40 50 60
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insights on the polarized redistribution of leukocyte integrins and their ligands
during leukocyte migration and immune interactions,” Immunol. Rev., vol. 218,
pp. 147–164, 2007.
[4] A. Aderem and D. M. Underhill, “Mechanisms of phagocytosis in macrophages,”
Annu. Rev. Immunol., vol. 17, pp. 593–623, 1999.
[5] D. M. Underhill and A. Ozinsky, “Phagocytosis of microbes: complexity in action,”
Annu. Rev. Immunol., vol. 20, pp. 825–852, 2002.
[6] J. Q. He, C. Wiesmann, and M. van Lookeren Campagne, “A role of macrophage
complement receptor CRIg in immune clearance and inflammation,” Mol. Im-
munol., vol. 45, pp. 4041–4047, 2008.
[7] M. Cinco, R. Murgia, G. Presani, and S. Perticarari, “Integrin CR3 mediates the
binding of nonspecifically opsonized Borrelia burgdorferi to human phagocytes and
mammalian cells,” Infect. Immun., vol. 65, pp. 4784–4789, 1997.
[8] J. B. Cornacoff, L. A. Hebert, W. L. Smead, M. E. VanAman, D. J. Birmingham,
and F. J. Waxman, “Primate erythrocyte-immune complex-clearing mechanism,”
197
J. Clin. Invest., vol. 71, pp. 236–247, 1983.
[9] Z. Chen, S. B. Koralov, and G. Kelsoe, “Complement C4 inhibits systemic au-
toimmunity through a mechanism independent of complement receptors CR1 and
CR2,” J. Exp. Med., vol. 192, pp. 1339–1352, 2000.
[10] B. L. Myones, J. G. Dalzell, N. Hogg, and G. D. Ross, “Neutrophil and monocyte
cell surface p150,95 has iC3b-receptor (CR4) activity resembling CR3,” J. Clin.
Invest., vol. 82, pp. 640–651, 1988.
[11] D. Mevorach, J. O. Mascarenhas, D. Gershov, and K. B. Elkon, “Complement-
dependent clearance of apoptotic cells by human macrophages,” J. Exp. Med.,
vol. 188, pp. 2313–2320, 1998.
[12] P. R. Taylor, A. Carugati, V. A. Fadok, H. T. Cook, M. Andrews, M. C. Carroll,
J. S. Savill, P. M. Henson, M. Botto, and M. J. Walport, “A hierarchical role for
classical pathway complement proteins in the clearance of apoptotic cells in vivo,”
J. Exp. Med., vol. 192, pp. 359–366, 2000.
[13] L. A. Trouw, A. M. Blom, and P. Gasque, “Role of complement and complement
regulators in the removal of apoptotic cells,” Mol. Immunol., vol. 45, pp. 1199–
1207, 2008.
[14] M. C. Carroll, “The role of complement in B cell activation and tolerance,” Adv.
Immunol., vol. 74, pp. 61–88, 2000.
[15] M. J. Walport, “Complement. Second of two parts,” N. Engl. J. Med., vol. 344,
pp. 1140–1144, 2001.
[16] K. B. Reid, “Activation and control of the complement system,” Essays Biochem.,
vol. 22, pp. 27–68, 1986.
[17] A. R. Duncan and G. Winter, “The binding site for C1q on IgG,” Nature, vol. 332,
pp. 738–740, 1988.
[18] J. H. Lu, B. K. Teh, L. Wang, Y. N. Wang, Y. S. Tan, M. C. Lai, and K. B. Reid,
“The classical and regulatory functions of C1q in immunity and autoimmunity,”
Cell. Mol. Immunol., vol. 5, pp. 9–21, 2008.
[19] T. Fujita, M. Matsushita, and Y. Endo, “The lectin-complement pathway–its role
in innate immunity and evolution,” Immunol. Rev., vol. 198, pp. 185–202, 2004.
[20] R. Roozendaal and M. C. Carroll, “Complement receptors CD21 and CD35 in
humoral immunity,” Immunol. Rev., vol. 219, pp. 157–166, 2007.
[21] H. Müller-Eberhard, “Molecular organization and function of the complement sys-
tem,” Annu. Rev. Biochem., vol. 57, pp. 321–347, 1988.
[22] J. Köhl, “Anaphylatoxins and infectious and non-infectious inflammatory diseases,”
Mol. Immunol., vol. 38, pp. 175–187, 2001.
[23] Z. Fishelson, M. K. Pangburn, and H. J. Müller-Eberhard, “Characterization of
the initial C3 convertase of the alternative pathway of human complement,” J.
Immunol., vol. 132, pp. 1430–1434, 1984.
[24] S. Bhakdi and J. Tranum-Jensen, “Molecular nature of the complement lesion,”
Proc. Natl. Acad. Sci. U.S.A., vol. 75, pp. 5655–5659, 1978.
[25] R. G. DiScipio and C. Berlin, “The architectural transition of human complement
component C9 to poly(C9),” Mol. Immunol., vol. 36, pp. 575–585, 1999.
[26] H. J. Müller-Eberhard, “The membrane attack complex of complement,” Annu.
Rev. Immunol., vol. 4, pp. 503–528, 1986.
[27] H. J. Müller-Eberhard, “Transmembrane channel-formation by five complement
proteins,” Biochem. Soc. Symp., vol. 50, pp. 235–246, 1985.
[28] R. DiScipio and I. Schraufstatter, “The role of the complement anaphylatoxins
in the recruitment of eosinophils,” Int. Immunopharmacol., vol. 7, pp. 1909–1923,
2007.
[29] M. L. Thomas, J. Janatova, W. R. Gray, and B. F. Tack, “Third component of
human complement: localization of the internal thiolester bond,” Proc. Natl. Acad.
Sci., vol. 79, pp. 1054–1058, 1982.
[30] M. Gadjeva, A. W. Dodds, A. Taniguchi-Sidle, A. C. Willis, D. E. Isenman, and
S. K. Law, “The covalent binding reaction of complement component C3,” J. Im-
munol., vol. 161, pp. 985–990, 1998.
[31] B. J. Janssen, A. Christodoulidou, A. McCarthy, J. D. Lambris, and P. Gros,
“Structure of C3b reveals conformational changes that underlie complement activ-
ity,” Nature, vol. 444, pp. 213–216, 2006.
[32] B. J. Janssen, E. G. Huizinga, H. C. Raaijmakers, A. Roos, M. R. Daha, K. Nilsson-
Ekdahl, B. Nilsson, and P. Gros, “Structures of complement component C3 provide
insights into the function and evolution of immunity,” Nature, vol. 437, pp. 505–
511, 2005.
[33] R. B. Sim, T. M. Twose, D. S. Paterson, and E. Sim,“The covalent-binding reaction
of complement component C3,” Biochem. J., vol. 193, pp. 115–127, 1981.
[34] A. Sahu, T. R. Kozel, and M. K. Pangburn, “Specificity of the thioester-containing
reactive site of human C3 and its significance to complement activation,” Biochem.
J., vol. 302 ( Pt 2), pp. 429–436, 1994.
[35] M. K. Pangburn, R. D. Schreiber, and H. J. Müller-Eberhard, “Formation of the
initial C3 convertase of the alternative complement pathway. Acquisition of C3b-
like activities by spontaneous hydrolysis of the putative thioester in native C3,” J.
Exp. Med., vol. 154, pp. 856–867, 1981.
[36] M. S. Winters, D. S. Spellman, and J. D. Lambris, “Solvent accessibility of native
and hydrolyzed human complement protein 3 analyzed by hydrogen/deuterium
exchange and mass spectrometry,” J. Immunol., vol. 174, pp. 3469–3474, 2005.
[37] P. Gros, F. J. Milder, and B. J. Janssen, “Complement driven by conformational
changes,” Nat. Rev. Immunol., vol. 8, pp. 48–58, 2008.
[38] M. D. Kirkitadze and P. N. Barlow, “Structure and flexibility of the multiple
domain proteins that regulate complement activation,” Immunol. Rev., vol. 180,
pp. 146–161, 2001.
[39] L. Kask, B. O. Villoutreix, M. Steen, B. Ramesh, B. Dahlbäck, and A. M. Blom,
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M. López-Trascasa, and S. R. de Córdoba, “Structural and functional characteri-
zation of factor H mutations associated with atypical hemolytic uremic syndrome,”
Am. J. Hum. Genet., vol. 71, pp. 1285–1295, 2002.
[95] P. Sánchez-Corral, C. González-Rubio, S. Rodŕıguez de Córdoba, and M. López-
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[133] D. Béchard, T. Gentina, M. Delehedde, A. Scherpereel, M. Lyon, M. Aumercier,
R. Vazeux, C. Richet, P. Degand, B. Jude, A. Janin, D. G. Ferning, A.-B. Tonnel,
and P. Lassalle, “Endocan is a novel chondroitin/dermatan sulfate proteoglycan
that promotes hepatocyte growth factor/scatter factor nitrogenic activity,” J. Biol.
Chem., vol. 276, p. 48341, 2001.
[134] R. H. Schwall, L. Y. Chang, P. J. Godowski, D. W. Kahn, K. J. Hillan, K. D.
Bauer, and T. F. Zioncheck, “Heparin induces dimerization and confers prolifer-
ative activity onto the hepatocyte growth factor antagonists NK1 and NK2,” J.
Cell Biol., vol. 133, pp. 709–718, 1996.
[135] M. Lyon, J. A. Deakin, and J. T. Gallagher, “The mode of action of heparan and
dermatan sulfates in the regulation of hepatocyte growth factor/scatter factor,” J.
Biol. Chem., vol. 277, pp. 1040–1046, 2002.
[136] J. A. Deakin and M. Lyon, “Differential regulation of hepatocyte growth fac-
tor/scatter factor by cell surface proteoglycans and free glycosaminoglycan chains,”
J. Cell. Sci., vol. 112 ( Pt 12), pp. 1999–2009, 1999.
[137] G. Hartmann, T. Prospero, V. Brinkmann, C. Ozcelik, G. Winter, J. Hepple,
S. Batley, F. Bladt, M. Sachs, C. Birchmeier, W. Birchmeier, E. Gherardi, and
O. Ozcelik, “Engineered mutants of HGF/SF with reduced binding to heparan
sulphate proteoglycans, decreased clearance and enhanced activity in vivo,” Curr.
Biol., vol. 8, pp. 125–134, 1998.
[138] H. Sakata, S. J. Stahl, W. G. Taylor, J. M. Rosenberg, K. Sakaguchi, P. T. Wing-
field, and J. S. Rubin, “Heparin binding and oligomerization of hepatocyte growth
factor/scatter factor isoforms. Heparan sulfate glycosaminoglycan requirement for
Met binding and signaling,” J. Biol. Chem., vol. 272, pp. 9457–9463, 1997.
[139] K. Mizuno, H. Inoue, M. Hagiya, S. Shimizu, T. Nose, Y. Shimohigashi, and
T. Nakamura, “Hairpin loop and second kringle domain are essential sites for hep-
arin binding and biological activity of hepatocyte growth factor,” J. Biol. Chem.,
vol. 269, pp. 1131–1136, 1994.
[140] V. Cioce, K. G. Csaky, A. M.-L. Chan, D. P. Bottaro, W. G. Taylor, R. Jensen,
S. A. Aaronson, and J. S. Rubin, “Hepatocyte growth factor (HGF)/NK1 is a
naturally occuring HGF/scatter factor variant with partial agonist/antagonist ac-
tivity,” J. Biol. Chem., vol. 271, p. 13110, 1996.
[141] N. A. Lokker and P. J. Godowski, “Generation and characterization of a compet-
itive antagonist of human hepatocyte growth factor, HGF/NK1,” J. Biol. Chem.,
vol. 268, pp. 17145–17150, 1993.
[142] R. Montesano, J. V. Soriano, K. M. Malinda, M. L. Ponce, A. Bafico, H. K.
Kleinman, D. P. Bottaro, and S. A. Aaronson, “Differential effects of hepatocyte
growth factor isoforms on epithelial and endothelial tubulogenesis,” Cell Growth
Differ., vol. 9, pp. 355–365, 1998.
[143] J. L. Jakubczak, W. J. LaRochelle, and G. Merlino, “NK1, a natural splice variant
of hepatocyte growth factor/scatter factor, is a partial agonist in vivo,” Mol. Cell.
Biol., vol. 18, pp. 1275–1283, 1998.
[144] A. Imberty, H. Lortat-Jacob, and S. Perez, “Structural view of glycosaminoglycan-
protein interactions,” Carbohydr. Res, vol. 342, p. 430, 2006.
[145] D. L. Rabenstein, “Heparin and heparan sulfate: structure and function,” Nat.
Prod. Rep., vol. 19, pp. 312–331, 2002.
[146] C. Prussin and D. D. Metcalfe, “IgE, mast cells, basophils, and eosinophils,” J.
Allergy Clin. Immunol., vol. 111(4), pp. S486–494, 2003.
[147] G. Nilsson, M. Johnell, C. H. Hammer, H. L. Tiffany, K. Nilsson, D. D. Met-
calfe, A. Siegbahn, and P. M. Murphy, “C3a and C5a are chemotaxins for human
mast cells and act through distinct receptors via a pertussis toxin-sensitive signal
transduction pathway,” J. Immunol., vol. 157, pp. 1693–1698, 1996.
[148] K. J. Bame, I. Venkatesan, H. D. Stelling, and S. Tumova, “The spacing of S-
domains on HS glycosaminoglycans determines whether the chain is a substrate
for intercellular heparanases,” Glycobiology, vol. 10, p. 715, 2000.
[149] M. Lyon and J. T. Gallagher,“Biospecific sequences and domains in heparan sulfate
and the regulation of cell growth and adhesion,” Matrix Biology, vol. 17, p. 485,
1998.
[150] K. J. Murphy, C. L. R. Merry, M. Lyon, J. E. Thompson, I. S. Roberts, and J. T.
Gallagher, “A new model for the domain structure of heparan sulfate based on the
novel specificity of K5 lyase,” J. Biol. Chem., vol. 279, pp. 27239–45, 2004.
[151] R. D. Rosenberg, “Biochemistry of heparin antithrombin interactions, and the
physiologic role of this natural anticoagulant mechanism,” Am. J. Med., vol. 87,
pp. 2S–9S, 1989.
[152] J. D. Esko and S. B. Selleck, “Order out of chaos: assembly of ligand binding sites
in heparan sulfate,” Annu. Rev. Biochem., vol. 71, pp. 435–471, 2002.
[153] M. Kato, H. Wang, M. Bernfield, J. T. Gallagher, and J. E. Turnbull, “Cell surface
syndecan-1 on distinct cell types differs in fine structure and ligand binding of its
heparan sulfate chains,” J. Biol. Chem., vol. 269, pp. 18881–18890, 1994.
[154] F. H. Blackhall, C. L. Merry, E. J. Davies, and G. C. Jayson, “Heparan sulfate
proteoglycans and cancer,” Br. J. Cancer, vol. 85, pp. 1094–1098, 2001.
[155] K. Fjeldstad and S. O. Kolset, “Decreasing the metastatic potential in cancers–
targeting the heparan sulfate proteoglycans,” Curr. Drug Targets, vol. 6, pp. 665–
682, 2005.
[156] A. G. Marguiles, V. S. Klimberg, S. Bhattacharrya, D. Gaddy, and L. J. Suva,
“Genomics and proteomics of bone cancer,” Clin. Cancer Res., vol. 12, pp. 6217s–
6221s, 2006.
[157] E. Feyzi, T. Saldeen, E. Larsson, U. Lindahl, and M. Salmivirta, “Age-dependent
modulation of heparan sulfate structure and function,” J. Biol. Chem., vol. 273,
pp. 13395–13398, 1998.
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of isotopically labelled recombinant beta-defensin for nmr studies,” Protein Expr
Purif, vol. 65, pp. 179–84, 2009.
[265] M. V. Sawai, H. P. Jia, L. Liu, V. Aseyev, J. M. Wiencek, P. B. McCray, T. Ganz,
W. R. Kearney, and B. F. Tack, “The NMR structure of human beta-defensin-
2 reveals a novel alpha-helical segment.,” Biochemistry, vol. 40(13), pp. 3810–6,
2001.
[266] F. Bauer, K. Schweimer, E. Kluver, J. R. Conejo-Garcia, W. G. Forssmann,
P. Rosch, K. Adermann, and H. Sticht, “Structure determination of human and
murine beta-defensins reveals structural conservation in the absence of significant
sequence similarity.,” Prot. Sci., vol. 10(12), pp. 2470–9, 2001.
[267] M. Hricovini and G. Torri, “Dynamics in aqueous solutions of the pentasaccharide
corresponding to the binding site of heparin for antithrombin III studied by NMR
relaxation measurements.,” Carbohydr. Res., vol. 268(2), pp. 159–75, 1995.
[268] A. Silipo, Z. Zhang, F. J. Canada, R. J. Linhardt, and J. Jiménez-Barbero, “Con-
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